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GENERAL INTRODUCTION 
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I. History of tuberculosis 
Tuberculosis has been a disease of mankind since ancient times but for long, its 
cause remained unknown. In 460 BC, Hippocrates defined phthisis as a contagious 
disease often seen in young people with symptoms such as fever in the afternoon, fierce 
cough, poor appetite, and high mortality [1]. 
In the 17
th 
century, due to the crowded living conditions and poor hygiene in the 
expanding cities tuberculosis became epidemic in Europe, and referred to as the Great 
White Plague – an epidemic that started abating only after 200 years.  
Tuberculosis epidemic then spread in Africa with an alarming morbidity and 
mortality rate of 700/100.000 population in 1912 [2] when the slaves brought the 
disease back home from Europe. Only until 1882, the hidden killer causing death to 
millions of people around the world was found by Robert Koch. Thanks to his research, 
the tubercle bacillus, the cause of one in seven deaths in the mid-19
th
 century was 
identified, and a new method was developed to grow Mycobacterium tuberculosis on 
cultures by using solid media made of potatoes and agar. This formed the scientific 
basis for future bio-molecular research into Mycobacterium tuberculosis [1]. 
 
II. Burden and epidemiology of tuberculosis worldwide and in Vietnam 
Tuberculosis (TB) is still a burden all over the world, especially in developing 
countries. Worldwide, every second there is 1 person infected with tuberculosis and one 
third of population is infected with this disease. 5-10% of TB-infected people will 
become diseased with tuberculosis during their life [3]. Without treatment, 70% of 
smear-positive TB patients and 20% of smear-negative but culture-positive TB patients 
die within 10 years [4]. Since anti-TB drugs have been used, the mortality rate of TB 
dramatically decreased, and cure rates of more than 90% have been recorded in clinical 
trials. Nevertheless, TB remains a major global health problem. In 1993, the World 
Health Organization (WHO) estimated 7–8 million cases and 1.3–1.6 million deaths 
occurred each year and proclaimed TB a global public health emergency [5]. HIV/AIDS 
has badly impacted on TB control [1]. Countries in Sub-Saharan Africa that have high 
prevalence of HIV have recorded TB incidence rates increasing two or three fold in the 
1990s [6]. 
According to the WHO, there were in 2011 about 8.7 million people infected 
with Mycobacterium tuberculosis (MTB), 13% of whom were co-infected with HIV, 
and about 1.4 million TB deaths around the world. Most of TB cases were notified in 
Asia (59%) and Africa (29%), and TB is the leading cause of adult deaths from an 
infectious disease after HIV, especially in women [7].  
In 2006, with a prevalence of smear-positive tuberculosis of 89 per 100,000 
population, Vietnam ranked 12 among the 22 countries with the highest burden of TB in 
the world, and ranked third in the Pacific Ocean – East Asia region after China and the 
Philippines (WHO, unpublished data, 2008). Hoa et al. conducted a TB prevalence 
survey in 2007, revealing that the prevalence rate of smear-positive tuberculosis was 
145 per 100,000 (95% CI: 110–180), which is 1.6 times higher than previously 
estimated [8], and higher in South Vietnam than in the Northern and Central parts of the 
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country. WHO estimated that in 2011, there were around 323,000 prevalent cases of TB 
(all forms) (95%CI: 148,000-563,000) in the whole of Vietnam [7]. 
The MTB Beijing genotype, which is one of the common genotypes in Vietnam, 
was estimated to be responsible for 35% of the TB cases in a rural area of Vietnam, and 
associated with young age and multidrug resistant (MDR) TB [9]. It is unclear whether 
this genotype is also associated with unfavorable treatment outcomes such as treatment 
failure or relapse, or with specific drug resistance-conferring mutations, and whether 
variable number of tandem repeats (VNTR) typing is as good as restriction fragment 
polymorphism (RFLP) typing in discriminating among strains of the Beijing genotype. 
These questions will be addressed in this thesis.  
 
III. Multidrug resistant tuberculosis 
Multidrug resistance worldwide 
Besides HIV co-infection, TB drug resistance has been threatening TB 
management in many countries around the world [10]. Generally considered a man-
made problem [11], the incidence of drug resistant TB has reached a record level and is 
becoming a serious threat to global health, with an estimated number of MDR cases 
(i.e., resistant to both rifampicin and isoniazid) in 2011 of 630.000 (460.000-790.000) 
among 12 million cases of TB worldwide [7]. In the hope of eliminating TB in the near 
future, the WHO has in its Global Plan to Stop TB 2011–2015 included the objectives 
that:  
 By 2015, all previous treated patients should be tested for MDR-TB  
 Any new TB patients, who are likely at high risk of MDR-TB (for example, 
those exposed to MDR-TB patients or living in settings with high prevalence of 
MDR-TB) should also be tested for MDR-TB using rapid tests by 2015, and  
 In recognition of the availability of rapid tests, more than 50% of tests for drug 
resistance among new TB patients and more than 90% of tests among previously 
treated patients should be done using rapid tests by 2015. 
 Among diagnosed cases of MDR-TB, at least 90% should have drug 
susceptibility results for a fluoroquinolone and an injectable drug 
(aminoglycoside, polypeptide), which are the mainstay of second-line treatment 
[12].  
 
Tuberculosis treatment and drug resistance in Vietnam  
From 1975 to 1988, two common regimens in Vietnam were 3 months of 
streptomycin (S), isoniazid (H) and pyrazinamide (Z) daily followed by 6 months of S 
and H biweekly (3SHZ/6S2H2) and 3 months of rifampicin (R), H and Z daily, 
followed by 6 months of R, H and ethambutol (E) biweekly (3RHZ/6R2H2E2), applied 
for new and previously treated TB patients, respectively. 
In 1981, a survey in 11 provinces in the Cuulong river delta showed a 
prevalence of streptomycin resistance of 64% that was slightly lower than in the North 
of Vietnam (67%) (reported by Dr. Tran Tan Quang, unpublished data). 
Directly Observed Treatment Short-course (DOTS), the core of the global 
strategy to control TB, was introduced in Vietnam in 1986, and short-course 
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chemotherapy (2SHRZ/6HE) was introduced for treatment new TB patients in 1989. 
DOTS coverage achieved 100% by 1997, and since then the WHO target for treatment 
success for new smear-positive cases has been met [13,14].  
In 2001, a survey of drug resistance reported among new TB patients the 
prevalence of resistance to any drug to be 26.3%, to isoniazid 16.6%, to rifampin 2.0%, 
to ethambutol 1.1%, to streptomycin 19.4%. Among previously treated patients the 
prevalence of any resistance was 62.9%, and of MDR 23.2%.[15]. Furthermore 80% of 
patients with a history of multiple first-line treatment courses (so called chronic TB 
patients) had MDR-TB [16]. In WHO drug resistance report 2010, Vietnam was one of 
27 high MDR-TB burden countries, with 2.7% (2–3.6) MDR-TB in new TB cases and 
19% (14.5–25.2) in previously treated TB cases [17]. 
 
Drug resistance mechanisms 
Rifampicin and isoniazid are two important drugs for first-line anti-tuberculosis 
treatment [18]. Whereas rifampicin resistance is usually coded in the core region of the 
rpoB gene, the mechanism of the resistance to isoniazid is quite complex with 
mutations conferring resistance located in several loci and genes (katG, inhA, ahpC, 
and, potentially, also ndh) [19-22]. Of the latter, mutations in codon 315 of the katG 
gene and in the promoter region of the inhA gene are the most common, occurring in 
50-100% of isoniazid resistant strains [21, 23]. Associations between katG codon 315 
mutations and MDR have been reported in several studies [24-26], and some suggested 
that these mutations were more frequent in clinical Beijing genotype strains [24]. 
Furthermore, population studies have suggested that strains with mutations in the katG 
315 codon or the inhA promoter region are more likely to spread than strains with other 
mutations [27, 28].  
  The genome of Mycobacterium tuberculosis contains many different regions 
including IS6110, a direct repeat locus which contains 10 to 50 copies of a 36-bp direct 
repeat, separated from one another by spacers that have different sequences, as well as 
many mycobacterial interspersed repeat units (MIRUs) [29]. Based on these specific 
regions several molecular techniques were developed for diagnosis of TB (IS6110 PCR) 
or molecular typing of MTB (RFLP, spoligotyping, and VNTR).  
 
IV-Molecular methods for diagnosis and typing of tuberculosis 
Molecular techniques for diagnosis 
 Since in 1985 the polymerase chain reaction (PCR) was invented by Kary 
Mullis [30], many kinds of PCR methods have been applied to detect MTB in clinical 
samples containing very few MTB organisms that cannot be detected by microscopic 
examination of Ziehl–Neelsen stained smears. The most notable was IS6110 PCR that 
has been applied in TB diagnosis in Vietnam since the 1990s. 
 As mentioned above, drug resistance especially MDR-TB is a serious problem 
that hampers the success of TB control worldwide. To cope with this problem, drug 
resistance patterns should be available as soon as possible to guide the therapy for 
MDR-TB patients. However, phenotypic drug susceptibility testing (DST) is a time-
consuming process because it requires culturing, which may take up to two months or 
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longer. Recently molecular drug resistance testing techniques were introduced such as 
the INNO-LiPA Rif.TB assay (rapid detection of rifampicin resistance) and the 
GenoType® MTBDRplus assay (rapid detection of rifampicin and isoniazid resistance). 
Their principle is a line-probe assay for the detection of M. tuberculosis complex and 
specific mutations in specific genes conferring drug resistance. The turnaround time is 
24 hours, and because of limited sensitivity with low bacterial load these methods are 
applied only for smear-positive samples.  
  
 
 
Figure: Mycobacterium tuberculosis genome. Reproduced with permission from [29]; 
copyright Massachusetts Medical Society. 
 
The GenoType® MTBDRplus assay, introduced in 2004, identifies M. 
tuberculosis complex and simultaneously detects mutations in the rpoB gene as well as 
mutations in the katG gene (associated with high-level isoniazid resistance) and inhA 
promoter region mutations (associated with low-level isoniazid resistance) [31].  
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Late 2009 GeneXpert MTB/RIF® was introduced, an assay that marked an 
obvious advance in molecular diagnosis of TB. GeneXpert is a cartridge-based real time 
PCR test for detecting MTB and screening for rifampicin resistance with high 
sensitivity even in smear-negative samples. With a turnaround time of less than 2 hours, 
it is easy to perform and has no requirement for skilled technicians [32]. 
Confronted with the situation of MDR-TB in the world, in June 2008 WHO 
endorsed the use of molecular line-probe assays for MDR-TB screening and the 
GenoType® MTBDRplus assay has since been introduced for routine practice in 
various countries [33-38]. WHO recommends that before using the assay in routine TB 
treatment and control, the performance of the assay in relation to the locally circulating 
M. tuberculosis bacteria should be validated [39]. As Vietnam is one of the 27 high 
MDR-TB burden countries [7], application of rapid DST detecting MDR-TB in 
Vietnam is necessary. 
 
Molecular techniques for typing 
Since the 1990s restriction fragment length polymorphism (RFLP) typing has 
been used, based on a difference in homologous DNA sequences that can be detected by 
the presence of IS6110 fragments of different lengths in MTB genome. A labeled 
IS6110 probe is hybridized with one or more target fragments after digestion by specific 
restriction endonucleases (PVU II), separated by electrophoresis and transferred onto a 
nylon membrane, thus revealing a unique blotting pattern characteristic to a specific 
genotype at a specific locus [40]. RFLP, as a molecular marker, was until recently 
considered the gold standard typing method in the molecular epidemiology of 
tuberculosis [41]. This method has been used to track TB outbreaks [42], to confirm 
recurrence of TB due to reactivation of the same strain or to re-infection with different 
strains [43], and to identify misdiagnosis due to laboratory cross-contamination [44, 
45]. 
Although RFLP revealed a high level of discrimination among MTB isolates, it 
was considered complicated, technically demanding, and time consuming. Moreover 
this technique cannot discriminate strains containing fewer than 5 copies of IS6110 
(low copy strains) and the complex RFLP patterns are difficult to interpret and 
exchange. 
In recent years, spoligotyping has become one of the most widely used 
genotyping methods for epidemiological studies of TB and for classification of MTB 
genotype families [46]. This method is based on PCR, amplifying the whole Direct 
Repeat (DR) region with a biotinylated specific primer. The biotin-labeled PCR 
products are hybridized to the immobilized spacer-oligos that represent spacers of 
known sequence. The presence of spacers is then visualized on film as black squares 
after incubation with streptavidin-peroxidase and ECL-detection 
(http://www.moleculartb.org /gb/pdf/protocols/SpoligoManual.pdf) [47].  
In comparison to RFLP, spoligotyping provides some important advantages: 
simplicity, rapidity, high reproducibility and stability of the results. However, its 
discriminatory power is much lower. Hence spoligotyping is only useful for 
Chapter 1 
 7 
classification of MTB strain families causing outbreaks, whereas another method (such 
as RFLP) needs to be used to track transmission between individual patients.  
The new generation genotyping of M. tuberculosis based on the detection of the 
variable number of tandem repeats (VNTRs) of mycobacterial interspersed repetitive 
units (MIRUs) is considered the next gold standard in the molecular epidemiology of 
tuberculosis [48]. VNTR or MIRU typing is also based on PCR amplification of 
multiple genomic loci to determine the number of tandem repeats at these sites. This 
typing is much easier than IS6110-RFLP typing, and is applicable to crude low-
concentration DNA extracts. Moreover, the results are expressed as numerical codes 
and are, therefore, easy to compare and exchange. Several studies indicated that VNTR 
typing is as discriminative as the RFLP typing method in discrimination of M. 
tuberculosis with multi-banded IS6110 RFLP [49, 50]. 
 
V-Molecular epidemiology of tuberculosis 
Molecular epidemiology can be used to determine the distribution of genotypes 
in different regions in the world, track outbreaks of TB, and distinguish recurrent TB 
disease due to relapses from that due to re-infection. It also allows studying possible 
associations between genotype and treatment outcomes, drug resistance, or other patient 
factors, and thereby can help identify reasons for treatment failure and relapse that 
affect the control of TB in specific regions or in the world in general. Based on such 
results we can possibly improve TB control by adjusting TB treatment regimens and 
recommending appropriate policies for TB diagnosis.  
 
Genotypes of tuberculosis  
The W-Beijing genotype, first described in 1995, has been encountered in many 
areas of the world [51-53]. Especially, it is among the predominant genotypes in most 
of countries of East and Southeast Asia (53, 54) and associated with drug resistance 
(high level in Cuba, the former Soviet Union, Vietnam, and South Africa) [53]. 
In Vietnam, 54% of new patients in urban areas were infected with the Beijing 
genotype, whereas this genotype was isolated in 35% TB patients in the rural South of 
Vietnam [9, 55]. In both studies the Beijing genotype was predominant in the youngest 
age groups, and was more common among patients with resistance to isoniazid or 
streptomycin. In the rural South it was also associated with MDR-TB [9].  
Previous studies suggested an association between relapse and Beijing genotype 
[56-58]. In a small study Lan et al. found that Beijing genotype was related to relapse 
and/or treatment failure but could not distinguish between the two [56]. A recent study 
in Indonesia suggested that M. tuberculosis Beijing genotype strains were associated 
with TB treatment failure, even in the absence of drug resistance [59]. However, it is 
unclear whether TB relapse is truly associated with genotype in Vietnam.  
Besides the Beijing genotype, East African Indian (EAI) strains are also a 
common genotype in South East Asian [60, 61]. In rural South Vietnam 49% of 
circulating strains were low copy strains, all belonging to the EAI genotype family [9]. 
Based on the single-nucleotide polymorphism typing described by Hershberg et al. [62], 
the Beijing genotype belongs to the modern lineage, and the EAI genotype seems to be 
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an evolutionary lineage more closely related to the common ancestor of the M. 
tuberculosis complex.  
Another genotype that is more frequent in South East Asia than in other 
continents is the no-copy genotype (M. tuberculosis strains without IS6110 in their 
genome) [63]. The first no-copy genotype strain was isolated from an Indian patient in 
1993 [64]. The prevalence of the no-copy genotype in India (about 11%) was much 
lower than that of the Beijing genotype [65]. Few studies have observed this genotype 
elsewhere. Anecdotal evidence shows the no-copy genotype circulates in Vietnam, but 
up to now no studies have focused on this specific strain. Its frequency in Vietnam is 
unknown, as are possible associations with drug resistance and other epidemic factors.  
 
Mixed tuberculosis infections  
In 1976 there were already anecdotal indications that TB patients can be re-
infected by another MTB strain and that infections with multiple strains exist. Using 
phage typing, Bates et al. [66] found different phage types of M. tuberculosis in single 
hosts. After that, TB mixed infections were confirmed by using molecular techniques in 
populations living in crowded conditions and/or with high HIV prevalence, including a 
high-density urban community [67] and a hospital [68] in South Africa and a prison in 
Georgia [69].  
However, the frequency of mixed infections in settings with a lower tuberculosis 
infection pressure (e.g. populations in less crowded conditions) and with lower HIV-
prevalence, such as Vietnam, is unknown. Also possible associations between TB 
mixed infections and poor treatment outcomes or severe symptoms have not been 
studied.  
 
Drug resistant mutations and treatment outcomes  
In Vietnam, isoniazid has been used since 1952 [70]. Since then isoniazid 
resistance has emerged and risen to relatively high levels with 16.6 % of new TB 
patients infected with MTB resistant to isoniazid in 2001 [15], and one of the 
predominant genotypes in Vietnam, the Beijing genotype [55], was also associated with 
MDR [9], isoniazid and streptomycin resistance [55]. Isoniazid is considered one of the 
main drugs in the first-line anti-tuberculosis treatment [18]. Isoniazid resistance is often 
due to mutations in the katG 315 codon or in the inhA promoter region [21, 23]. Some 
studies showed that katG 315 codon mutations were more frequent among patients 
infected with Beijing genotype strains [24] and related to MDR [23], furthermore these 
mutations possibly have higher transmission fitness [27]. These differences in isoniazid 
resistance-conferring mutations may also be related to other characteristics of MTB 
strains as well as to treatment outcomes. There are, however, very few studies on the 
mutations underlying resistance to anti-tuberculosis drugs and treatment outcome. 
Therefore, the observation of the association between mutations causing isoniazid 
resistance with genotype as well as with treatment outcomes is important. 
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VI-Aim of the thesis 
This thesis describes the distribution of MTB genotypes, drug resistance 
mutations and their association with treatment outcomes and other patient factors, as 
well as assesses the validity of new molecular methods in diagnosis and typing, with the 
aim of providing an overview of the characteristics of tuberculosis in Vietnam relevant 
for policies by the Vietnamese National TB Program to improve its management and 
treatment. Specifically, this thesis attempts to address 5 questions:  
1-What is the validity of the Genotype® MTBDRplus line-probe assay for detecting 
multidrug-resistant tuberculosis and what are the frequencies of mutations in the rpoB 
core region, the katG315 codon and the inhA promoter region in Vietnam?  
2- Do mutations in the katG 315 codon and in the inhA promoter region impact on TB 
treatment outcomes; and is there any association between those mutations with MTB 
genotype?  
3- Do TB mixed infections and the no-copy IS6110 strains occur in Vietnam? Are there 
any associations between these and drug resistance or other epidemic factors?  
4- Is VNTR typing truly a good method to replace RFLP typing for discriminating 
among Beijing genotype strains in Vietnam? 
5- Is there any association between MTB genotype and first-line treatment failure or 
relapse rate in Vietnam?  
 
VII-Outline the thesis  
In Chapter 2, we describe the specificity and sensitivity of Genotype® 
MTBDRplus test. We also estimate the frequency of mutations of rpoB, katG315 codon 
and inhA promoter region among multidrug-resistant strains collected in a nationwide 
drug-resistance survey. In Chapter 3, we show that mixed infections were truly present 
in Vietnam and estimate the proportion of smear-positive TB cases that have mixed 
infections. We also describe the association between mixed infection with drug 
resistance and other epidemic factors. In Chapter 4 and 5, we assess the association 
between genotype and relapse and first-line treatment failure in Vietnam. In Chapter 6, 
we describe the frequency of mutations in katG codon315 and the inhA promoter region 
in strains resistant to isoniazid, and assess the association between those mutations and 
treatment outcomes and MTB genotype. In Chapter 7, we describe the frequency of no-
copy strains in a rural area of Vietnam and the association between these strains and 
drug resistance as well as other epidemic factors. In Chapter 8, we make a comparison 
of the discriminating value among Beijing genotype strains of VNTR typing versus that 
of RFLP typing. Chapter 9 gives an overall discussion of the studies. This is followed 
by English and Dutch summaries of the thesis. 
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Abstract 
 
Background 
To control multidrug resistant tuberculosis (MDR-TB), the drug susceptibility profile is 
needed to guide therapy. Classical drug susceptibility testing (DST) may take up to 2 to 
4 months. The GenoType® MTBDRplus test is a commercially available line-probe 
assay that rapidly detects Mycobacterium tuberculosis (MTB) complex, as well as the 
most common mutations associated with rifampin and isoniazid resistance. 
We assessed sensitivity and specificity of the assay by using a geographically 
representative set of MTB isolates from the South of Vietnam. 
 
Methods 
We re-cultured 111 MTB isolates that were MDR, rifampin-resistant or pan-susceptible 
according to conventional DST and tested these with the GenoType® MTBDRplus test. 
 
Results 
By conventional DST, 55 strains were classified as MDR-TB, four strains were 
rifampicin mono-resistant and 52 strains were susceptible to all first-line drugs. The 
sensitivity of the GenoType® MTBDRplus was 93.1% for rifampicin, 92.6% for 
isoniazid and 88.9% for the combination of both; its specificity was 100%. The positive 
predictive value of the GenoType® MTBDRplus test for MDR-TB was 100% and the 
negative predictive value 90.3%. 
 
Conclusions 
We found a high specificity and positive predictive value of the GenoType® 
MTBDRplus test for MDR-TB which merits its use in the MDR-TB treatment program 
in Vietnam. 
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Background 
Tuberculosis (TB) is an important disease in developing countries [1]. A major 
concern is the occurrence of multidrug resistant (MDR) TB [2], which is characterized 
by resistance to both rifampicin and isoniazid (INH). MDR-TB is difficult to treat and 
associated with increased treatment failures and relapses. In patients with previously 
untreated pulmonary TB, inappropriate treatment may lead to selection for bacteria with 
drug resistance associated mutations [3]. 
 Vietnam ranks 14
th
 among the countries with the highest burden of TB; the 
incidence of TB is highest in the southern part of the country [1]. In 2005, South 
Vietnam notified 29,789 new smear positive cases yielding an estimated prevalence of 
92.8 per 100,000 (NTP, unpublished data, 2006). M. tuberculosis resistance to INH is 
common (16-25% among new patients) [4, 5]. Among patients experiencing a first 
episode of TB these two studies reported MDR-TB rates of 2 and 4%, and of 23% and 
27% among previously treated patients, respectively [4,5], whereas 80% chronic 
patients had MDR-TB [6]. Genetically, approximately half of the strains belongs to the 
East-African Indian clade whereas the other half are of the Beijing genotype, which was 
found to be strongly associated with (multi-) drug resistance [7,8]. 
To control MDR-TB, drug resistance patterns should be available to guide the 
therapy of the patient. However, phenotypic drug susceptibility testing (DST) is a time-
consuming process because it requires culturing, which may take up to two months or 
longer. As long as no DST results are available, the patient will be treated with standard 
first-line anti-TB drugs. Rapid diagnosis of MDR-TB will permit an earlier start with 
second-line drug treatment for patients with MDR-TB and may thus decrease the risk of 
treatment failure, relapse, amplification of DR, and continuing transmission of MDR-
TB. 
The vast majority of resistance to rifampicin is caused by mutations located in 
the 81-bp hotspot region of the rpoB gene [9]. Mutations conferring resistance to INH 
are located at several genomic loci (katG, inhA and kasA) [10-14]. Varying by 
geographic area, 50 to 100% of INH resistant strains have mutations in codon 315 of 
the katG gene or in the promoter region of the inhA gene [13,15,16]. 
The GenoType® MTBDRplus assay (Hain Lifescience, Nehren, Germany) is a 
commercially available assay that combines detection of MTB complex with prediction 
of resistance to rifampicin and INH. In the assay a multiplex PCR is followed by 
hybridization of the obtained DNA amplicons to membrane-bound probes. The assay 
combines detection of MTB complex with detection of mutations in the 81-bp hotspot 
region of rpoB, at codon 315 of the katG gene and in the inhA promoter region. It was 
found to have high sensitivity and high specificity for rifampicin and INH resistance 
and performs well when applied directly to AFB smear-positive sputum specimens [15, 
17-20]. A recent meta-analysis pooled all these studies and calculated pooled sensitivity 
and specificity rates of 99% (95% confidence interval (CI), 96%-100%) and 99% (95% 
CI, 98%-100%) respectively for rifampicin resistance, and of 96% (93-98%) and 100% 
(99-100%), respectively for isoniazid resistance [21]. 
In June 2008, the World Health Organization (WHO) endorsed the use of 
molecular line probe assays for MDR-TB screening [22], and the GenoType® 
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MTBDRplus assay has since been introduced for routine practice in various countries 
[15,17-20,23]. The WHO recommends that before using the assay in routine TB 
treatment and control, the performance of the assay, in relation to the locally circulating 
M. tuberculosis bacteria, should be validated [22]. 
The National Tuberculosis Control Program of Vietnam intends to use this test 
in support of Programmatic Management of DR-TB (PMDT) on sputum specimens of 
all MDR-TB suspects (i.e., those failing category 1 treatment and those being smear-
positive after 3 months of category 2 treatment). The Genotype® MTBDRplus assay 
will be used to select patients with rifampicin resistant isolates for PMDT. Therefore, 
we assessed the test’s sensitivity and specificity in diagn sing MDR-TB at the 
laboratory of Pham Ngoc Thach Hospital (PNTH) using a geographically representative 
set of M. tuberculosis isolates with known phenotypic resistance patterns from the 
South of Vietnam. 
 
Methods 
Study population 
We selected MTB isolates from the latest nationwide TB drug resistance survey 
(DRS) in Vietnam conducted in 2004-2005. This survey was carefully designed as to 
cover all geographical parts of Vietnam, and the set of samples thus provided a national 
estimate of drug resistance for Vietnam. DST was done by the two national reference 
laboratories, one of which was at PNTH in Ho Chi Minh City. The DRS was part of the 
WHO/IUATLD Global Project on TB Drug Resistance Surveillance and followed 
WHO guide ines [24]. PNTH’s  ab rat ry participates in an annua  internati na  
proficiency study on DST together with laboratories in Korea and Australia, with results 
that are concordant to those of other laboratories for more than 95 % of the tests. 
Complete DST results were available for 1,826 patients with smear-positive TB, 
from 80 different TB clinics throughout the country. Of these, 1,044 (57%) specimens 
were collected in the South of Vietnam and tested in PNTH (910 from new patients and 
134 from previously treated patients). Sputum specimens were processed according to 
standard procedures [24]. 
After centrifugation, sediment was inoculated on Löwenstein-Jensen (LJ) 
medium and incubated at 37°C for 4 to 8 weeks followed by species identification of 
culture-positive samples. DST for isoniazid (0.2 µg/ml), streptomycin (4 µg/ml), 
ethambutol (2 µg/ml), and rifampicin (40 µg/ml) was performed using LJ media 
following the proportion method [25].  
Isolates from all 30 new and 29 re-treatment cases that were either identified as 
MDR-TB (n=55) or resistant to rifampicin (n=4) by phenotypic DST were included in 
this study. In addition, from the isolates that were susceptible to all tested first-line 
drugs from new and re-treatment patients, we randomly selected 52 isolates, so that the 
total number of tested strains was 111. 
 
GenoType® MTBDRplus testing 
GenoType® MTBDRplus testing was performed blinded from the phenotypic 
DST results. The selected MTB isolates were re-cultured from the -70°C freezer and 
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subjected to the GenoType® MTBDRplus test acc rding t  the manufacturer’s 
recommendations (www.hainlifescience.de). By multiplex PCR the rpoB, katG and 
inhA genes were amplified and the resulting biotin-labeled amplicons were hybridized 
to DNA probes bound to membrane strips. Hybridization was detected by addition of a 
streptavidin/alkaline phosphatase (AP) conjugate and an AP mediated staining reaction. 
For each gene, the GenoType® MTBDRplus assay tests for presence of so-called wild-
type (WT) and mutant (MUT) probes, the first comprising the most important resistant 
areas of the respective genes and the second some of the most common resistance 
mediating mutations. Next to that, the TUB zone hybridizes with amplicons generated 
from all members of the Mycobacterium complex and can thus serve for species 
identification. The membrane-bound DNA probes included eight rpoB wild-type 
probes, four rpoB mutant probes (with D516V, H526Y, H526D, and S531L mutations), 
one katG wild-type probe, two katG mutant probes (with S315T1 and S315T2 
mutations), two inhA wild-type probes and four inhA mutant probes (with C15T, A16G, 
T8C, and T8  mutati ns) [26]. F    wing the manufacturer’s instructi ns (www.hain-
lifescience.de), susceptibility to isoniazid and rifampicin was defined as hybridization 
to all the wild type probes and no hybridization to the mutant probes. A strain that 
revealed hybridization to both a mutant probe and to the corresponding wild type probe 
was considered to represent a heterogeneous population of bacteria or a mixed infection 
of a sensitive and a resistant strain. 
 
Species identification 
M. tuberculosis was identified by smear microscopy followed by a positive 
niacin reaction [27]. Further species identification was performed using Innolipa 
Mycobacteria v2 (Innogenetics, Gent, Belgium), if a discrepancy was found between 
initial species identification and results from the GenoType® MTBDRplus assay (i.e., 
no hybridization with the TUB band). 
 
DNA fingerprinting and sequencing 
 In order to identify possible cases of mixed infection, spoligotyping [28] and 
IS6110 restriction fragment length polymorphism (RFLP) [29] were applied to single 
colonies growing on standard culture medium and medium supplemented with 
tuberculostatics. DNA patterns were scanned and analyzed by using Gelcompar 
software (Applied Maths, Sint-Martens-Latum, Belgium) as previously described [30]. 
The Beijing genotype was defined by spoligotyping as any isolate without Direct 
Repeat spacers 1–34 and the presence  f ≥3  f the spacers 35–43 [31]. Other genotypes 
were defined as described by Brudey et al. [32]; including the Vietnam genotype (EAI-
VNM) that belongs to the East African Indian genotype family of M. tuberculosis and is 
the most frequent genotype in this study site [8]. 
Sequencing of the rifampin resistance-determining region (RRDR) of the rpoB 
gene was performed for strains that had discordant results for rifampicin according to 
conventional DST and the GenoType® MTBDRplus test. The 350 bp fragment of the 
rpoB gene was amplified using outer primers RPOBF (5′- GGGAGCGGAT 
GACCACCCA3′) and RPOBR 
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 (5′- CGGTACGGCGTTTCGATGAAC-3′). The primers were designed using Primer 
Express version 2.0 software (Applied Biosystems Inc, Foster City, CA, USA) [33]. 
 
Ethical approval 
The study protocol was approved by the Research Board of Pham Ngoc Thach 
hospital. Since this study used stored isolates with known drug resistance patterns and 
no additional procedures on the patients were involved; individual informed consent 
was not obtained. 
 
Statistical methods 
Data were double entered in EpiData version 3.1 (http://www.epidata.dk) by two 
separate study assistants. Discrepancies were checked against the crude data. Chi-
squared tests were performed using Epi Info version 6.04 (http://www.cdc.gov/ 
epiinfo/). Results were considered significant at P < 0.05. 
 
Results 
Concordance between conventional DST and GenoType® MTBDRplus assay 
Of 111 isolates tested, there was one MDR strain that lacked the TUB band. 
Although this strain was earlier identified as M. tuberculosis, further species 
identification identified the strain as M. avium-intracellulare (MAIS). Spoligotyping 
after re-culturing this isolate showed that it was a mixture of M. tuberculosis and MAIS. 
Since the GenoType® MTBDRplus assay did not identify this strain as MDR-TB, all 
ana yses describing the assay’s perf rmance inc ude 110 is  ates,  f which 58 were 
resistant to rifampicin by conventional DST. 
Based on phenotypic DST, 54 strains were MDR-TB, four strains were 
rifampicin mono-resistant and 52 strains were susceptible to all first-line drugs. 
Considering the phenotypic DST method as the gold standard, the GenoType® 
MTBDRplus test correctly identified 48 of 54 MDR-TB strains (88.9%, 95% CI: 77.4-
95.8%); 54 of 58 rifampicin resistant strains (93.1%, 95% CI: 83.3-98.1%); 50 of 54 
INH resistant strains (92.6%, 95% CI: 82.1-97.9%); and all susceptible strains (100%, 
95% CI: 93.2-100 %). The specificity for detecting MDRTB was 100%. The overall 
concordance of the GenoType® MTBDRplus test and phenotypic DST was 94.5% 
(104/110). Sensitivities, specificities and predictive values are listed in Table 1. 
 
Table 1. The sensitivity, specificity, positive predictive value (PPV) and negative 
predictive value (NPV) and 95% confidence intervals of the GenoType® MTBDRplus 
assay on 110 M. tuberculosis cultures isolates in the South of Vietnam. 
 Rifampicin Isoniazid Multi-drug resistance 
Sensitivity 93.1% (83.3-98.1) 92.6% (82.1-97.9) 88.9% (77.4-95.8) 
Specificity 100% (93.2-100) 100% (93.6-100) 100% (93.6-100) 
PPV 100% (93.4-100) 100% (92.9-100) 100% ( 92.6-100) 
NPV 92.9% (82.7-98.0) 93.3% (83.8-98.1) 90.3% (80.1-96.4) 
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Sequencing the RRDR of the rpoB gene of the four strains with discordant results 
for rifampicin revealed that one strain possessed the H526L mutation which is not 
present on the membrane strips; in the three remaining strains no mutations were 
detected in the rpoB gene. 
 
Frequency of drug resistance associated mutations 
Mutation patterns produced by the GenoType® MTBDRplus test are displayed in 
Table 2. Among the 54 RIF resistant TB strains detected by this test, the frequency of 
rpoB mutations was: 27 S531L (50%), 6 H526Y (10.9 %), 3 D516V (5.5 %), 1 H526D 
(1.8%), 7 missing WT2 (12.7%), 10 missing WT3 (18.1%), 6 missing WT4 (10.9%), 14 
missing WT7 (25.5%), 26 missing WT8 (48%), and no case missing WT1, WT5 or 
WT6. 
Among 50 INH resistant TB strains as identified by the GenoType® 
MTBDRplus test, katG mutations occurred in 43 (86%) and inhA mutations in 9 strains 
(18%). Two of the 43 (5%) strains with a katG codon 315 mutation had an additional 
mutation in the inhA promoter region. The most frequently observed katG mutation was 
katG S315T1 (in 38 of 43 strains, 88.4%), whereas katG S315T2 (2.3%) and unknown 
mutations (i.e., no hybridization to the katG WT nor to either of the mutation probes, 
9.3%) occurred less frequently. All 9 strains with a mutation in the inhA promoter 
region had an inhA C15T mutation (Table 2). 
 
Detection of mixed bacterial populations 
With this rapid assay four possible mixtures were detected, although one of 
these was not identified by the assay as M. tuberculosis due to a lacking TUB band and 
was later identified to contain MAIS. These four phenotypically rifampicin resistant 
isolates were demonstrated to carry mutations in the rpoB gene and/or in the katG gene 
or the inhA promoter region, but did not lack hybridization on any of the wild type 
probes. By using DNA fingerprinting one of these isolates was confirmed to be a 
mixture of two MTB strains (spoligotype T1 and an undefined type; RFLP type T1 and 
Beijing), and the isolate lacking the TUB band (number 12647) was identified as a 
mixture of a MTB strain (spoligotype U) and a non-tuberculous mycobacterium (note 
that spoligotyping yielded a weak signal for M. tuberculosis for one single colony 
culture of this isolate) (Table 3, Figure 1). In the two remaining samples mixed bacterial 
populations could not be detected. After spoligotyping which revealed no differences as 
it has a very low resolution among Beijing strains, we also performed IS6110 RFLP 
typing on single colony cultures of each of these two samples and found they all had 
identical banding patterns (Table 3). 
 
Discussion 
In this study, the GenoType® MTBDRplus assay correctly identified 93.1%, 
92.6% and 88.9% of the rifampicin, INH and combined resistance (MDR), respectively 
and had 100% specificity for each. The sensitivity of detection of rifampicin resistance 
was similar to that reported from Germany, Italy, Finland, France, Denmark, Turkey 
and Taiwan (92-100%, p>0.05) [15,17-20,26,34,35]. The GenoType® MTBDRplus 
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assay failed to detect four (6.8%) of the rifampicin resistant strains in our study, which 
was caused either by a rare mutation which is not present on the strips (n=1) or by 
probable mutations in other genomic regions of the rpoB gene (n=3). The sensitivity for 
detection of isoniazid resistance in our study was 91.2%, which was similar to reports 
from Germany, Finland, Denmark and Taiwan (84 –100%, p>0.05) [15,17-
20,26,34,35], but higher than reported from Turkey, Italy, France and the Caribbean 
(35-73%, P<0.05) [17,18,20,36]. For MDR-TB the sensitivity of the test was somewhat 
lower than reported from other research [21]. 
 
 
Table 2. Mutation patterns following from the GenoType ® MTBDRplus assay. 
rpoB mutations katG mutations inhA mutations Frequency Proportion 
D516V S315T1 -- 1 0.9 
D516V unknown * -- 1 0.9 
D516V -- C15T 1 0.9 
H526D S315T1 -- 1 0.9 
H526Y S315T1 -- 5 4.6 
S531L unknown * -- 2 1.8 
S531L S315T1 C15T 1 0.9 
S531L S315T1 -- 16 14.6 
S531L S315T2 -- 1 0.9 
S531L -- C15T 4 3.6 
S531L -- -- 2 1.8 
H526Y + S531L -- -- 1 0.9 
unknown * S315T1 -- 13 11.8 
unknown * -- -- 3 1.8 
unknown * unknown * C15T 1 0.9 
unknown * -- C15T 1 0.9 
-- S315T1 -- 1 0.9 
-- -- C15T 1 0.9 
Total number of strains with any mutations 56 50.9 
-- -- -- 54 49.1 
Total number of strains 110 100 
* unknown mutation: no hybridization to one or more of the wild type probes nor to any of the 
mutation probes. 
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Figure 1. Patterns of multiple Mycobacterium spp. Infections as obtained by RFLP and 
spoligotyping techniques. The first four isolates have only one band by RFLP (non-
Beijing) and spoligotype T1; the 5
th
 sample is a mixture of Beijing genotype (as 
obtained by RFLP) and spoligotype T1. The 6
th
 sample has no RFLP banding pattern 
and an undefined spoligotype, whereas for the last three isolates no banding patterns 
were found by RFLP and spoligotyping, probably as a result of the presence of non-
tuberculous mycobacteria (NTM or MOTT). 
 
The distribution of mutations identified in our study is significantly different from 
that reported from other continents. We found that the S531L mutation in the rpoB gene 
occurred most frequently (50%) among rifampicin resistant strains. This mutation 
occurred even more frequently in a collection of isolates from South Africa (70.5%, 
p=0.014) [23]. In our study only 36 (66.7%) MDR-TB strains had a mutation that could 
be identified by one of the four rpoB mutant probes present on the strip, whereas this 
was much higher in South Africa (91% (81/89)) [23]. Thus, the assay performs better 
detecting rpoB specific mutations that confer rifampicin resistance in South Africa than 
in Vietnam. For INH resistance, mutations in the katG gene were by far most common 
(86%) and the S315T1 mutation was found most frequently (88.4%) in our population. 
From South Africa, Van Rie et al. [37] reported similar results, whereas Barnard and 
colleagues [23] reported that this mutation occurred less frequently (37.6%; p=0.01). In 
our study 18% of INH resistant MTB strains carried a mutation in the inhA promoter 
region (invariably C15T) which is considerably lower than the 40% reported in 
Barnard’s study (p= 0.007). It sh u d be n ted that we  n y tested MDR-TB isolates, 
whereas Barnard’s study a s  inc uded INH m n -resistant strains and MDR-TB may 
be primarily associated with katG mutations that generally confer high levels of INH 
resistance [38]. 
The GenoType® MTBDRplus assay can detect mixtures of drug resistant and 
drug susceptible bacterial populations. In this study four mixtures were found: three 
mixtures of M.tuberculosis strains and one mixture of a M. tuberculosis strain and an M. 
avium complex strain. This indicates that even in a high prevalence area like Vietnam a 
minor proportion of the TB cases is caused by a mixture of non-tuberculous 
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mycobacteria and MTB. The GenoType® MTBDRplus assay may not be sensitive 
enough to be used for species identification in case of mixed bacterial populations, 
since the M. tuberculosis and M. avium mixture revealed no TUB band. 
Mixed infections were confirmed by typing a limited number of single colony 
cultures by spoligotyping and RFLP. In two samples that seemed to consist of a mixture 
when tested with the GenoType® MTBDRplus assay, presence of a mixed infection 
could not be confirmed which could have been the result of testing only a limited 
number of single colony cultures. With the 100% specificity of the GenoType® 
MTBDRplus assay to detect MDR in M. tuberculosis isolates, no patient would be 
inappropriately treated with category 4 (MDR-TB) treatment if this test would be used 
in routine for rapid MDR-TB diagnosis. On the other hand, 6.9% of patients would not 
receive appropriate category 4 treatment (which is based on detection of rifampicin 
resistance) if identification of MDR-TB patients is done using only the GenoType® 
MTBDRplus test. 
 
Conclusions 
Overall, the GenoType® MTBDRplus test is reliable, rapid and easy to perform 
for the simultaneous detection of rifampicin and INH resistance in M. tuberculosis. 
With high sensitivity for detection of rifampin resistance and high specificity for MDR, 
we conclude that this test strongly facilitates adequate treatment of MDR-TB patients, 
long before the results of conventional DST are available. Because discordance still 
exists between the conventional and molecular approach of DST and susceptibility of 
bacteria to drugs is defined as inhibition of growth, we recommend that the GenoType® 
MTBDRplus test should serve as an early guidance of therapy, which should be 
followed by a phenotypic DST confirmation for all suspected MDR-TB patients. 
Incorporation of the molecular test in the National Tuberculosis Program is an 
important step forward in the rapid diagnosis of MDR-TB among suspected patients in 
the PMDT program. The application of the molecular test directly to clinical material 
with sufficient bacteria will further speed up the turnaround time of the rapid diagnosis 
of MDR-TB and will be the next step of implementation. 
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Table 3. Identification of mixed TB infection by spoligotyping and RFLP.* 
Strain 
no. 
TUB 
Rifampin  Isoniazid  
Spoligotype 
RFLP type + 
Spoligotype 
WT MUT  WT MUT  
10484 + + Mut 2A & 3  + -  Beijing Identical Beijing 
11256 + + Mut3  + katG Mut1 & inhA Mut1  T1+ undefined type T1 + Beijing 
11901 + + Mut3  + inhA Mut1  Beijing Identical Beijing 
12467 - - +  + katG Mut1  U + No band U + No band 
* TUB: M. tuberculosis confirmation band; WT: wild type; MUT: mutant 
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Abstract 
 
Background 
Tuberculosis patients may be infected with or have disease caused by more than one 
Mycobacterium tuberculosis strain, usually referred to as “mixed infecti ns.” These 
have mainly been observed in settings with a very high tuberculosis incidence and/or 
high HIV prevalence. We assessed the rate of mixed infections in a population-based 
study in rural Vietnam, where the prevalences of both HIV and tuberculosis are 
substantially lower than those in previous studies looking at mixed infections. 
 
Methods 
In total, 1,248 M. tuberculosis isolates from the same number of patients were subjected 
to IS6110 restriction fragment length polymorphism (RFLP) typing, spoligotyping, and 
variable-number-tandem-repeat (VNTR) typing. We compared mixed infections 
identified by the presence of (i) discrepant RFLP and spoligotype patterns in isolates 
from the same patient and (ii) double alleles at ≥ 2 loci by VNTR typing and assessed 
epidemiological characteristics of these infections.  
 
Results 
RFLP/spoligotyping and VNTR typing identified 39 (3.1%) and 60 (4.8%) mixed 
infecti ns, respective y (C hen’s kappa statistic, 0.57). The number  f   ci with d ub e 
alleles in the VNTR pattern was strongly associated with the proportion of isolates with 
mixed infections according to RFLP/ spoligotyping (P<0.001). Mixed infections 
occurred more frequently in newly treated than in previously treated patients, were 
significantly associated with minor X-ray abnormalities, and were almost significantly 
associated with lower sputum smear grades.  
 
Conclusions 
Although the infection pressure in our study area is lower than that in previously 
studied populations, mixed M. tuberculosis infections do occur in rural South Vietnam 
in at least 3.1% of cases. 
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Introduction 
For a long time it was assumed that a tuberculosis (TB) infection protects against 
a subsequent infection. In fact, vaccination against infectious diseases is based on this 
principle. However, in 1976 there were already anecdotal indications that TB patients 
can be re-infected by another Mycobacterium tuberculosis strain and that infections 
with multiple strains exist. Using phage typing, Bates et al. [2] found different phage 
types of M. tuberculosis in single hosts. The occurrence of infections with multiple M. 
tuberculosis strains was confirmed by using DNA fingerprinting techniques, first at the 
turn of the century in selected patients by Yeh et al. [25] and by Braden et al. [3] and 
then more recently in larger patient populations [14, 15, 22]. The introduction of 
molecular techniques offered new possibilities for studying the natural history of TB 
infection more extensively. PCR assays targeting particular predominant M. 
tuberculosis genotype families were developed, and by applying these methods to 
clinical material, Warren et al. f und that the rate  f  ccurrence  f “mixed infecti ns,” 
i.e., infections with multiple M. tuberculosis strains, amounted to 19% of examined 
patients in South Africa [22]. 
High rates of mixed infections have been found in populations living in crowded 
conditions, including a high-density urban community [22] and a hospital [7] in South 
Africa and a prison in Georgia [15]. However, the frequency of mixed infections in 
human populations with a lower tuberculosis infection pressure (e.g., populations under 
less crowded conditions and with a lower HIV prevalence) is unknown. Although the 
burden of TB is high in South Vietnam, with a prevalence of smear-positive TB of 
219/100,000 population (95% confidence interval [CI], 145 to 294/100,000) (9), it is 
much lower than the prevalence in the studied areas in South Africa (1,000/100,000) 
[22]. Similarly, the prevalence of HIV among TB patients is lower in Vietnam than in 
South Africa (8.2% versus 50 to 80%) [18; Brand South Africa Media Service].  
We studied the occurrence of mixed infections in a population-based study in a 
rural area in South Vietnam using IS6110 restriction fragment length polymorphism 
(RFLP) typing and spoligotyping [11, 20]. The former method is used to distinguish M. 
tuberculosis isolates at the strain level to study patient-to-patient transmission but also 
enables determination of the genotype to which the M. tuberculosis strain belongs, 
while the latter method can be used only for genotype determination [4]. It is known 
from previous studies that about 35% of the M. tuberculosis isolates from South 
Vietnam are of the Beijing genotype, while about 49% of the isolates represent the East 
African Indian (EAI) genotype (previously known as the Vietnam genotype) [1, 5]. The 
predominance of these two M. tuberculosis genotype families in South Vietnam and 
their highly characteristic IS6110 RFLP and spoligotype patterns enabled us to detect 
possible mixed infections with strains of these different genotypes in a reliable way by 
comparing the results of both typing methods. In addition, mixed infections were 
detected by the visualization of double alleles in variable number-tandem-repeat 
(VNTR) typing patterns [13, 15]. In this study, we were able to compare the sensitivity 
of the various typing approaches to detect mixed infections; however, because much is 
unknown about the evolution of VNTR patterns, we used RFLP/spoligotype results to 
quantify the occurrence of mixed infections and investigate possible risk factors for 
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mixed infections. This is the first report of mixed infections in rural Vietnam, where the 
population density and HIV infection prevalence are low and TB incidence is moderate, 
in contrast to settings in previous studies looking at mixed infections. 
 
 
Materials and methods 
Patient population 
The study area consisted of three adjacent rural districts in Tien Giang Province, 
situated in the Mekong River Delta in southern Vietnam.     patients aged ≥15 years, 
resident in the study area, and registered for treatment of smear-positive pulmonary TB 
between 1 January 2003 and 31 December 2005 at the participating District 
Tuberculosis Units or at the provincial TB hospital were eligible for inclusion in the 
study [10]. By interviews using pre-structured questionnaires, we collected data on the 
sex, age, M. bovis BCG vaccination, X-ray abnormalities, educational level, marital 
status, occupation, and history of treatment of all participants. HIV testing was not done 
routinely. Treatment outcomes were based on routine smear examination [24], as 
described by Buu et al. [5]. Buu et al. previously found that tuberculosis is usually 
transmitted outside the household in the study area [6]; therefore, epidemiological links 
between patients were not assessed in in-depth interviews for the purpose of this study. 
 
Mycobacterial isolates 
Sputum specimens were kept refrigerated and were transported to Pham Ngoc 
Thach Tuberculosis and Lung Disease Hospital in Ho Chi Minh City, Vietnam, within 
72 h after collection. Specimens were decontaminated and liquefied with 1% N-
acetylcysteine, 2% NaOH, inoculated on modified Ogawa medium, and incubated at 
37°C. Cultures were examined for growth after 1, 2, 4, 6, and 8 weeks of incubation. 
Cultures with no growth after 8 weeks were reported to be negative. M. tuberculosis 
was identified using the niacin and nitrate tests [10]. 
 
Drug susceptibility testing  
Drug susceptibility testing was performed by the proportion method following the 
guidelines of the World Health Organization and the International Union against 
Tuberculosis and Lung Disease [23]. Criteria for drug resistance were ≥ 1% colony 
growth [10] at 28 or 40 days compared to the growth on the drug-free control medium 
at the following drug concentrations: isoniazid, 0.2 g/ml; rifampin, 40 g/ml; 
streptomycin, 4 g/ml; and ethambutol, 2 g/ml. Multidrug resistance (MDR) was 
defined as resistance to both rifampin and isoniazid. 
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DNA typing 
We included all 1,248 patients (66% of the eligible population) with isolates on 
which all 3 typing methods were applied (RFLP, spoligo-, and VNTR typing). Genomic 
DNA was extracted from positive cultures by using a method described earlier [21]. 
IS6110 RFLP typing and spoligotyping were performed according to the internationally 
standardized methods [11, 20]. VNTR typing was done using 15 loci, as described by 
Supply et al. [17]. 
 
Definition of mixed infections by RFLP, spoligo and VNTR typing  
All isolates that yielded discrepant results with regard to M. tuberculosis genotype 
family in RFLP and spoligotyping were subjected to both typing methods for a second 
time from the same DNA to ensure the reproducibility of the observation. Beijing and 
EAI genotypes were assigned as reported elsewhere on the basis of the IS6110 RFLP 
and spoligotyping patterns [1, 4, 12]. Isolates that repeatedly had a spoligotype 
characteristic of the EAI genotype and an IS6110 RFLP pattern characteristic of a 
Beijing genotype strain [12], or the other way around, or a spoligotype characteristic of 
the Beijing or EAI genotype and an IS6110 RFLP pattern characteristic of another 
genotype, or the other way around, were considered to represent a mixed infection. 
VNTR typing has been shown to be sensitive in the detection of mixed infections by 
revealing double alleles, with mixed infections defined as double alleles in two or more 
VNTR loci [13, 15]. Because mixtures of two strains of the same genotype are virtually 
impossible to detect by using only RFLP or spoligotyping, we used the VNTR typing 
results to check the number of potentially missed mixed infections. We defined the 
occurrence of double alleles at at least two VNTR loci to be potential mixed infections. 
However, at present, the sensitivity of VNTR typing for the detection of mixed 
infections is unknown and double alleles could also represent evolution of the 
bacterium. Therefore, we do not report the mixed-infection rate according to VNTR 
typing, but we typed all 1,248 isolates by VNTR, RFLP, and poligotyping to compare 
their sensitivities for the detection of mixed M. tuberculosis infections as a first step for 
future studies. Furthermore, VNTR typing was done since the data were also collected 
for other studies performed to present an overview of genotypes in this part of Vietnam 
and to check for relapse versus new infections. 
 
Re-culture of sputum for analysis of single colonies 
We repeated RFLP and spoligotyping twice for all 39 mixed infections from their 
DNA (extracted from cultures), and we got the same results. Ideally, to exclude mixed 
infections that occur due to cross-contamination during the culture processing, studies 
on mixed infections should be performed on original sputum samples. For two of the 
assumed mixed-infection isolates, we tried to confirm the observation and exclude 
laboratory cross-contamination by using a bacteriological approach. Pretreated sputum 
specimens, stored at -20°C, were recultured on 7H10 agar plates to grow single 
colonies. Spoligotyping was applied to five or six single colonies of each of the isolates. 
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Data analysis 
The Gene Marker software, version 1.5 (Softgenetics, PA), was used for analysis 
and automated allele calling of the VNTR patterns. The Bionumerics software, version 
3.0 (Applied Maths, Sint-Martens Latem, Belgium), was used for the analysis and 
comparison of IS6110 RFLP, spoligotype, and VNTR patterns. Data were entered into 
Epi Info software, version 6.04 (Centers for Disease Control and Prevention, Atlanta, 
GA). Double entry was done on a 20% random sample (50% in 2003) of all records. 
Discrepancies were observed in <1% of all records and in <0.05% of all fields. 
Analyses were performed in Epi Info, version 6.04, and Stata, version 10SE (Stata 
Corporation, College Station, TX).  
For comparison of categorical variables, we used the chi-square and two-sided 
Fisher’s exact tests as appr priate, with trends acr ss  rdered categ ries assessed by 
Cuzick’s test f r trend. Results were considered significant at P values of <0.05. 
Associations between mixed infections and explanatory variables were expressed as 
odds ratios; confounding effects were investigated by stratified analysis using the 
Mantel-Haenszel test. 
 
 
Results 
During the period from January 2003 to December 2005, 1,890 patients were 
eligible for inclusion, and isolates from 1,248 (66%) of those patients had complete 
IS6110 RFLP, spoligo-, and VNTR typing results and were available for the analyses. 
Of these, 931 (74.6%) isolates were from male patients and 317 (25.4%) were from 
female patients with a median age of 50 years (25
th
 and 75
th
 percentiles, 37 and 66 
years, respectively). Eleven hundred seven (88.7%) were new patients, 139 (11.1%) 
were relapse patients, and the remaining 2 cases were of unknown status. 
 
Identification of mixed infections identified by IS6110 RFLP, spoligotyping and 
VNTR typing 
Thirty-nine (3.1%) of 1,248 isolates had RFLP and spoligotype patterns that 
represented different M. tuberculosis genotype families and were considered to be 
mixed infections. Repeated RFLP and spoligotype analysis from the same DNA 
confirmed the mixed infections for all 39 isolates. Twenty-eight isolates (71.8%) 
represented a mixture of Beijing and EAI strains, 5 isolates (12.8%) were a mixture of a 
Beijing strain and a strain of another genotype (not EAI), 5 isolates (12.8%) were a 
mixture of an EAI strain and a strain of another genotype (containing more than 4 
IS6110 copies in RFLP analysis and not belonging to the Beijing genotype), and 1 
(2.6%) was a mixture of a Haarlem and another strain (Figure 1). Overall, the study 
population, including the mixed-infection isolates, contained 549 (42.7%) EAI strains, 
461 (35.8%) Beijing strains, and 277 (21.5%) strains of other genotypes. These rates of 
EAI and Beijing genotypes of M. tuberculosis were similar to those reported previously 
for the prevalence of these genotypes in rural areas of South Vietnam (49% for EAI and 
35% for Beijing [5]), but the prevalence of the Beijing genotype was lower than that 
observed in Hanoi and Ho Chi Minh City [1]. 
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Figure 1. Mixed infections detected by IS6110 RFLP and spoligotyping. Spoligotypes 
and IS6110 RFLP patterns of the M. tuberculosis isolates that were identified as mixed 
infections on the basis of discordant genotyping results. The dendrogram (shown on the 
left) shows the similarity of the spoligotype patterns, as determined by using the Dice 
coefficient and unweighted-pair group method using average linkages for clustering. To 
the right of the IS6110 RFLP patterns, the interpreted genotype families are indicated, 
as determined by spoligotyping and IS6110 RFLP typing, respectively. 
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VNTR typing detected 122 (9.8%) of 1,248 isolates with double alleles at at least 
one locus, and 60 (4.8%) of these isolates revealed double alleles at two or more loci 
(Table 1). Of these 60 isolates, 31 (51.7%) isolates had not been identified as being 
mixed infections by combining the results of RFLP and spoligotyping and 29 (48.3%) 
isolates represented mixed infections confirmed by RFLP and spoligotyping. Thus, of 
the 39 mixed-infection isolates detected by RFLP and spoligotyping, 29 (74.4%) were 
confirmed by VNTR typing (Table 1). Comparing the RFLP/ spoligotyping and VNTR 
typing results for the isolates revealed that the percentage of mixed infections detected 
by RFLP and spoligotyping of isolates strongly increased with the number of loci at 
which double alleles were found (P<0.001; Figure 2). While only 3.2% (2/62) of 
isolates contained mixed infections (on the basis of RFLP/spoligotyping), when only a 
single VNTR locus had double alleles, this proportion was more than 80% for isolates 
that had double alleles in five or more VNTR loci. Among isolates that had two, three, 
or four loci with double alleles, the proportions of mixed infections were 12.5%, 20.0%, 
and 44.4%, respectively. Of 1,126 strains having single alleles, 0.7% (8/1,126) were 
mixed infections, according to combined RFLP and spoligotyping analysis (Table 1). 
The agreement between the two definitions that we used in this study (discrepant 
genotype results between RFLP and spoligotyping and double alleles at at least 2 loci 
with VNTR typing) was 96.7% (Tab e 1), and C hen’s kappa statistic was 0.57.  
Of the 60 isolates that had two or more double alleles in VNTR typing, 29 
represented a mixed infection on the basis of the combination of the RFLP and 
spoligotype results; 25 of these were a mixture of Beijing and EAI genotypes, 3 were a 
mixture of EAI and another genotype, and 1 was a mixture of a Beijing and another 
genotype. For 31 of the 60 isolates that had two or more double alleles in VNTR typing, 
no mixed infection was detected with RFLP and spoligotyping. 
 
Table 1. Comparison of sensitivity of detection of mixed M. tuberculosis infections by 
VNTR typing and by combined typing with IS6110 RFLP and spoligotyping 
Pattern by IS6110 
RFLP and 
spoligotyping 
combined 
No. of isolates showing the following by 15-locus 
VNTR typing 
 
Double alleles in two 
or more loci 
Double allele at 
one locus 
All single 
alleles 
Total 
Mixed infection     
 Yes   29  2  8    39 
 No  31  60  1118  1209 
Total  60  62  1126  1248 
 
 
Re-culturing of mixed infection isolates 
Since identification of mixed infection by culture was not the primary purpose of 
this study, no attention was given to the phenotypic nature of the cultures. Only after we 
discovered several samples to contain mixed infections did we decide to reculture these. 
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Unfortunately, enough material to reculture the sputum sample was available for only 
two samples. For two of the assumed mixed infections for which original sputum 
specimens were still available, pretreated sputum specimens were recultured directly on 
7H10 agar plates and spoligotyping was applied to five or six single colonies of each of 
these two isolates. For one specimen, three colonies yielded Beijing-specific 
spoligotype patterns, while two other colonies revealed an EAI spoligotype. For the 
other specimen, only Beijing spoligotypes were obtained. Thus, a mixed infection was 
confirmed microbiologically for one of the two isolates.  
In terms of microbiology, we observed that the colonies of Beijing genotype 
isolates were often smooth and large, with a diameter of more than 2 mm, while the 
colonies of EAI genotype strains were often dry and small, with a diameter of less than 
1 mm. 
 
 
Figure 2. Correlation between the heterogeneity in VNTR patterns and the detection of 
mixed infections by combined IS6110 RFLP and spoligotyping among 1,248 M. 
tuberculosis isolates. The percentage of mixed infections by (IS6110 
RFLP/spoligotyping) is indicated for isolates showing VNTR patterns with no double 
alleles (n = 1,126), a double allele at 1 VNTR locus (n =62), or double alleles at 2 to 9 
different VNTR loci (n = 60). 
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Table 2. Patient and TB disease characteristics for patients with mixed M. tuberculosis 
infections. 
Characteristic  No. (%) of patients P value
a
 
Total Mixed infections 
Total 1248  39  (3.1)  
District    
Cai Lay 575  22  (3.8) 0.299 
Chau Thanh 392  8  (2.0)  
Cai Be 281  9  (3.2)  
Sex     
Male 931  29  (3.1) 1.000 
Female 317  10  (3.2)  
Age (yr)    
15-34 246  9  (3.7) 0.884 
35-64 657  20  (3.0)  
≥ 65 344  10  (2.9)  
Unknown 1  0  (0)  
Treatment history    
New 1107  38  (3.4) 0.17 
Previously treated 139  1  (0.7)  
Unknown 2  0  (0)  
Treatment outcome    
Favourable 1226  39  (3.2) 1.000 
Unfavourable 23  0  (0)  
Abnormalities on x-ray    
Minor 90  8  (8.9) 0.001 
Medium 590  22  (3.7)  
Major 562  9  (1.6)  
Unknown  6  0  (0)  
Smear grade
b
    
Negative or scanty 194   8  (4.1) 0.117
c
 
1+ 557   21  (3.8)  
2-3+ 484  9  (1.9)  
Missing 13  1  (7.7)  
Duration of cough (wk)    
<4 324  10  (3.1)  
4-7 469  14  (3.0)  
≥ 8 455  15  (3.3)  
Fever    
Present 1108   36  (3.2) 0.613 
Absent 140   3  (2.1)  
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Table 2, continued. Patient and TB disease characteristics for patients with mixed M. 
tuberculosis infections. 
Characteristic  No. (%) of patients P value
a
 
Total Mixed infections 
Night sweats    
Present  748  27  (3.6) 0.249 
Absent 500  12  (2.4)  
Weight loss    
Present  1223   38  (3.1) 0.551 
Absent 25  1  (4.0)  
Isoniazid    
Resistant 246   8  (3.3) 0.840 
Sensitive 1002   31  (3.1)  
Streptomycin    
Resistant 341   15  (4.4) 0.142 
Sensitive 907   24  (2.6)  
Multidrug resistant    
Yes 50   3  (6.0) 0.203 
No 1198   36  (3.0)  
a
 Ca cu ated by Fisher’s exact test. 
b
 The results in the reference lab; maximum grading of two smear examinations. 
c
 Cuzick’s test for trend, P =0.054. 
 
Epidemiological and clinical characteristics of mixed infections 
There were no significant associations between the probability of having a mixed 
infection and the district of residence, age, sex, treatment history, treatment delay, 
presence  f systemic sympt ms, treatment  utc me,  r the is  ates’ resistance t  
isoniazid or streptomycin or multidrug resistance (Table 2). However, mixed infections 
were significantly less likely to occur in patients with extensive X-ray abnormalities 
(P<0.001), and there was a nearly significant trend for lower sputum smear grades 
among mixed infections (P = 0.054), with both findings suggesting less extensive 
pathology in patients with mixed infections. Taking a medium severity of X-ray 
abnormalities as the reference, the odds of a mixed infection was 2.52 times (95% CI, 
1.08 to 5.87) higher for minor X-ray abnormalities and 0.42 times (95% CI, 0.19 to 
0.92) lower for major X-ray abnormalities. For sputum smear grading, taking a 1+ 
grade as the baseline, the odds of mixed infection was not higher for negative or scanty 
smears (1.10 times; 95% CI, 0.48 to 2.52) but was 0.48 time lower for 2+ or 3+ smears 
(95% CI, 0.22 to 1.07). In stratified analyses, the odds ratios for the association of 
mixed infection with either severity of X-ray abnormalities or sputum smear grade were 
not affected by any of the variables in Table 2, nor were X-ray abnormalities or sputum 
smear grade clearly associated with a specific genotype (EIA, Beijing, or other) among 
the single infections (data not shown). 
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  On the basis of demographic information, epidemiological links between patients 
with mixed infections were considered highly unlikely. Patients with mixed infections 
were distributed equally over the three different provinces; lived in different 
communities; were from different sexes, age classes, and socioeconomic classes; had 
different types of jobs; and did not occur within the same household (data not shown). 
 
 
Discussion 
Our study shows that mixed tuberculosis infections also occur outside settings 
with extremely high TB incidences and population densities. The proportion of mixed 
tuberculosis infections found in rural South Vietnam in this study was 3.1% when 
identified by combined RFLP and spoligotyping results and 4.8% when identified by ≥ 
2 loci with double alleles in VNTR typing, which are similar to the proportion reported 
from South Africa by Richardson et al. (2.3%) [14] but lower than that found in 
Georgia (13.1%) [15] or in South Africa by Warren et al. (19%) [22] and Cohen et al. 
(9%) [7]. These differences in the proportions of mixed infections could be explained 
by differences in the methodology of detection. The study from Georgia defined mixed 
infections on the basis of RFLP typing as well as VNTR typing [15]. If we would have 
used a definition for mixed infections adding RFLP/spoligotyping and VNTR results, 
our study would have identified (39 + 31)/1,248, or 5.6%, mixed infections. Moreover, 
a number of mixed infections in the Georgian study were detected only after typing of 
multiple specimens from a single patient [15], and the study by Cohen et al. in South 
Africa focused on pooled multiple samples from autopsy patients [7], while we typed 
only one specimen per patient. The study in South Africa by Warren et al. [22] used a 
methodology based on PCR probes distinguishing Beijing from non-Beijing strains 
which is more sensitive for identifying mixed infections than the RFLP typing-based 
method applied by Richardson et al. [14] that we also used. In addition, differences in 
the densities of human populations and risk of TB infection are likely to have played a 
role. The study in Georgia took place in a crowded prison with a TB incidence of 
5,995/100,000, the study by Warren et al. was performed in an urban area with a TB 
incidence of as high as 1,000/100,000 [22], and the study by Cohen et al. was 
performed in a highly HIV-infected hospital population [7]. In these settings, cross-
infection could easily occur. In contrast, our study was performed in a rural area in 
Vietnam with a population density of only 837/km2 and an observed TB incidence of 
new smear-positive cases of 100/100,000 in 2005 (National Tuberculosis Program 
Vietnam, unpublished data), and cross-infection may be expected to be less common 
under these circumstances. Finally, HIV infection may increase the potential for 
acquiring mixed TB infections [16], and the prevalence of HIV infection among TB 
patients was higher in the South African studies (at least 10% [22] and 94% [7]) than in 
ours.  
To identify mixed infections in our study, we used RFLP and spoligotyping, in 
which strains of the EAI and Beijing genotypes can be recognized easily. It is likely that 
mixed infections between a Beijing and an EAI strain are easier to detect by a Beijing 
RFLP pattern and an EAI spoligotype than the other way around because the Beijing 
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RFLP pattern can mask the EAI RFLP pattern and the EAI spoligotype can mask the 
Beijing spoligotype. Therefore, the combination of methods is necessary to detect the 
mixture. The Beijing RFLP type and EAI spoligotype mixture is also the mixture that 
we most frequently detected in this study. We did not find any mixtures of the reverse 
type: an EAI RFLP type and a Beijing spoligotype. This is because an EAI strain can be 
visualized by RFLP typing only when the Beijing strain is present in a very low 
concentration compared to the EAI strain in a sample. In such a case, in spoligotyping, 
the EAI strain will also be amplified and visible in the spoligotyping pattern. The 
spoligotype of the Beijing strain that would be present in the sample would be masked 
by the EAI spoligotype. RFLP and VNTR typing have been used before by Shamputa et 
al. to detect mixed infections [15]. Our study showed that RFLP and spoligotyping can 
also be used for detection of mixed infections. 
A disadvantage of our approach is that we probably underestimated the true rate 
of mixed infections in Vietnam. The fact that we detected 60 strains with double alleles 
in at least two VNTR loci suggests that VNTR typing is a more sensitive method to 
detect mixed infections than RFLP/spoligotyping. Neither RFLP nor spoligotyping can 
independently detect a mixture of two strains of the same genotype very efficiently [8], 
whereas VNTR typing results can show double alleles at chromosomal loci and thus in 
principle also detect multiple strains of the same genotype. On the other hand, 8/39 
(21%) of the mixed infections were missed by VNTR typing (Table 1). We found that 
the more loci with double alleles an isolate showed in VNTR typing, the higher the 
probability was that these were also identified as mixtures by combined RFLP and 
spoligotyping (Fig. 2). At present, the sensitivity of VNTR typing for the detection of 
mixed infections is unknown, and double alleles could also represent evolution of the 
bacterium [13]; therefore, we did not define the mixed-infection rate according to 
VNTR results, but we typed all 1,248 isolates by VNTR, RFLP, and spoligotyping to 
compare the sensitivities of these methods to detect mixed M. tuberculosis infections as 
a first step for future studies. 
With 100% of the cases being cured, we do not have an indication that mixed 
infections led to higher failure rates. In fact, they were associated with less extensive 
pulmonary pathology than single infections. Although this is based on routine chest X-
ray results that were not standardized as part of our study, we found this association 
across all three districts, suggesting that it does not reflect observer bias. Moreover, we 
found a similar pattern with regard to sputum smear grading (which had been done 
centrally): mixed infections were associated with a lower degree of smear positivity. 
Interestingly, neither of these associations was determined by underlying differences in 
duration of cough or presence of systemic symptoms such as fever, night sweats, and 
weight loss. This suggests that the observed associations do not reflect early diagnosis 
(i.e., the patient still had limited pulmonary pathology), for example, because of a 
higher incidence of systemic symptoms with mixed than with single infections. This 
finding requires further studies; one hypothesis could be that patients with multiple 
infections have an increased immunological tolerance to M. tuberculosis infections. 
This may be due to HIV infection, for which we did not test. However, other causes are 
likely to play a role as well, since mixed infections occurred equally among both sexes 
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and all age groups, while HIV infection among TB patients in Vietnam is strongly 
associated with young age (<35 years) and male sex (18). It is also interesting that 
mixed-infection cases were not related to a history of TB treatment, as they occurred in 
3.4% of the new patients, compared to 0.72% of the patients with recurrent TB. This 
finding was in agreement with the report from Georgia [15]. In contrast, Warren et al. 
[22] found that multiple infections were more frequent in relapse cases. 
Although we cannot completely exclude the possibility that (part of) the mixed 
infections detected in our study were the result of errors or cross-contamination in the 
laboratory, various observations support our finding. The mixed infections were found 
in all three districts, with the highest frequency of mixed infections being in the district 
with the highest TB rate, and at different points in time. Furthermore, repeated analysis 
with all three DNA typing methods invariably confirmed the initially obtained results. 
Finally, to check for the possibility of cross-contamination, we recultured single 
colonies of the only two sputum specimens that were still available and could confirm 
mixed bacterial populations in one of these two with typing of only a very limited 
number of single colonies. This suggests that the observed discordant results between 
RFLP and spoligotyping results indeed represented mixed infections.  
There were some limitations to our study. First, we did not perform HIV testing, 
so we could not study the relationship between HIV and mixed infections, although at 
0.5% the HIV prevalence is still very low in rural Vietnam [19]. Second, we did not 
store all sputum samples for reculture to recheck for mixed infections. Third, the ability 
of RFLP and spoligotyping to detect mixtures of strains with the same genotype is 
limited. Fourth, VNTR typing is thought to be more sensitive than RFLP and 
spoligotyping to detect mixed infections, but the exact sensitivity of VNTR typing for 
the detection of mixed infections is unknown. Finally, the number of mixed infections 
that we identified was relatively small, thereby limiting the power of our study to detect 
significant associations with potential risk factors. 
We believe that the observed 3.1% of mixed infections in the rural part of South 
Vietnam represents a minimum estimate, as the approach explored by combining RFLP 
and spoligotyping has a restricted detection limit. Most likely, due to the visual aspect 
involved in this approach, mixed infections that have more uneven ratios between the 
number of bacteria of the respective strains will go unnoticed. With the application of 
VNTR typing, which may be more sensitive in the detection of mixed infection, the true 
magnitude of this phenomenon may be unraveled in the future. 
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Abstract 
Background  
In Vietnam, the Mycobacterium tuberculosis Beijing genotype is associated with multi-
drug resistance and is emerging.   p ssib e exp anati n f r this gen type’s success is 
an increased rate of relapse.  
 
Methods 
In a prospective cohort study, isolates from patients with smear-positive tuberculosis 
were subjected to drug susceptibility testing and to spoligotyping and variable number 
of tandem repeats typing before treatment and after recurrence of tuberculosis. 
 
Results  
Among 1068 patients who were actively followed up over 18 months for recurrence, 23 
relapse cases occurred (1.39 cases/100 person-years). After adjustment for genotype, 
tuberculosis treatment history, and drug resistance, relapse was significantly associated 
with the Beijing genotype (adjusted hazard ratio [aHR], 5.48; 95% confidence interval 
[CI], 2.06–14.55) and isoniazid resistance (aHR, 5.91; 95% CI, 2.16–16.16).  
 
Conclusions 
The strongly increased relapse rate in tuberculosis cases caused by Beijing strains 
probably contributes to the successful spread of this genotype in Vietnam and 
elsewhere. 
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Background 
Despite extensive control efforts, tuberculosis (TB) remains a major public 
health problem with an estimated 8.8 million cases and almost 1.4 million deaths per 
year worldwide [1]. On the basis of several techniques [2], molecular epidemiological 
studies have identified genotype families of Mycobacterium tuberculosis, including the 
Beijing genotype, which is among the predominant genotypes in East and Southeast 
Asia [3-6]. The Beijing genotype has gained particular attention because of its 
association with multi-drug resistant tuberculosis (MDR-TB), both in outbreaks and in a 
number of population-based studies [7-11]. In addition, its association with young adult 
age in several settings suggests the Beijing genotype is emerging [3,9,10]. The cause 
and consequence of this possible shift in the population structure of Mycobacterium 
tuberculosis has not been studied sufficiently. Although Beijing genotype strains have 
shown increased virulence in animal studies, data on altered pathogenesis in humans 
have remained inconclusive [4]. While one study from Indonesia found increased rates 
of treatment failure in cases caused by Beijing strains [12], other studies did not [13-
16]. Reports of increased relapse rates with Beijing strains have been more consistent 
[14,17,18], although their study designs (case-control and/or passive follow-up) allow 
for alternative interpretations.  
In Vietnam, the Beijing genotype is highly prevalent, causing about 40% of the 
TB cases [3,10], and is associated with resistance to streptomycin and isoniazid [3], as 
well as with MDR-TB [10], providing an ideal environment to study epidemiological 
phenomena associated with Beijing genotype infections. For treatment of previously 
untreated tuberculosis patients (new cases), the Vietnamese National Tuberculosis 
Program (NTP) uses an 8-month regimen with isoniazid, rifampicin, streptomycin and 
pyrazinamide administered for 2 months, followed by isoniazid and ethambutol for 6 
months (ie, the 2HRSZ/6HE regimen). Although reported failure rates with this regimen 
are low (e.g. 1.7% in the south of Vietnam in 2010 [unpublished data]), there is concern 
about its potential role in the development of MDR-TB [5]. A study in Ho Chi Minh 
City found that 15 of 23 patients (65%) who did not respond to 2HRSZ/6HE treatment 
had acquired MDR-TB during treatment [11]. Also the rate of recurrent TB in Vietnam 
is high, as is the proportion of TB patients with a history of cured TB (13.3% in the 
south of the country, [unpublished data]). This high relapse rate may be due to use of 
ethambutol instead of rifampicin in the continuation phase [19], but it may also be 
associated with the high prevalence of the Beijing genotype among Mycobacterium 
tuberculosis isolates from previously treated patients in this country [10, 17]. 
We studied the association between culture-proven treatment relapse and the 
Beijing genotype in a prospective cohort study among patients in Vietnam with smear-
positive pulmonary TB who were initially cured by first-line treatment.  
 
Methods 
Recruitment of patients and study design  
This prospective cohort study was performed in three adjacent rural districts in 
the Mekong River Delta in southern Vietnam. Nested in a population–based study of 
TB cases spanning four years, the cohort included all patients consecutively diagnosed 
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and registered for treatment from 1 July 2005 through 30 June 2007. Details of the 
study site and procedures have been described elsewhere [10, 16]. 
In brief, a   patients in the study area aged ≥15 years and with a diagnois of 
smear-positive pulmonary TB were eligible for enrolment and provided 2 sputum 
specimens for smear examination and M. tuberculosis culture before treatment. 
Enrolled patients were followed up during standard first-line treatment, with sputum 
smear microscopy and culture performed at the end of treatment (after 8 months). 
Patients whose sputum smear and culture were negative for M. tuberculosis were visited 
by study staff twice, at around 9 and 18 months after treatment completion. In addition, 
data were collected if patients reported during these 18 months, patients reported with 
symptoms at any of the participating TB clinics. Patients who had any symptom 
suggesting recurrent TB during these visits or who themselves consulted a participating 
clinic provided two sputum specimens for smear and culture. Data were also collected 
from clinic reports, death certificates and interviews with family members, to determine 
any intermediate tuberculosis treatment received elsewhere and causes of death among 
the study patients 
Ethical clearance was obtained from the ethical health committee of the Ho Chi 
Minh City Council. All included patients provided written informed consent.  
 
Laboratory procedures  
Sputum specimens were kept refrigerated and transported to Pham Ngoc Thach 
Hospital in Ho Chi Minh City within 72 hours after collection. Specimens were 
decontaminated and liquefied with 1% N-Acetylcystine, 2% NaOH, inoculated on 
modified Ogawa medium and incubated at 37ºC. Cultures were examined for growth 
after 1, 2, 4, 6 and 8 weeks of incubation. Results of cultures with no growth after 8 
weeks were reported as negative. M. tuberculosis was identified using the niacin and 
nitrate tests [20]. Drug susceptibility testing was performed by the proportion method 
[21]. Criteria for drug resistance were growth of ≥1%  f the c   ny forming units at 28 
or 42 days compared with the drug-free control medium, at the following drug 
concentrations: isoniazid 0.2 g/ml, rifampicin 40 g/ml, streptomycin 4 g/ml and 
ethambutol 2 g/ml. MDR-TB was defined as resistance to both rifampicin and 
isoniazid. Pretreatment drug resistance testing was performed at a later stage on stored 
isolates and results were not used for patient management, in accordance with 
Vietnamese NTP guidelines prevailing at the time of the study.  
Genomic deoxyribonucleic acid (DNA) was extracted from M. tuberculosis 
positive cultures by using a previously described method [22]. Spoligotyping was 
performed according to the internationally standardized methods [23]. Variable Number 
of Tandem Repeats (VNTR) typing was done using 15 loci, as described by Supply et al. 
[24]. 
 
Definitions  
We defined the cohort for the present analyses as all patients who were sputum 
smear- and culture-negative at the end of treatment, and we defined follow-up time as 
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the period between the date of completion of treatment and the date of the 18-month 
visit, a bacteri   gica  diagn sis  f recurrent TB,  r  f the patient’s death, whichever 
came first. Recurrent TB was defined as any case in this cohort of culture-positive TB 
observed during the follow-up period. Unfavorable treatment outcomes were defined as 
recurrent TB or death during the follow-up period. Recurrent TB was considered to be 
due to M. tuberculosis re-infection if the pretreatment and follow-up isolates had 
different spoligotypes or VNTR types that differed by ≥ 2 loci. We defined relapse as 
recurrent TB caused by the same strain, with strain identity confirmed by detection of 
identical spoligotypes and identical VNTR profiles in pretreatment and follow-up 
isolates, or by detection of identical spoligotypes and VNTR types that differed by no 
more than a single locus [24].The Beijing genotype was defined by spoligotyping as 
any isolate without direct-repeat spacers 1–34 and the presence of at least 3 of the 
spacers 35–43 [25]. Other genotypes were defined as described by Brudey et al. [2]. 
 
Data analysis  
Data were double entered in EpiInfo v6.04 (Centers for Disease Control and 
Prevention, Atlanta GA, USA); discrepancies were corrected on the basis of the raw 
data. Analyses were performed in Stata v10SE (Stata Corp, College Station TX, USA).  
For significance testing on comparisons of categorical variables, the Chi-square 
test or the 2-sided Fisher’s exact test was used as appr priate.  ss ciati ns between 
genotype and outcome were assessed by survival analysis using the log-rank test. We 
based our primary analysis on relapse as the outcome; patients with TB re-infection 
were censored in this analysis.  
We considered genotype, categorized as Beijing versus all other genotypes 
together, as our explanatory variable of interest, and considered age, sex, TB treatment 
and TB drug resistance as potential confounders. In similar secondary analyses, we took 
recurrent TB and unfavorable treatment as separate outcomes. Multivariable analyses 
were done by Cox proportional hazard modeling. P values for contribution to 
multivariate models, including interaction, were based on the likelihood ratio test. All 
tests were done at the 5% significance level. 
 
Results 
Of 1,331 patients enrolled in the treatment cohort, 1,073 were smear and culture 
negative at the end of treatment and included for follow-up in the present study. 
Detailed characteristics of these patients are shown in Table 1. We excluded 5 patients 
for loss to follow-up directly following the end of treatment (Figure 1). Of the 1,068 
patients available for analysis, 984 (92.1%) initially had new TB and 84 (7.9%) had 
been previously treated; 816 (76.4%) were male, and 252 (23.6%) were female. 
Pretreatment isolates from 357 patients (33.4%) belonged to the Beijing genotype, and 
those from 711 patients (66.6%) belonged to other genotypes. Among these other 
genotypes, the most prevalent was the East African Indian genotype (411 patients, 
[38.5%]). Pretreatment drug resistance patterns included resistance to streptomycin in 
isolates from 271 patients (25.4%); resistance to isoniazid, in those from 200 (18.7%); 
resistance to rifampicin, in those from 24 (2.2%); resistance to ethambutol, in those 
Chapter 4 
50 
from 12 (1.1%); multi-drug resistance, in those from 22 (2.1%); and combined 
resistance to streptomycin and isoniazid in those from 134 (12.5%; Table 2). 
The follow-up period ranged from 2.1 to 28.1 months (some patients who were 
not found at the 18-month visit were visited again at a later point in time), with a mean 
of 18.4 months. There were 20 deaths during follow-up: 1 due to TB, 2 due to accidents 
and 17 due to other causes. For 1 patient, no death certificate was available. Symptoms 
requiring collection of sputum at any time during follow-up were reported by 198 
patients (18.5%). Of these, sputum samples were obtained for 185, and valid culture 
results were available for 181 (97.8%). Culture results were positive at any time point 
for 35 of 181 patients (19.3%). Of these 35 cases of recurrent TB, 12 were due to re-
infection with a different strain. The 12 re-infection strains differed from the 
pretreatment strains by different spoligotype and VNTR type, for 3 patients and by 
different VNTR type, for 9. 
 
Relapse 
Relapse with the same strain was thus recorded in 23 patients (incidence rate 
1.39 cases/100 person-years of follow-up). Of these, 17 patients (73.1%) had Beijing 
genotype infections, compared with 340 of 1,045 (32.5%) with no relapse (p<0.001). 
Survival analysis also showed a significantly higher relapse rate for patients with 
Beijing genotype infections than for patients with other genotypes (p<0.001; Figure 2). 
In univariate analysis, relapse was significantly associated with the Beijing genotype 
(hazard ratio [HR], 5.90 vs non-Beijing, p<0.001) as well as with resistance to 
streptomycin (HR, 3.19; p=0.006) or isoniazid (HR, 5.81; p<0.001). There was no 
significant association between relapse and history of TB treatment, age, sex, resistance 
to ethambutol or rifampicin or MDR-TB (p=0.129; Table 2). After adjustment for 
genotype, history of TB treatment, isoniazid resistance, streptomycin resistance and 
MDR, relapse remained associated with Beijing genotype (adjusted HR [HR
adj
], 5.48; 
95% confidence interval [CI], 2.06-14.55) and with isoniazid resistance (HR
adj
 5.91; 
95%CI, 2.16-16.16), but not with streptomycin resistance (Table 2).There were no 
significant interactions for the association with relapse between genotype and drug 
resistance or treatment history.  
For the multivariate Cox regression model, the overall departure from the 
proportional hazards assumption was non-significant (p=0.487), whereas this departure 
was almost significant (p=0.051) for genotype. Inspection of the log-log transformed 
survival curves suggested convergence after 18 months of follow-up, when 1 relapse 
case among Beijing infections and 2 relapse cases among non-Beijing infections 
occurred, for equal incidence rates of 3.24 cases/100 (95%CI, <0.1-15.2) and 3.24 
cases/100 person-years (95%CI, 0.3-9.6), respectively. We therefore repeated the Cox 
model for the first 18 months of observation only, which showed a similar pattern of 
associations with significant hazard ratios for Beijing genotype (HR
adj 
7.40, 95%CI, 
2.36-23.22, p<0.001) and isoniazid resistance (HR
adj 
4.73, 95%CI, 1.58-14.20, 
p=0.006).  
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Table 1. Characteristics of 1073 patients who were cured after first-line tuberculosis 
treatment, Vietnam. 
Characteristic No Percentage  
Age, ( yrs) 
  
<35 95 8.9 
35-64 703 65.5 
≥65 275 25.6 
Sex   
Male  819 76.3 
Female 254 23.7 
District   
Chau Thanh 329 30.7 
Cai Lay 397 37 
Cai Be 347 32.3 
Marital status   
Married 821 76.5 
Widowed 106 9.9 
Single 146 13.6 
Education    
Primary school 621 57.9 
Secondary school or higher 452 42.1 
Profession   
Farmer or Gardener 589 54.9 
Student or Salaried worker 287 26.7 
House wife 49 4.6 
Elderly or Jobless 148 13.8 
History of tuberculosis treatment   
New cases 989 92.2 
Previously treated 84 7.8 
M. tuberculosis genotype   
Beijing 360 33.6 
East African-Indian 412 38.4 
Other 301 28.0 
Pretreatment drug resistance pattern    
Any streptomycin resistance  273 25.4 
Any isoniazid resistance 201 18.7 
Any rifampicin resistance 24 2.2 
Any ethambutol resistance 12 1.1 
Combined streptomycin and isoniazid resistance 135 12.6 
Multidrug resistance 22 2.1 
Abbreviation: M. tuberculosis, Mycobacterium tuberculosis. 
 
Chapter 4 
52 
Enrolled in treatment cohort: 1331
Smear-and culture-negative result at 
end of treatment: 1073
Not included in 
follow-up: 5
Unfavorable outcomes: 55
Alive with no tuberculosis 
at end of follow-up: 1013
Recurrent tuberculosis: 35
Deaths: 20
Tuberculosis: 1
Accident: 2
Other causes: 17
Relapse: 23
Reinfections: 12
Eligible for analysis: 1068
Figure 1. Study flow chart. 
 
Recurrent TB and unfavorable outcomes  
We may have misclassified relapse cases as re-infections, or as deaths. 
Therefore, in secondary analyses we assessed the associations between genotype and 
recurrent TB and unfavorable outcomes (ie, recurrent TB or death). Of 35 of 1,068 
(3.3%) patients who had recurrent TB, 27 (77.1%) had Beijing genotype infections 
before start of treatment (difference with no recurrence, p<0.001). The pattern of 
univariate and multivariate associations for recurrent TB was similar to that for relapse 
(Table 3), with significant associations in the multivariate model for Beijing genotype 
infections (HR
adj 
5.47; 95%CI, 2.35-12.73) and for isoniazid resistance (HR
adj
 2.65; 
95%CI, 1.10-6.34). Of the 20 patients who died during follow-up, 7 (35.0%) had 
Beijing genotype infections compared to 350 of 1,048 (33.4%) who survived (p=0.880). 
Unfavorable outcomes were recorded for 55 of 1,068 patients (5.1%), including 34 
(61.8%) with Beijing genotype infections (difference with favorable outcomes, 
p<0.001). After adjustment for age, sex, history of TB treatment and MDR, unfavorable 
outcomes remained associated with Beijing genotype (HR
adj
 3.23; 95%CI, 1.81-5.80). 
 
Time intervals 
There were no significant differences in time interval from cure to re-infection 
or recurrent TB between Beijing and non-Beijing genotype (19.8 versus 21.3 months, 
and 13.9 versus 17.2 months, respectively; p>0.05 for each comparison). However, the 
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average time from cure to relapse was shorter in patients infected with Beijing genotype 
strains than in patients infected with other strains (10.5 versus 15.8 months; p=0.031; 
Table 4). 
 
Drug resistance amplification 
Among the 21 relapse cases that had non-MDR isolates before treatment, 
amplification of drug resistance occurred in 4 of 15 patients (26.7%) infected by Beijing 
genotype strains, compared with 0 of 6 patients infected with other strains (p=0.429). 
Of the 4 cases involving non-MDR Beijing genotype strains in which amplification 
occurred, 3 had become MDR, with 1 initially monoresistant to isoniazid, and 2 initially 
resistant to both isoniazid and streptomycin.  
 
 
 
 
 
Figure 2. Survival curve for tuberculosis relapse among 1068 patients followed up after 
cure with first-line tuberculosis treatment in Vietnam, by genotype (other vs Beijing). 
P<0.001, by the log-rank test, for differences between genotypes. 
 
 
  
Table 2. Univariate and multivariate analyses of tuberculosis relapse after cure among 1068 patients who were initially smear positive, Vietnam. 
 
Variable 
 
Cases, 
No. 
Incidence, 
Cases/100 
PYFU 
 
Unadjusted 
HR 
 
P 
 
Adjusted 
HR
a
 
 
95% CI 
 
P 
Overall  23 1.39 
     
Age, yrs    0.798    
<35  3 2.05 1     
35-64  14 1.32 0.64     
≥65  6 1.39 0.68     
Sex    0.446    
Male   19 1.51 1     
Female  4 1.01 0.67     
District    0.528    
Chau Thanh  5 1.00 1     
Cai Lay  10 1.68 1.76     
Cai Be  8 1.44 1.16     
History of TB treatment    0.518   0.116 
New cases  22 1.44 1  1   
Previously treated  1 0.72 0.55  0.20 0.03-1.50  
M. tuberculosis genotype    <0.001   <0.001 
Beijing  17 3,13 5.90  5.48 2.06-14.55  
Non Beijing  6 0.54 1  1   
  
 
 
Table 2, continued. Univariate and multivariate analyses of tuberculosis relapse after cure among 1068 patients who were initially smear 
positive, Vietnam. 
 
Variable 
 
Cases, 
No. 
Incidence, 
Cases/100 
PYFU 
 
Unadjusted 
HR 
 
P 
 
Adjusted 
HR
a
 
 
95% CI 
 
P 
Pretreatment drug resistance pattern
b
 
       
Any streptomycin resistance   12 2.88 3.19 0.006 0.83 0.29-2.31 0.714 
Any isoniazid resistance  13 4.25 5.81 <0.001 5.91 2.16-16.16 0.001 
Any rifampicin resistance   2 5.26 3.53 0.150    
Any ethambutol resistance  0 0 UD     
Combined streptomycin and isoniazid 
resistance 
 9 4.38 4.47 0.001    
Multidrug resistance  2 5.76 3.84 0.129 1 0.21.-4.73 0.999 
Abbreviations: CI, confidence interval; HR, hazard ratio; M. tuberculosis, Mycobacterium tuberculosis; PYFU, person-years of follow-up; UD, undetermined. 
a
 Based on Cox proportional hazards modeling including all variables mentioned for the multivariate model. 
b
 Reference category consists of all patients with isolates without this pattern of resistance. 
 
  
Table 3. Univariate and multivariate analyses of tuberculosis recurrence after cure among 1068 patients who were initially smear positive, 
Vietnam. 
 
Variable 
 
Cases, 
No. 
Incidence, 
Cases/100 
PYFU 
 
Unadjusted 
HR 
 
P 
 
Adjusted 
HR
a
 
 
95% CI 
 
P 
Total  35 2.11 
     
Age,yrs     0.479    
<35  5 3.43 1     
35-64  22 2.04 0.52     
≥65  8 1.87 0.58     
Sex    0.463    
Male   24 1.91 1     
Female  11 2.81 1.32     
District    0.672    
Chau Thanh  9 1.81 1     
Cai Lay  14 2.35 1.43     
Cai Be  12 2.15 1.09     
History of TB treatment    0.471   0.393 
New cases  31 2.04 1  1   
Previously treated   4 3.11 1.5  0.61 0.19-1.90  
M. tuberculosis genotype    <0.001   <0.001 
Beijing  27 4.97 6.00  5.47 2.35-12.73  
Non Beijing  8 0.72 1  1   
  
 
 
Table 3, continued. Univariate and multivariate analyses of tuberculosis recurrence after cure among 1068 patients who were initially smear 
positive, Vietnam. 
 
Variable 
 
Cases, 
No. 
Incidence, 
Cases/100 
PYFU 
 
Unadjusted 
HR 
 
P 
 
Adjusted 
HR
a
 
 
95% CI 
 
P 
Pretreatment drug resistance 
pattern
b
 
       
Any streptomycin resistance  18 4.31 2.51 0.011 0.88 0.37-2.12 0.780 
Any isoniazid resistance  16 5.28 3.25 0.001 2.65 1.10-6.34 0.029 
Any rifampicin resistance  4 10.51 3.89 0.037    
Any ethambutol resistance  1 5.34 2.98 0.359    
Combined streptomycin and isoniazid 
resistance  
 12 5.84 2.87 0.009    
Multidrug resistance  4 11.53 4.23 0.029 1.58 0.46-5.41 0.466 
Abbreviations: CI, confidence interval; HR, hazard ratio; M. tuberculosis, Mycobacterium tuberculosis; PYFU, person-years of follow-up. 
a
 Based on Cox proportional hazards modeling including all variables mentioned for the multivariate model. 
b
 Reference category consists of all patients with isolates without this pattern of resistance. 
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Table 4. Interval between tuberculosis cure and recurrence, by M. tuberculosis 
genotype, among patients in Vietnam. 
Event Mean ± SD, months Range, months P 
a
 
Recurrence    
Beijing 13.9 ± 5.7 11.0-16.7 0.122 
Non Beijing 17.2 ± 7.2 12.4- 21.9  
Relapse    
Beijing 10.5 ± 5.6 7.7-13.4 0.031 
Non Beijing 15.8 ± 5.7 9.8-21.8  
a
 Compared with non-Beijing genotype infections. 
 
 
Discussion  
We observed that patients infected by Beijing genotype strains had a 5.48-times 
increased risk of relapse as compared to patients infected with other genotypes. This 
association was independent of TB treatment history and pretreatment drug resistance 
pattern, and was robust to possible misclassification of relapse cases as reinfections and 
of missed relapse cases due to death. It confirms earlier observations from Vietnam [17] 
and Singapore [18], as well as from a multi-country clinical trial [14], which each had 
limitations due to case-control design, passive follow-up and/or marginal significance 
of the observed difference. The relative risk of relapse for Beijing versus non-Beijing 
strains was larger in our study (5.48) than in the multi-country trial in which patients 
were also followed actively for recurrent TB (2.2) [14]. This difference may reflect the 
overall higher relapse rate in Vietnam that is likely associated with the use of the 8-
month 2HRSZ/6HE regimen for new patients [19]. It also suggests that the effect of 
Beijing genotype on relapse rates may be stronger with the 8-month regimen than with 
the 6-month regimen, which includes a 4 month continuation phase of isoniazid-
rifampicin. Furthermore, relapse in our study was significantly associated with 
resistance to isoniazid but not with resistance to streptomycin or MDR, probably 
reflecting the use of isoniazid-ethambutol in the continuation phase of treatment. 
There are a number of possible explanations for the increased relapse rate in TB 
cases caused by Beijing genotype infections. Higher relapse rates may in fact reflect 
increased failure rates for Beijing genotype infections but with very low bacterial loads, 
resulting in negative cultures at the end of treatment. Once drug treatment is stopped 
these remaining bacilli start replicating again, causing symptoms and yielding positive 
culture results within months. This may explain why we observed shorter intervals 
between cure and relapse in cases caused by Beijing strains. However, our earlier study 
found no association between genotype and treatment failure [16], and no other study 
clearly did so, except for one from Indonesia [4, 12]. Alternatively, increased relapse 
rates may reflect increased rates of progression from latent infection to disease. In this 
hypothesis residual bacilli that during TB treatment become contained in granulomas, 
as they are during latent infection, reactivate, and Beijing bacilli do so more efficiently 
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than other genotype bacilli. Indeed, a study from Gambia, although based on low 
numbers of cases, suggested that Beijing strains have higher rates of progression from 
latent infection to disease [26]. 
The observed association of the Beijing genotype and relapse is probably due to a 
combination of factors. In animal models, Beijing strain bacilli escape from immune 
responses more efficiently than other genotype bacilli [27, 28]. Moreover, they grow 
more rapidly in human macrophages [29], which may provide them with a higher 
potential for progressing from latent infection to disease than other strains. 
Note that our findings do not imply that the overall proportion of Beijing strain 
infections that progress to disease is increased as compared to other genotype 
infections. In fact, they suggest that the relapse rate for cases caused by Beijing strains 
is only increased during the first 18 months following cure, which would translate into a 
lower average incubation period rather than into a higher cumulative incidence of 
disease progression. 
The observed increased relapse rate for Beijing strain infections was independent 
of (multi)drug resistance. The strong association in this site [10,16] and elsewhere 
[30,31] between Beijing genotype and MDR-TB implies that these increased relapse 
rates also result in increased spread of MDR-TB. Moreover, although differences were 
not significant, amplification to MDR-TB was observed for Beijing strains but not for 
other genotype strains in the present study. A potential explanation is provided by 
recent in vitro and mouse model data suggesting that Beijing bacteria, in comparison to 
the also prevalent East African Indian bacteria, have a higher intrinsic resistance to 
treatment by rifampicin, as well as a higher mutation frequency regarding the 
generation of rifampicin resistant mutants [32]. It would be interesting to subject 
Beijing genotype isolates that caused relapses after curative treatment to mutation 
analysis in fluctuation assay [32].  
A higher rate of early relapse for TB cases caused by Beijing strains may explain 
several epidemiological observations that have thus far remained elusive. First, it would 
explain why, in Vietnam, the proportion of TB cases due to Beijing infections seems to 
increase [3,10], and why the Beijing genotype infections are more common in patients 
with a history of TB treatment than in new patients [10]. For Vietnam, an increased 
relapse rate for Beijing strains seems reason to replace the 8-month regimen by the 
internationally recommended 6-month regimen. Second, increased early relapse rates 
and/or shorter incubation periods for Beijing strains would predict that these strains 
have a selective advantage under conditions of very high transmission rates. This 
selective advantage may explain the high prevalence of Beijing strain infections in 
prisons and its association with history of imprisonment in former Soviet Union 
countries, and, in combination with a higher rate of acquisition/amplification of drug 
resistance, the rapid spread of MDR-TB caused by Beijing strains in these settings [8, 
9].  
There are potential limitations to our study. Human immunodeficiency virus 
(HIV) testing was not routinely performed for all patients. However, although 
situational data on HIV prevalence were not available, the HIV infection prevalence in 
Vietnam is estimated to be 0.4% of the adult population, with substantially lower 
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prevalence in rural provinces than in major cities [33]. Furthermore, HIV infection is 
not known to affect the risk of TB relapse. A recent study from Malawi showed HIV 
infection to be associated with an increased rate of TB re-infection but not with an 
increased rate of relapse, despite the use, as in Vietnam, of an 8-month first-line 
regimen that included rifampicin for the first 2 months only [34]. We did not collect 
data on the extent of radiographic abnormalities in our study patients, and some studies 
have suggested an association between Beijing genotype infection and pretreatment 
cavitation, a known risk [4]. However, the majority of published studies on this subject 
showed no such associations, and those that did suggest increased prevalence of 
cavitation among Beijing strains had no non-Beijing control group [35], found 
differences in radiographic patterns but not specifically for cavitation [36] or found no 
association after multivariate adjustment for confounding [9]. Therefore we believe that 
extent of pulmonary cavitation is an unlikely confounder for the association between 
genotype and relapse rate in our study. The follow up time for recurrence was, on 
average, 18 months, which may be too short to pick up all cases of TB relapse, and 
indeed our analyses suggested that the observed difference in relapse rates relates to this 
early phase only. Therefore, our findings cannot be extrapolated to longer time periods 
following cure. However, it is known that the recurrence of TB is highest in the first 2 
years after treatment, after which it gradually decreases [37, 38]. 
 
Conclusions  
Our study revealed that Beijing genotype infection is a strong and independent 
risk factor for relapse after first-line treatment. This may explain, at least in part, the 
emergence of TB due to Beijing infections in Vietnam and elsewhere. 
 
Acknowledgements 
We thank all TB patients who participated in this study and the staff of the 
National Tuberculosis Program of Tien Giang province for recruiting the patients as 
well as the staff of the National Tuberculosis Program of Pham Ngoc Thach hospital for 
supervision and checking data. Dai Viet Hoa, Phan Thi Hoang Anh, and other staff in 
Pham Ngoc Thach laboratory are deeply thanked for performing culture, spoligotyping, 
RFLP and VNTR typing. We are grateful to Anne-Marie van den Brandt, Mimount 
Enaimi and Arnout Mulder, Jessica de Beer and other staff of the Tuberculosis 
Reference Laboratory at the National Institute for Public Health and the Environment 
(The Netherlands) for providing us the knowledge and practice on the molecular 
techniques used in this study. We thank Dr. Maxine Caws and her staff at the laboratory 
of the Oxford University Clinical Research Unit (Ho Chi Minh City) for their help in 
performing the VNTR typing.  
 
References 
1.  World Health Organization. Global tuberculosis control report 2011. 
WHO/HTM/TB/2011.16. Geneva: World Health Organization, 2011 
2.  Brudey K, Driscoll JR, Rigouts L, Prodinger WM, Gori A, Al-Hajoj SA, et al. 
Mycobacterium tuberculosis complex genetic diversity: mining the fourth international 
Chapter 4 
61 
spoligotyping database (SpolDB4) for classification, population genetics and 
epidemiology. BMC Microbiol 2006; 6:23. 
3.  Anh DD, Borgdorff MW, Van LN, Lan NT, van Gorkom T, Kremer K, et al. 
Mycobacterium tuberculosis Beijing genotype emerging in Vietnam. Emerg Infect Dis 
2000; 6:302-5. 
4.  Hanekom M, Gey van Pittius NC, McEvoy C, Victor TC, Van Helden PD, Warren RM. 
Mycobacterium tuberculosis Beijing genotype: a template for success. Tuberculosis 
(Edinb) 2011; 91:510-23. 
5.  Glynn JR, Kremer K, Borgdorff MW, Rodriguez MP, Soolingen DV. Beijing/W 
genotype Mycobacterium tuberculosis and drug resistance. Emerg Infect Dis 2006; 
12:736-43. 
6.  Filliol I, Driscoll JR, Van Soolingen D, Kreiswirth BN, Kremer K, Valetudie G, et al. 
Global distribution of Mycobacterium tuberculosis spoligotypes. Emerg Infect Dis 2002; 
8:1347-9. 
7.  Bifani PJ, Plikaytis BB, Kapur V, Stockbauer K, Pan X, Lutfey ML, et al. Origin and 
interstate spread of a New York City multidrug-resistant Mycobacterium tuberculosis 
clone family. JAMA 1996; 275:452-7. 
8.  Toungoussova OS, Sandven P, Mariandyshev AO, Nizovtseva NI, Bjune G, Caugant DA. 
Spread of drug-resistant Mycobacterium tuberculosis strains of the Beijing genotype in 
the Archangel Oblast, Russia. J Clin Microbiol 2002; 40:1930-7. 
9.  Drobniewski F, Balabanova Y, Nikolayevsky V, Ruddy M, Kuznetzov S, Zakharova S, et 
al. Drug-resistant tuberculosis, clinical virulence, and the dominance of the Beijing strain 
family in Russia. JAMA 2005; 293:2726-31. 
10.  Buu TN, Huyen MN, Lan NT, Quy HT, Hen NV, Zignol M, et al. The Beijing genotype 
is associated with young age and multidrug-resistant tuberculosis in rural Vietnam. Int J 
Tuberc Lung Dis 2009; 13:900-6. 
11.  Johnson R, Warren RM, van der Spuy GD, Gey van Pittius NC, Theron D, Streicher EM, 
et al. Drug-resistant tuberculosis epidemic in the Western Cape driven by a virulent 
Beijing genotype strain. Int J Tuberc Lung Dis 2010; 14:119-21. 
12.  Parwati I, Alisjahbana B, Apriani L, Soetikno RD, Ottenhoff TH, van der Zanden AG, et 
al. Mycobacterium tuberculosis Beijing genotype is an independent risk factor for 
tuberculosis treatment failure in Indonesia. J Infect Dis 2010; 201:553-7. 
13.  Feng JY, Su WJ, Tsai CC, Chang SC. Clinical impact of Mycobacterium tuberculosis W-
Beijing genotype strain infection on aged patients in Taiwan. J Clin Microbiol 2008; 
46:3127-9. 
14.  Burman WJ, Bliven EE, Cowan L, Bozeman L, Nahid P, Diem L, et al. Relapse 
associated with active disease caused by Beijing strain of Mycobacterium tuberculosis. 
Emerg Infect Dis 2009; 15:1061-7. 
15.  Nahid P, Bliven EE, Kim EY, Mac Kenzie WR, Stout JE, Diem L, et al. Influence of M. 
tuberculosis lineage variability within a clinical trial for pulmonary tuberculosis. PLoS 
One 2010; 5:e10753. 
16.  Buu TN, Huyen MN, van Soolingen D, Lan NT, Quy HT, Tiemersma EW, et al. The 
Mycobacterium tuberculosis Beijing genotype does not affect tuberculosis treatment 
failure in Vietnam. Clin Infect Dis 2010; 51:879-86. 
17.  Lan NT, Lien HT, Tung le B, Borgdorff MW, Kremer K, van Soolingen D. 
Mycobacterium tuberculosis Beijing genotype and risk for treatment failure and relapse, 
Vietnam. Emerg Infect Dis 2003; 9:1633-5. 
Chapter 4 
62 
18.  Sun YJ, Lee AS, Wong SY, Paton NI. Association of Mycobacterium tuberculosis 
Beijing genotype with tuberculosis relapse in Singapore. Epidemiol Infect 2006; 
134:329-32. 
19.  Jindani A, Nunn AJ, Enarson DA. Two 8-month regimens of chemotherapy for treatment 
of newly diagnosed pulmonary tuberculosis: international multicentre randomised trial. 
Lancet 2004; 364:1244-51. 
20.  International Union Against Tuberculosis and Lung Disease. Technical guide-sputum 
examination for tuberculosis direct microscopy in low-income countries. 5
th
 ed. Paris: 
The Union, 2000. 
21.  World Health Organization. Guideline for surveillance of drug resistance in tuberculosis. 
Geneva: World Health Organization, 2003. 
22.  van Soolingen D, de Haas PEW, Kremer K. Restriction fragment length polymorphism 
typing of mycobacteria. In: T. Parish, Stoker NG, eds. In: Mycobacterium tuberculosis 
protocols. Totowa, New Jersey, USA: Humana Press Inc., 2001:165-203. 
23.  Kamerbeek J, Schouls L, Kolk A, van Agterveld M, van Soolingen D, Kuijper S, et al. 
Simultaneous detection and strain differentiation of Mycobacterium tuberculosis for 
diagnosis and epidemiology. J Clin Microbiol 1997; 35:907-14. 
24.  Supply P, Allix C, Lesjean S, Cardoso-Oelemann M, Rusch-Gerdes S, Willery E, et al. 
Proposal for standardization of optimized mycobacterial interspersed repetitive unit-
variable-number tandem repeat typing of Mycobacterium tuberculosis. J Clin Microbiol 
2006; 44:4498-510. 
25.  Kremer K, Glynn JR, Lillebaek T, Niemann S, Kurepina NE, Kreiswirth BN, et al. 
Definition of the Beijing/W lineage of Mycobacterium tuberculosis on the basis of 
genetic markers. J Clin Microbiol 2004; 42:4040-9. 
26.  de Jong BC, Hill PC, Aiken A, Awine T, Antonio M, Adetifa IM, et al. Progression to 
active tuberculosis, but not transmission, varies by Mycobacterium tuberculosis lineage 
in The Gambia. J Infect Dis 2008; 198:1037-43. 
27.  Dormans J, Burger M, Aguilar D, Hernandez-Pando R, Kremer K, Roholl P, et al. 
Correlation of virulence, lung pathology, bacterial load and delayed type hypersensitivity 
responses after infection with different Mycobacterium tuberculosis genotypes in a 
BALB/c mouse model. Clin Exp Immunol 2004; 137:460-8. 
28.  Lopez B, Aguilar D, Orozco H, Burger M, Espitia C, Ritacco V, et al. A marked 
difference in pathogenesis and immune response induced by different Mycobacterium 
tuberculosis genotypes. Clin Exp Immunol 2003; 133:30-7. 
29.  Wu S, Barnes PF, Samten B, Pang X, Rodrigue S, Ghanny S, et al. Activation of the eis 
gene in a W-Beijing strain of Mycobacterium tuberculosis correlates with increased SigA 
levels and enhanced intracellular growth. Microbiology 2009; 155:1272-81. 
30.  Ferro BE, Nieto LM, Rozo JC, Forero L, van Soolingen D. Multidrug-resistant 
Mycobacterium tuberculosis, Southwestern Colombia. Emerg Infect Dis 2011; 17:1259-
62. 
31.  Makinen J, MarJAMAki M, Haanpera-Heikkinen M, Marttila H, Endourova LB, 
Presnova SE, et al. Extremely high prevalence of multidrug resistant tuberculosis in 
Murmansk, Russia: a population-based study. Eur J Clin Microbiol Infect Dis 2011; 
30:1119-26. 
32. de Steenwinkel JE, Ten Kate MT, de Knegt GJ, Kremer K, Aarnoutse RE, Boeree MJ, et al. 
Drug Susceptibility of Mycobacterium tuberculosis Beijing Genotype and Association 
with MDR-TB. Emerg Infect Dis 2012; 18:660-3. 
Chapter 4 
63 
33. UNAIDS Country factsheet Vietnam. Available at: http://www.unaids.org/en/ 
regionscountries/countries/Vietnam/. Accessed 4 October 2012 
34.  Crampin AC, Mwaungulu JN, Mwaungulu FD, Mwafulirwa DT, Munthali K, Floyd S, et 
al. Recurrent TB: relapse or reinfection? The effect of HIV in a general population cohort 
in Malawi. AIDS 2010; 24:417-26. 
35.  van Rie A, Warren RM, Beyers N, Gie RP, Classen CN, Richardson M, et al. 
Transmission of a multidrug-resistant Mycobacterium tuberculosis strain resembling 
"strain W" among noninstitutionalized, human immunodeficiency virus-seronegative 
patients. J Infect Dis 1999; 180:1608-15. 
36.  Feng JY, Su WJ, Liu LY, Tsai CC, Chang SC. Radiological presentation of pulmonary 
tuberculosis infected by the W-Beijing Mycobacterium tuberculosis strain. Int J Tuberc 
Lung Dis 2009; 13:1387-92. 
37.  Migliori GB, Espinal M, Danilova ID, Punga VV, Grzemska M, Raviglione MC. 
Frequency of recurrence among MDR-tB cases 'successfully' treated with standardised 
short-course chemotherapy. Int J Tuberc Lung Dis 2002; 6:858-64. 
38. Fox W, Ellard GA, Mitchison DA. Studies on the treatment of tuberculosis undertaken by 
the British Medical Research Council tuberculosis units, 1946-1986, with relevant 
subsequent publications. Int J Tuberc Lung Dis 1999; 3:S231-79. 
  
Chapter 4 
64 
 
 
  
CHAPTER 5 
The Mycobacterium tuberculosis Beijing genotype does not affect 
tuberculosis treatment failure in Vietnam 
 
Tran N. Buu
1
, Mai N. T. Huyen
1
, Dick van Soolingen
2,3
, Nguyen T. N. Lan
1
, Hoang T. 
Quy
1
, Edine W. Tiemersma
4
, Martien W. Borgdorff
5
, and Frank G. J. Cobelens
5
 
 
1. Pham Ngoc Thach Tuberculosis and Lung Disease Hospital, Ho Chi Minh City, 
Vietnam. 
2. Departments of Pulmonary Diseases and Medical Microbiology, Radboud 
University Nijmegen, Nijmegen, the Netherlands. 
3. Tuberculosis Reference Laboratory, National Institute for Public Health and the 
Environment (RIVM), Bilthoven, the Netherlands. 
4. KNCV Tuberculosis Foundation, The Hague, The Netherlands. 
5. Academic Medical Center, Amsterdam, the Netherlands. 
 
Clinical Infectious Diseases 2010, 51(8):879-886 
Chapter 5 
66 
Abstract 
 
Background 
Studies have suggested that the Mycobacterium tuberculosis Beijing genotype causes 
more severe clinical disease and higher treatment failure rates with standard regimens, 
possibly in association with an increased risk of acquiring drug resistance. We studied 
the effect of genotype on treatment failure in a rural area in Vietnam where multidrug 
resistance is strongly associated with the Beijing genotype.  
 
Methods 
In a population-based prospective cohort study, patients with smear-positive 
tuberculosis were tested before and after treatment by spoligotyping and drug 
susceptibility analysis. Reinfections were excluded by DNA fingerprinting. The 
outcome was treatment failure based on culture.  
 
Results 
Of 1106 patients eligible for analysis, 33 experienced treatment failure (3.0%; 95% 
confidence interval [CI], 2.1%–4.1%). The proportion of failure was 5.3% (95% CI, 
0.3%–7.9%) among 380 patients with Beijing genotype infections. Multidrug-resistant 
tuberculosis strongly predicted failure (odds ratio [OR], 114; 95% CI, 30–430). After 
adjusting for multidrug-resistant tuberculosis, treatment failure was not associated with 
the Beijing genotype (adjusted OR, 0.7; 95% CI, 0.3–2.0). Amplification of drug 
resistance occurred in 3 patients (0.3%; 95% CI, 0.1%–0.7%) and was associated with 
multidrug resistance at baseline (P = .004) but not with the Beijing genotype. No 
multidrug resistance was created.  
 
Conclusion  
The Beijing genotype was not associated with treatment failure in Vietnam; apparent 
associations were explained by the strong association of this genotype with multidrug 
resistance. Amplification of resistance in this patient population was rare.  
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Introduction 
 Despite the DOTS (directly observed treatment, short course) strategy, global 
tuberculosis control still faces challenges [1]. One of increasing importance is resistance 
of Mycobacterium tuberculosis to antituberculosis drugs. Drug resistance, especially 
multidrug-resistant (MDR) tuberculosis (ie, resistance to at least isoniazid and 
rifampin), has been a leading cause of failure with the standard first-line treatment 
regimens used in most high-burden countries [2–4]. Patients with MDR tuberculosis 
can be cured with second-line drugs but at much higher cost and with much more severe 
adverse effects [5–7]. In 2008, the World Health Organization (WHO) estimated that 
3.6% of all incident tuberculosis cases globally are MDR, with proportions of MDR 
tuberculosis ranging from 0% to 28% among new and from 0% to 61.6% among 
previously treated patients [8].  
 A related threat to tuberculosis control may be the Beijing genotype. This 
genotype has been associated with young age [9–11], altered response to treatment [12], 
and drug resistance [13–16], suggesting recent emergence and increased bacterial 
fitness. In Vietnam, the Beijing genotype is associated with MDR tuberculosis and a 
history of tuberculosis treatment [17], suggesting that Beijing strain infections are more 
difficult to treat, leading to higher rates of treatment failure. This may be mediated by 
higher rates of resistance amplification, as suggested by a study from Uzbekistan [18], 
but it is unclear whether such an association exists irrespective of the pretreatment drug 
resistance pattern.  
 We conducted a prospective population-based cohort study to assess whether 
failure of standard first-line tuberculosis treatment is associated with genotype and 
whether this association is modified by drug resistance. A secondary objective was to 
assess drug resistance acquisition and amplification rates, as well as their association 
with genotype.  
 
Methods 
Study population and design 
 The study area consisted of 3 adjacent rural districts in Tien Giang Province, 
which is situated in the Mekong River delta in southern Vietnam at a 70-km distance 
from Ho Chi Minh City. The characteristics of the study site have been described 
elsewhere [17].  
 The design was a prospective cohort nested in this population- based study that 
collected data on all smear-positive patients given diagnoses of tuberculosis in this area 
between 2003 and 2007. Eligible for inclusion were all patients aged ≥15 years who 
were resident in the study area and registered for treatment of smear-positive pulmonary 
tuberculosis between 1 July 2005 and 30 June 2007 at the participating district 
tuberculosis units or at the provincial tuberculosis hospital. Eligible patients were 
included after provision of written informed consent. Excluded were patients receiving 
treatment for the current tuberculosis episode for >2 weeks before registration.  
 Diagnosis of smear-positive tuberculosis was done by microscopic examination of 
at least 2 Ziehl-Neelsen-stained sputum smears and followed international definitions 
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[19, 20]. All included patients were requested to submit 2 sputumspecimens that were 
sent for culture.  
 We performed sputum cultures for all enrolled patients who completed treatment 
(ie, after 8 months). Since in DOTS treatment these patients are considered to have 
experienced failure and stop treatment, we also performed cultures for new patients who 
had a positive sputum smear result at 5 months. Patients submitted 2 sputum samples on 
2 consecutive days, including at least 1 morning sample, after receiving instruction on 
effective expectoration.  
 Tuberculosis was treated in accordance with the guidelines of the Vietnam 
National Tuberculosis Control Program [21]. Patients not previously treated for 
tuberculosis (new patients) were treated with 2 months of daily streptomycin (S), 
isoniazid (H), rifampin (R), and pyrazinamid (Z; intensive phase), followed by daily 
ethambutol (E) and isoniazid for 6 months (continuation phase; category 1 regimen). 
Previously treated patients were given all 5 drugs (SHRZE) daily for 2 months, then 4 
drugs (HRZE) for 1 more month followed by RHE 3 days per week for 5 months 
(category 2 regimen). All doses were given under direct observation as long as patients 
were given rifampin, irrespective of treatment phase or regimen.  
 Scientific and ethical clearance was obtained from the Ethical Health Committee 
of the Ho Chi Minh City Council. Pretreatment drug resistance testing was done later 
and was not used to guide treatment decisions. All patients, including those identified 
with MDR infections, received treatment following the guidelines of the National 
Tuberculosis Control Program of Vietnam.  
 Based on an expected 6.5% culture-based failure rate and a prevalence of Beijing 
genotype infections in this population of 35% [4, 17], we calculated that enrollment of 
1023 patients would be sufficient to detect a 2-fold increased failure rate among Beijing 
genotype infections at 80% power.  
 
Laboratory methods 
 Sputum samples were kept refrigerated and transported to the Tuberculosis 
Reference Laboratory in Ho Chi Minh City within 7 days. At the laboratory, 1 smear 
examination (Ziehl-Neelsen staining) was performed for each specimen. Sputum 
specimens were subsequently decontaminated and liquefied with 1% N-acetyl-L-
cysteine-2% NaOH, inoculated on modified Ogawa medium, and incubated at 37°C 
[22]. Cultures with no growth after 8 weeks were reported as negative. M. tuberculosis 
was identified by the niacin and nitrate tests. Drug susceptibility testing was done by the 
proportion method, in accordance with WHO/International Union Against Tuberculosis 
and Lung Disease guidelines. Criteria for drug resistance were ≥1% colony growth at 
28 or 40 days compared with that in the drug-free control medium at the following drug 
concentrations: isoniazid, 0.2 µg/mL; rifampin, 40 µg/mL; streptomycin, 4 µg/mL; and 
ethambutol, 2 µg/mL [22]. Standard operational procedures and checks on 
consecutively identified strains by resistance pattern and genotype were used to prevent 
and detect cross-contamination.M. tuberculosis isolates were genotyped by 
spoligotyping using the standardized method [23] and were fingerprinted by IS6110-
based restriction fragment-length polymorphism (RFLP) typing and 15-loci variable 
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number of tandem repeat (VNTR) typing, to exclude reinfection and laboratory cross-
contamination [24–27].  
 
Definitions 
 Previously treated patients were defined as having been treated with 
antituberculosis drugs for ≥1 month; otherwise, participants were deemed to be new 
patients. Treatment failure occurred if a patient had (1) a positive sputum smear and/or 
culture result after 5 months or at the end of the 8th month of category 1 treatment or 
(2) a positive sputum smear and/or culture result at the end of the 8th month of category 
2 treatment [19].  
 The Beijing genotype was defined by spoligotyping as any isolate without direct-
repeat spacers 1–34 and the presence of ≥3 of the spacers 35–43 [25]. Other genotypes 
were defined as described by Brudey et al, including the Vietnam genotype (EAI-
VNM) that belongs to the East African Indian genotype family of M. tuberculosis and 
that is the most frequent genotype in this study site [17, 26]. Treatment adherence was 
ascertained from the routine treatment cards kept at the district tuberculosis unit. 
Adherence to treatment was defined as regular if a patient had taken antituberculosis 
drugs regularly both in the intensive and continuation phase. Adherence was defined as 
irregular for those patients who had not taken antituberculosis drugs regularly. Positive 
culture results for follow-up samples were considered due to reinfection if the 
pretreatment and follow-up isolate had different spoligotypes or if they had identical 
spoligotypes but either different RFLP patterns or VNTR types that differed for ≥2 loci 
[27].  
 
Data management 
 Data were double-entered in EpiInfo software, version 6.04 (Centers for Disease 
Control and Prevention); discrepancies were corrected on the basis of the raw data. 
Analyses were performed in Stata software, version 8 (StataCorp). Patients with 
negative culture results or cultures that grew nontuberculosis mycobacteria, as well as 
cases of reinfection and changes of drug regimen during treatment, were excluded from 
the analyses of failure and resistance acquisition and amplification. In these analyses, 
treatment failure was based on the culture results only.  
 F r significance testing  f c mparis ns  f categ rica  variab es, either the χ2 test 
or the 2-sided Fisher exact test was used as appropriate. Multivariate analyses were 
done by logistic regression modeling. P values for contributing to multivariate models, 
inc uding interacti n, were based  n the  ike ih  d rati  χ2 test; P values for 
contributing to models of individual strata of variables were based on the Wald test. All 
tests were done at the 5% significance level.  
 
Results 
 During the study period, 1364 patients with smear-positive pulmonary 
tuberculosis were registered for treatment, and 1331 enrolled in the study (Figure 1). 
Pretreatment culture results were available for 1295 patients; 1213 of the cultures grew 
M. tuberculosis and were subjected to drug susceptibility testing and molecular typing. 
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Of the 1213 patients who were finally included in the cohort analysis, we excluded 95, 
because of death (49), loss of data (32), defaulting (10) and transferring out (4); 
therefore, culture results were available for 1118 (92.2%). Of the 1118 remaining 
patients, 41 had positive follow- up culture results (3.7%). Of these, 8 patients were 
classified as having reinfections (including 5 infected with Beijing genotype strains) 
and 4 had changed treatment regimen; these patients were also excluded from the final 
analysis. No case of cross-contamination was found. 
 
Sm(+) P. TB registered: 1364
Inclusion criteria not met: 33
Enrolled: 1331
Missing data: 33
Sputum submitted for culture: 1298
Other technical errors: 3
Results available: 1295
Culture positive: 1233
Culture negative: 62
NTM: 20
M. tuberculosis genotype: 1213
Missing data: 95
- Defaulting: 10
- Transferring out: 4
- Lost data: 32
- Death: 49
Available for analysis: 1106
Exclusion: 12
- Regimen changed: 4
- Reinfection: 8
 
Figure 1. Study enrollment and inclusion and exclusion of patients. NTM, 
nontuberculosis mycobacteria; Sm (+) P.TB, smear-positive pulmonary tuberculosis. 
 
 
Of the 1106 patients eligible for analysis, 1010 were new (91.3%) and 96 were 
previously treated. The prevalence of Beijing genotype infections was 34.4% 
(380/1106) overall, 31.8% (321/1010) among new patients, and 61.5% (59/96) among 
previously treated patients (P < .001). Treatment failure was recorded in 23 patients 
(2.1%; 95% confidence interval [CI], 1.4%–3.0%) on the basis of direct smear 
microscopy, in 33 patients (3.0%; 95% CI, 2.1%–4.1%) on the basis of culture, and in 
39 patients (3.5%; 95% CI, 2.6%–4.7%) on the basis of either. MDR tuberculosis was 
strongly associated with the Beijing genotype: 17 (5.3%) of 321 versus 5 (0.7%) of 689 
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among new cases (risk ratio, 7.5; P < .001) and 17 (28.8%) of 59 versus 3 (8.1%) of 37 
among previously treated cases (risk ratio, 3.6; P = .019).  
In univariate analysis, treatment failure was significantly associated with infection 
with the Beijing genotype (odds ratio [OR] vs non-Beijing, 2.9). Failure was also 
associated with MDR (OR vs pansusceptible to all first-line antituberculosis drugs 
tested, 106), with drug resistance other than MDR (OR vs pansusceptible to all first-line 
antituberculosis drugs tested, 5.1), and with history of tuberculosis treatment (OR vs 
new patients, 6.0) (Table 1). 
After adjustment for drug resistance, treatment history, treatment adherence, and 
demographic factors (Table 1), treatment failure remained associated with MDR 
(adjusted OR, 114; 95% CI, 30–431) but did not remain associated with the Beijing 
genotype (adjusted OR, 0.71; 95% CI, 0.3–2.0) or with a history of tuberculosis 
treatment (adjusted OR, 1.7; 95% CI, 0.6–5.4) (Table 1). We found no interaction 
between genotype and other variables that affected failure.  
To investigate the apparent confounding effect of MDR on the association 
between failure and genotype, we compared the various combinations of genotype and 
MDR, taking non-MDR/ non-Beijing genotype infections as the reference stratum 
(Table 2). Among new patients, the odds of failure for non-MDR/ Beijing genotype 
infections was not increased (OR, 0.8; 95% CI, 0.2–3.0), whereas it was strongly and 
similarly increased for MDR/non-Beijing (OR, 50.0; 95% CI, 5.1–447) and for MDR/ 
Beijing genotype infections (OR, 52.5; 95% CI, 14.2–198). Among previously treated 
patients, the corresponding ORs were 0 (95% CI, 0.0–14.3), 16.5 (95% CI, 0.0–1122), 
and 47.1 (95% CI, 4.7–1161). 
Since death during treatment may be a consequence of treatment failure, we 
conducted a secondary analysis taking failure and death as the combined outcome. The 
association with the Beijing genotype remained unchanged (adjusted OR, 0.8; 95% CI, 
0.6 –1.5). Because the proportion of Beijing genotype infection among reinfected 
patients was high, we also reincluded all reinfected cases. This slightly increased the 
relative risk of failure for Beijing infections, but it remained small and non-significant 
(adjusted OR, 1.26; 95% CI, 0.6 – 2.9).  
Amplification of tuberculosis drug resistance was recorded in 3 patients (0.3%; 
95% CI, 0.1% – 0.7%), including one of 1064 with initially non-MDR strains (0.1%) 
and 2 of 42 with initially MDR strains (4.8%, P=0.004). The amplification rates among 
new and previous treated patients were 0.2% and 1.0%, respectively (Table 3), and were 
similar between patients infected with the Beijing genotype and patients infected with 
other strains (risk ratio 0.95; P>0.99). 
Among new patients, 1 case of acquired drug resistance occurred from an initially 
pansusceptible strain to monoresistance to isoniazid. One additional non-Beijing strain 
developed resistance to all 4 drugs (SHRE) from initial MDR (RHE). Of 12 cases of 
failure during category 2 treatment, 1 strain (Beijing genotype) amplified resistance to 
all 4 drugs (RHES) from initial resistance to RHS. 
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Table 1. Univariate and multivariate associations with treatment failure versus cure 
among patients with smear-positive pulmonary tuberculosis in rural Vietnam. 
Category, parameter All 
Failure 
n (% )
a
 
Crude 
OR
b
 
Adjusted OR 
c 
(95% CI) 
P 
d
 
All 1106  33  (3.0%)    
District     0.028 
Chau Thanh 338  9  (2.7%) 1 1  
Cai Lay 403  5  (1.2%) 0.5 0.1 (0.1 – 1.5)  
Cai Be 365  19  (5.2%) 2.0 2.0 (0.8 – 5.1)  
Age     0.724 
<35 years 255  15  (5.9%) 2.7 1.7 (0.4 – 7.1)  
35 – 64 years 589  12  (2.0%) 0.9 1.5 (0.5 – 5.0)  
≥65 years 262  6  (2.3%) 1 1  
Sex     0.814 
Male 843  23  (2.7%) 1 1  
Female 263  10  (3.8%) 1.4 0.89 (0.3 – 2.4)  
Marital status     0.500 
Married 843  22  (2.6%) 1 1  
Widowed/Divorced 108  2  (1.9%) 0.7 0.95 (0.2-5.0)  
Single 155  9  (5.8%) 2.3 2.1 (0.6 – 7.0)  
Genotype     0.509 
Non-Beijing 726  13  (1.8%) 1 1  
Beijing 380  20  (5.3%) 3.1 0.7 (0.3 – 2.0)  
History of tuberculosis     0.348 
New patients 1010  21  (2.1%) 1 1  
Previously treated patients 96  12  (12.5%) 6.0 1.7 (0.6 – 5.4)  
Drug susceptibity testing     <0.001 
Pansusceptible 
e
 944  8  (0.9%) 1 1  
Drug resistant, not MDR 120  5  (4.2%) 5.1 2.6 (0.8 – 8.1)  
Multidrug resistant 42  20  (47.6%) 106.4 114 (30 – 431)  
Treatment adherence     0.801 
Regular 931  29  (3.1%) 1 1  
Irregular 175  4  (2.3%) 0.7 1.2 (0.4 – 4.0)  
Note. CI, confidence interval; OR, odds ratio; MDR: multidrug resistant 
a
 Row percentages. 
b 
Unadjusted ORs. 
c 
ORs adjusted by logistic regression modelling for all other variables in the model. 
d 
P value for multivariable association. 
e
 With all first line drugs tested 
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Table 2. Association of multidrug-resistant (MDR) tuberculosis status and genotype 
with treatment failure among patients with smear-positive pulmonary tuberculosis. 
MDR tuberculosis status 
and genotype 
All 
Failure 
n (%) 
OR(95% CI) P  
All smear positive 1106  33 (3.0)   
Non MDR/non-Beijing 718  10 (1.4) 1  
Non MDR/Beijing 346  3  (0.9) 0.6 (0.1 – 2.5) >0.05a 
MDR/non-Beijing 8  3  (37.5) 42.5 (6.9 – 250.7) <0.05a 
MDR/Beijing 34  17  (50.0) 70.8 (26.0 – 197.6) <0.001 
New patients 1010  21  (2.1)   
Non MDR/non-Beijing 684  9  (1.3) 1  
Non MDR/Beijing 304  3  (10) 0.8 (0.2 – 3.0) >0.05a 
MDR/non-Beijing 5  2  (40.0) 50.0 (5.1 – 446.7) <0.05a 
MDR/Beijing 17  7  (41.2) 52.5 (14.2 – 197.8) <0.001 
Previously treated 
patients 
96  12  (12.5)   
Non MDR/non-Beijing 34  1  (2.9) 1  
Non MDR/Beijing 42  0  (0.0) 0.0 (0.0 – 14.3) >0.05a 
MDR/non-Beijing 3  1  (33.3) 16.5 (0.0 – 1122.8) >0.05a 
MDR/Beijing 17  10  (58.8) 47.1 (4.7 – 1161.1) <0.001a 
Note. MDR, multidrug resistant; CI, confidence interval; OR, odds ratio. 
a
 Fisher exact test. 
 
 
 
 
 
 
Discussion 
In this study, treatment failure was strongly associated with MDR, whereas 
genotype, especially the Beijing genotype, was not an independent predictor of failure. 
Because the prevalence of drug resistance and MDR was considerably higher among 
the Beijing genotype than among other genotypes, drug resistance and MDR 
confounded the association between genotype and treatment failure: the univariate 
association between Beijing genotype and treatment failure completely disappeared 
after adjustment for differences in pretreatment drug resistance and other patient 
characteristics. Moreover, we found no interactions—that is, the effect of genotype on 
treatment failure did not vary by drug resistance pattern or treatment history. Therefore, 
the probability of cure or treatment failure is equal among patients infected with strains 
with the same pretreatment pattern of tuberculosis drug resistance irrespective of 
whether the strain is of the Beijing genotype. 
 
  
Table 3. Drug resistance pattern before treatment and at failure, confirmed by sputum culture 
  No. Drug resistance pattern in patients with treatment failure 
Pretreatment drug 
resistance pattern 
Total 
no. 
with 
failure 
Pan-
susceptible 
Mono-
resistance to H 
Mono-
resistance to S 
Resistance 
to HS 
Resistance 
to HES 
Resistance 
to RHS 
Resistance 
to HSRE 
New patients 1010 21        
 Pansusceptible
a 
705 6 5 1
b 
0 0 0 0 0 
 Monoresistance to H 51 0 0 0 0 0 0 0 0 
 Monoresistance to S 127 1 0 0 1 0 0 0 0 
 Monoresistance to R 2 0 0 0 0 0 0 0 0 
 Resistance to HS 100 4 0 0 0 4 0 0 0 
 Resistance to HES 3 1 0 0 0 0 1 0 0 
 Resistance to RHE 2 1 0 0 0 0 0 0 1
b
 
 Resistance to RHS 12 4 0 0 0 0 0 4 0 
 Resistance to HSRE 8 4 0 0 0 0 0 0 4 
Previously treated 
patients 96 12        
 Pansusceptible
a
 33 0 0 0 0 0 0 0 0 
 Monoresistance to H 14 1 0 1 0 0 0 0 0 
 Monoresistance to S 12 0 0 0 0 0 0 0 0 
 Resistance to HS 15 0 0 0 0 0 0 0 0 
 Resistance to HES 2 0 0 0 0 0 0 0 0 
 Resistance to RH 1 0 0 0 0 0 0 0 0 
 Resistance to RHS 10 5 0 0 0 0 0 4 1
b 
 Resistance to HSRE 9 6 0 0 0 0 0 0 6 
Note. E, ethambutol; H, isoniazid; R, rifampin; S, streptomycin. 
a 
With all first-line drugs tested. 
b
 Resistance amplification. 
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Our findings are similar to those of a smaller study conducted in Taiwan [28] but 
are different from those of a study conducted in Ho Chi Minh City, Vietnam [29], 
possibly because that study had too few patients to distinguish the effect of genotype on 
failure from that on relapse; there might still be a difference in relapse rates between 
different genotypes [30]. Indeed, if Beijing genotype strains were more likely to 
manifest a slower response to treatment, the relapse rate could be more affected than the 
failure rate. 
Our findings also differ from those of a recent hospital-based cohort study 
conducted in Indonesia that, after adjustment for drug resistance, observed a 1.9 times 
higher failure rate (P = .04) for infections with the Beijing genotype comparedwith 
other genotypes [31]. That study had resistance data for only 59% of enrolled patients 
and did not exclude reinfections, which may have lead to incomplete adjustment for 
confounding. 
Alternatively, the differences between these study results may reflect the low 
failure rates in our study (3.0%) compared with those in Ho Chi Minh City (4.3% on the 
basis of smear examination only) [29] and Indonesia (8.8%) [31]. This suggests a high 
level of treatment adherence in this rural site, possibly limiting the risk of failure as well 
as of resistance amplification. 
Indeed, acquisition or amplification of tuberculosis drug resistance during 
treatment (0.3% overall and none to MDR) was less than expected. In Uzbekistan, 
amplification occurred in 1.2% of patients with initially susceptible or monoresistant 
strains but in 17% of patients with initially polyresistant strains [18]. That study also 
suggested a higher risk of amplification among Beijing strains than among non-Beijing 
strains, whereas we did not observe such difference. The differences between that study 
and ours could relate to differences in treatment regimens used for new patients. 
Whereas in our study the continuation phase consisted of daily isoniazid and 
ethambutol for 6 months, in Uzbekistan this was 4 months of rifampin and isoniazid 
(with ethambutol added in the case of baseline rifampin or isoniazid resistance), and 
dosing was thrice weekly. This long period of rifampin in combination with the 
intermittent dosing could enhance amplification of resistance to rifampin, in particular 
if combined resistance to isoniazid and ethambutol or streptomycin is already present 
[32]. The study from Ho Chi Minh City also reported higher amplification rates: 65% of 
patients who experienced treatment failure without MDR tuberculosis at baseline 
underwent amplification to MDR tuberculosis [33]. Although the same treatment 
regimen was used as in our study, poorer treatment adherence in Ho Chi Minh City 
relative to that in the rural Mekong River delta could be a possible explanation [9, 34]. 
In addition, our study was underpowered to detect an effect of genotype on 
amplification of drug resistance. 
Taken together, these observations suggest that the Beijing genotype could be a 
risk factor for resistance amplification and treatment failure, but only if adherence to 
tuberculosis treatment is poor or treatment is given intermittently. 
In one-fifth of the patients with treatment failure, the posttreatment strain differed 
from the strain isolated before treatment, suggesting that reinfection is common in 
Vietnam as it is in other areas in which the incidence of tuberculosis is high [35, 36]. 
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This high rate of reinfection may, however, also reflect the presence of multiple 
infections by different strains before start of treatment, which has also been observed in 
other highincidence settings [37]. An infecting strain that remained undetected by our 
typing methods because of low numbers of bacilli in the pretreatment sputum specimen 
may have been detected as the posttreatment strain, in particular when it was drug 
resistant (Table 3) [38]. In such a case there would be treatment failure rather than 
reinfection, and we cannot exclude that this occurred. However, given that the study 
question was whether genotype affects treatment outcome irrespective of pretreatment 
drug resistance and that half of the patients with treatment failure were infected with 
pansusceptible strains, this is unlikely to have affected our conclusions.  
Our study had some other limitations. First, the failure rate in our study was lower 
than assumed, thus limiting the statistical power for finding an increased failure rate 
with Beijing genotype infections if it existed. Nonetheless, the adjusted relative risk of 
failure with Beijing genotype infections was in fact <1, and the probability of observing 
our data if the true relative risk was 1.9 (as in the Indonesian study) was <2.5%. 
Second, we did not follow-up for relapse after treatment. Third, our data are 
representative only of patients with smear-positive pulmonary tuberculosis, which 
limits the generalizability of our findings to smear-negative and extrapulmonary 
tuberculosis. Next, we did not test for human immunodeficiency virus (HIV) infection, 
while a positive association between HIV infection and the Beijing genotype has been 
suggested for tuberculous meningitis [38]. However, HIV infection is not known to 
affect treatment failure rates for pulmonary tuberculosis [39], making it unlikely that 
HIV infection would have confounded the association between genotype and failure. 
Finally, sputum collection, transport conditions, and potential overdecontamination 
(given that culture contamination was not observed) could have affected the sensitivity 
of culture at the end of treatment, resulting in underestimation the failure rate. Because 
this is unlikely to have been different between genotypes, it would have lead to reduced 
statistical power but not to bias of the relative risk estimate [40] – that is, it would not 
have affected our conclusions. 
In conclusion, failure of tuberculosis treatment with a standard first-line regimen 
was strongly associated with multidrug resistance but not with the Beijing genotype. 
Neither was the Beijing genotype associated with amplification of tuberculosis drug 
resistance. Our study suggests that the Beijing genotype does not affect tuberculosis 
treatment outcomes in settings with good treatment adherence and low prevalence of 
drug resistance and MDR. 
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Abstract 
 
Background 
Isoniazid resistance is highly prevalent in Vietnam. We investigated the molecular and 
epidemiological characteristics and the association with first-line treatment outcomes of 
the main isoniazid resistance mutations in Mycobacterium tuberculosis in codon 315 of 
the katG and in the promoter region of the inhA gene. 
 
Methods 
Mycobacterium tuberculosis strains with phenotypic resistance to isoniazid from 
consecutively diagnosed smear-positive tuberculosis patients in rural Vietnam were 
subjected to Genotype® MTBDRplus testing to identify katG and inhA mutations. 
Treatment failure and relapse were determined by sputum culture. 
 
Results 
In total 227of 251 isoniazid-resistant strains (90.4%) had detectable mutations: 75.3% 
in the katG315 codon and 28.2% in the inhA promoter region. KatG315 mutations were 
significantly associated with pre-treatment resistance to streptomycin, rifampicin and 
ethambutol, but not with the Beijing genotype, and predicted both unfavorable 
treatment outcome (treatment failure or death) and relapse inhA promoter region 
mutations were only associated with resistance to streptomycin and relapse. 
 
Conclusions 
In tuberculosis patients, M. tuberculosis katG315 mutations but not inhA mutations are 
associated with unfavorable treatment outcome. InhA mutations do, however, increase 
the risk of relapse, at least with treatment regimens that contain only isoniazid and 
ethambutol in the continuation phase.  
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Introduction 
With 8.8 million cases notified and 1.4 million deaths in 2010, tuberculosis (TB) 
remains a major burden to global health [1]. In addition to rifampicin, isoniazid is an 
important drug in first-line anti-tuberculosis treatment [2]. Mycobacterium tuberculosis 
(MTB) strains resistant to at least both rifampicin and isoniazid are referred to as multi-
drug resistant (MDR). Both multidrug resistance and resistance to isoniazid without 
concomitant rifampicin resistance are associated with poor response to first-line 
treatment [3,4]. Whereas rifampicin resistance is usually encoded in a part of the rpoB 
gene, the mechanism of resistance to isoniazid is more complex with mutations 
conferring resistance in several genomic loci, such as katG, inhA, ahpC, and potentially, 
ndh [5-8]. Mutations in codon 315 of the katG gene (katG315) and in the promoter 
region of the inhA gene are by far most common. KatG315 mutations occur in 50-95% 
of isoniazid-resistant strains [6, 9, 10] whereas 20-42% of such strains have mutations 
in the promoter region of the inhA gene [6, 10, 11], depending on the geographic region 
studied.  
Isoniazid is activated by the enzyme catalase peroxidase, encoded by katG [12]. 
KatG mutations lead to high- eve  is niazid resistance (t  ≥1.0 µg/m  in 7H10 agar) 
[13]. The inhA gene encodes an enoyl acyl carrier protein reductase involved in fatty 
acid synthesis. These fatty acids are the target of the active derivative of isoniazid. InhA 
mutations usually lead to low-level isoniazid resistance (resistant to 0.2 µg /ml in 7H10 
agar) [13, 14]. 
KatG315 mutations have been shown to be associated with MDR-TB and TB 
transmission [15, 16]. Such mutations were more frequent among patients infected with 
Beijing genotype strains [17, 18], which are common in East Asia including Vietnam 
[19, 20], and related to drug resistance [20, 21], as well as to relapse in various areas 
[22, 23]. These differences in isoniazid resistance-conferring mutations may also be 
related to other characteristics of MTB strains, as well as to treatment outcomes. There 
are, however, very few studies on the mutations underlying resistance to anti-TB drugs 
and treatment outcome. We therefore studied the epidemiology of katG and inhA 
mutations in MTB isolates and the clinical characteristics of the respective patients in 
Vietnam, where the prevalence of smear-positive TB was 197/100,000 in 2006-2007 
[24] and resistance to isoniazid is common (16 to 25% in new patients) [25]. For this we 
assessed MTB genotype and TB treatment outcomes in association with katG and inhA 
mutations in a prospective, population-based study.  
 
Materials and methods 
Study subjects  
The study area consisted of three adjacent rural districts in Tiengiang Province in 
the Mekong River Delta in Southern Vietnam. Details of the study have been described 
elsewhere [26].  
From 1 July 2005 to 30 June 2007, a   patients aged ≥15 years, resident in the 
study area and registered for treatment of smear-positive pulmonary TB, were eligible 
for inclusion after provision of written informed consent. Excluded were patients who 
received treatment for more than two weeks before registration. Ethical clearance for 
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the study was obtained from the ethical health committee of the Ho Chi Minh City 
Council.  
According to the guidelines of the Vietnam National TB Control Program [27] 
patients with no history of treatment with anti-TB drugs for >1 month (i.e. new TB 
cases) were treated with 2 months of daily streptomycin (S), isoniazid (H), rifampicin 
(R) and pyrazinamide (Z), followed by daily ethambutol (E) and isoniazid for 6 months 
(2SHRZ/6EH). Previously treated patients were given all five drugs (SHRZE) daily for 
2 months, then four drugs (HRZE) for one more month, followed by RHE 3 days per 
week for 5 months. All doses were given under directly observed treatment as long as 
patients were given rifampicin, irrespective of treatment phase or regimen. Drug 
susceptibility testing was done later, and results were not used to modify treatment 
regimens. Treatment adherence was confirmed from the treatment cards kept at the 
district tuberculosis unit (DTU).  
 
Study design 
The purpose of the present study was to quantify possible associations between 
isoniazid resistance-conferring mutations in the MTB strain isolated before treatment 
and MTB genotype and patient characteristics among all TB patients, and between pre-
treatment isoniazid resistance-conferring mutations and treatment outcomes (treatment 
failure and relapse) among new TB cases. New TB patients were followed up during 
standard first-line treatment with sputum smear microscopy at months 3, 5
 
and 8 and 
with sputum culture at the end of treatment (after 8 months, or after 5 months if the 
month 5 smear was positive). Participants whose sputum smear and culture were 
negative for MTB at the end of treatment were visited by study staff twice thereafter, at 
around 9 and 18 months after treatment completion, or later if not encountered. In 
addition, data were collected during this period on study participants reporting with TB 
symptoms at any of the study clinics. Participants who had any complaints suggesting 
recurrent TB during these visits, or when they themselves consulted a participating 
clinic, provided two sputum specimens for smear and culture. The data were also 
collected on any intermediate TB treatment elsewhere, and on causes of death among 
the study patients based on clinic reports, death certificates and interviews with family 
members. 
 
Laboratory methods 
Sputum specimens were kept refrigerated and transported to Pham Ngoc Thach 
Hospital in Ho Chi Minh City within 72 h after collection. They were decontaminated 
and liquefied with 1% N-acetylcystine, 2% NaOH, inoculated on modified Ogawa 
medium and incubated at 37ºC. Cultures were examined for growth after 1, 2, 4, 6 and 8 
weeks of incubation. Cultures with no growth after 8 weeks were reported as negative. 
MTB was identified using the niacin and the nitrate tests. 
Drug susceptibility testing (DST) was performed using the proportion method on 
Löwenstein-Jensen (LJ) medium [28]. Criteria for drug resistance were ≥1%  f the 
colony forming units grown at 28 or 42 days compared to the drug-free control medium 
at the following drug concentrations: isoniazid 0.2 g/ml, rifampicin 40 g/ml, 
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streptomycin 4 g/ml and ethambutol 2 g/ml [28]. All isoniazid-resistant MTB strains 
that were isolated were subjected to testing by GenoType® MTBDRplus that combines 
detection of MTB complex with detection of mutations in the 81-bp hotspot region of 
rpoB, at codon 315 of the katG gene and in the inhA promoter region [15]. All baseline 
and follow-up isolates from patients with positive follow-up MTB cultures were 
subjected to molecular typing by spoligo and Variable Number of Tandem Repeats 
(VNTR) typing. Bacterial DNA was extracted from positive cultures using an earlier 
described method [29]. Spoligotyping was performed according to the internationally 
standardized method [30], and VNTR typing was done using 15 loci [31]. 
 
Definitions  
Previously treated patients were those who received 1 month or more of anti-TB 
drugs in the past. Cure was defined as a negative sputum smear examination and culture 
in the last month of treatment and on at least one previous occasion, and treatment 
failure as any positive sputum smear or culture at 5 months or later during treatment. 
Treatment completion was defined as having completed treatment without meeting the 
criteria for being classified as cure or failure.  
Recurrent TB was defined as any case of positive smear and/or culture during the 
follow-up period among the cured patients [32]. We defined a case of recurrent TB as 
relapse if the initial and follow-up MTB isolates had identical spoligotypes and VNTR 
patterns,  r if the VNTR patterns differed by ≤1   cus, and as reinfecti n if  therwise 
[31]. Unfavorable treatment outcome was referred to as treatment failure or death and 
related to the treatment period only.  
Genotypes were based on spoligotyping. The Beijing genotype was defined as any 
isolate without direct-repeat spacers 1 to 34 and the presence of at least three of the 
spacers from 35 to 43 [33]. Other genotypes, including the East African-Indian (EAI) 
genotype that is predominant in Vietnam, were defined as described by Brudey et al. 
[34]. 
 
Data analysis  
Data were double entered in Epi-Info (version 6.04; Centers for Disease Control 
and Prevention, Atlanta GA); discrepancies were corrected based on the raw data. 
Analyses were performed in Stata (version 10SE; Stata Corporation, College Station, 
TX).  
For comparison of categorical variables we used the chi-squared and two-sided 
Fisher’s exact tests as appropriate. Associations of katG315 or inhA mutations with 
explanatory variables before start of treatment were expressed as odds ratios; 
confounding effects were investigated by multivariable logistic regression modeling. In 
the analysis of treatment failure, mutations in katG and inhA were assessed by 
multivariable logistic regression as explanatory variables, along with covariates that 
showed confounding effects, potentially including age, sex, residence, resistance to 
other drugs, the MTB genotype, pre-treatment smear grading and extent of chest X-ray 
abnormalities, and treatment adherence. Only variables that showed confounding effects 
for the association between resistance mutations and the outcome were retained in the 
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final model. Since patients who died during treatment may reflect treatment failures, we 
repeated this analysis taking failure or death as unfavorable treatment outcome. For the 
association with relapse we did a similar analysis using multivariable Cox' proportional 
hazard modeling. P values for contribution to multivariate models, including 
interaction, were based on the likelihood ratio test. All tests were done at the 5% 
significance level. 
 
Results 
After excluding 151 patients (Figure 1), pre-treatment data were available for 
analysis for 1,213 (88.9%) of 1,364 registered patients. Of these, 924 were male 
(76.2%); the mean age was 50 years (standard deviation [SD] = 18.3; range 15 to 102). 
There were 1,102 (90.9%) new patients and 111 (9.1%) patients previously treated for 
TB.  
Of 1,213 M. tuberculosis pretreatment isolates, 69 (5.7%) were monoresistant to 
isoniazid, 146 (12.4%) were monoresistant to streptomycin, 128 (10.6%) were resistant 
to isoniazid and streptomycin, and 47 (3.9%) were multidrug resistant (see Table S1 in 
the supplemental material). Monoresistance to isoniazid was more frequent among 
previously treated patients than among new TB patients (12.6% versus 5.0%, P<0.05), 
whereas the proportion of other monoresistance patterns did not significantly differ 
between previously treated and new patients.  
 
Isoniazid resistance-conferring mutations 
Of the 251 (20.7%) phenotypically isoniazid resistant MTB strains, 227 (90.4%) 
exhibited mutations by GenoType® MTBDRplus testing; 171 (75.3%) had mutations or 
no reaction on wild type (WT) probes in katG315 including 167 (97.7%) with katG 
S315T1 mutations. Sixty-four (28.2%) had mutations in the inhA promoter region, 
including 61 (95.3%) involving inhA C15T mutations. Only 8 of 227 (3.5%) strains 
with a katG315 mutation had an additional mutation in the inhA promoter region (Table 
1). 
 
Characteristics for katG315 mutations  
There were no significant associations between the probability of having a strain 
with a katG315 mutati n and the patient’s district, type  f residence, age  r presence  f 
mutations in the inhA promoter region. However, katG315 mutations were significantly 
more frequent among women (odds ratio [OR] 1.4), among patients previously treated 
for TB (OR 5.3), among strains that were resistant to rifampicin (OR 27.7), 
streptomycin (OR 16.9) or ethambutol (OR 62.1), and among strains that belonged to 
the Beijing genotype (OR 3.2). 
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Table 1. Results of isoniazid resistance mutations detected by Genotype® MTBDRplus 
test among 227 tuberculosis patients with phenotypic resistance to isoniazid in Vietnam. 
 
 
In a multivariable model katG315 mutations remained associated (adjusted OR 
[OR
adj
]; 95% confidence interval [CI]) with previous TB treatment (2.6; 1.4-4.8), 
resistance to rifampicin (4.5; 1.8-11.1), ethambutol (12.0; 2.7-54.4) or streptomycin 
(15.0; 9.4-23.9), as well as with female sex (1.9; 1.2-3.0), but not with the Beijing 
genotype (1.3; 0.8-2.2) or EAI genotype (1.7; 0.9-3.0) compared to all other genotypes 
together (Table 2). When leaving resistance to other drugs than isoniazid out of the 
model, the Beijing genotype (2.6; 1.7-4.1), but not the EAI genotype was associated 
with katG315 mutation. When adding resistance to only one of the three other drugs to 
the model, the Beijing genotype was still significantly associated with katG315 
mutations after adjustment for rifampicin (2.2; 1.4-3.4) or ethambutol resistance (2.5; 
1.6-4.0), whereas this association disappeared after adjustment for streptomycin 
resistance (1.5; 0.9-2.5). 
 
 Mutation(s)  Frequency 
 katG inhA  No of patients % Total 
 
WT(315) absent  
 
171 75.3 
 
MUT1 (S315T1)  
 
167 73.6 
 
MUT2(S315T2)  
 
0 0 
 
 WT (-15/-16) absent 
 
56 24.7 
 
 WT (-8) absent 
 
5 2.2 
 
 MUT1(C15T) 
 
61 26.9 
 
 MUT2 (A16G) 
 
0 0 
 
 MUT3A (T8C) 
 
0 0 
 
 MUT3B (T8A) 
 
3 1.3 
 
MUT1 (S315T1) MUT1(C15T) 
 
8 3.5 
  
Table 2. Univariable and multivariable associations with patient characteristics, genotype, and anti-TB drug resistance for katG codon 315 
mutations at the start of treatment (baseline). 
Characteristic 
or parameter 
No of 
patients 
katG mutations  OR (95% CI)
a
  
p No. %  Crude Adjusted 
Total no. of subjects 1213       
Sex       0.009 
Male  924 120 13  1 1  
Female 289 51 17.7  1.4 (1.0-2.05) 1.9 (1.2-3.0)  
Age (yrs)       0.349 
<25 119 16 13.5  1 1  
25 to 49 528 79 15  1.1 (0.6-2.0) 1.7 (0.8-3.7)  
≥50 566 76 13.4  1.0 (0.6-1.8) 1.7 (0.8-3.7)  
History of tuberculosis       0.002 
New  1102 126 11.4  1 1  
Previously treated 111 45 40.5  5.3 (3.4-8.2) 2.6 (1.4-4.8)  
District         
Cailay 440 60 13.6  1   
Caibe 418 57 13.6  1.0 (0.7-1.5)   
Chauthanh 355 54 15.2  1.1 (0.8-1.7)   
Residence        
On waterway 457 67 14.7  1   
On provincial road 624 91 14.6  1.0 (0.7-1.4)   
On national road 132 13 9.9  0.6 (0.3-1.2)   
Genotype family       0.203 
East African Indian 461 40 8.7  0.9 (0.6-1.5) 1.7 (0.9-3.0)  
Beijing 407 98 24.1  3.0 (2.0-4.6) 1.3 (0.8-2.2)  
Other 345 33 9.6  1 1  
  
 
 
Table 2, continued. Univariable and multivariable associations with patient characteristics, genotype, and anti-TB drug resistance for katG 
codon 315 mutations at the start of treatment (baseline). 
Characteristic 
or parameter 
No. of 
patients 
katG mutations  OR (95% CI)a  
P No. %  Crude Adjusted 
Rifampicin resistance       <0.001 
No 1163 132 11.4  1 1  
Yes 50 39 78  27.7 (13.1-58.6) 4.5 (1.8-11.1)  
Streptomycin resistance       <0.001 
No 889 36 4.1  1 1  
Yes 324 135 41.7  16.9 (10.7-26.7) 15.0 (9.4-23.9)  
Ethambutol resistance       <0.001 
No 1184 145 12.3  1 1  
Yes 29 26 89.7  62.1 (17.2-224.4) 12.0 (2.7-54.4)  
InhA mutation       <0.001 
No 1149 163 14.2  1 1  
Yes 64 8 12.5  0.9 (0.4-1.9) 0.2 (0.1-0.5)  
a “ djusted” means adjusted f r a    ther variab es in the m de , CI, C nfidence interva ;OR, Odds rati , TB: Tubercu  sis. 
 
  
Table 3. Univariable and multivariable associations with patient characteristics, genotype, and anti-TB drug resistance for the inhA promoter 
region mutations at the start of treatment (baseline). 
Characteristic 
or parameter 
No of 
patients 
inhA mutations  OR (95% CI)
a
  
p No. %  Crude Adjusted 
Total 1,213       
Sex       0.184 
Male  924 46 5.0  1 1  
Female 289 18 6.2  1.3 (0.7-2.2) 1.5 (0.8-2.7)  
Age (yrs)       0.453 
<25 119 4 3.4  1 1  
25-<50 528 30 5.7  1.7 (0.6-5.0) 1.9 (0.6-5.9)  
≥50 566 30 5.3  1.6 (0.6-4.7) 1.7 (0.6-5.1)  
History of tuberculosis       0.025 
New  1102 51 4.6  1 1  
Previously treated 111 12 11.7  2.7 (1.4-5.2) 2.5 (1.2-5.4)  
District       0.066 
Cailay 440 14 3.2  1 1  
Caibe 418 31 7.4  2.4 (1.3-4.7) 2.1 (1.1-4.1)  
Chauthanh 355 19 3.4  1.7 (0.9-3.5) 1.3 (0.6-2.8)  
Residence        
On waterway 457 25 5.5  1   
On provincial road 624 32 5.1  0.9 (0.6-1.6)   
On national road 132 7 5.3  1.0 (0.4-2.3)   
Genotype family       0.276 
East African-Indian 461 21 4.6  0.7 (0.4-1.4) 1.0 (0.5-2.0)  
Beijing 407 22 5.4  0.9 (0.5-1.6) 0.6 (0.3-1.2)  
Other 345 21 6.1  1 1  
  
 
 
Table 3, continued. Univariable and multivariable associations with patient characteristics, genotype, and anti-TB drug resistance for the inhA 
promoter region mutations at the start of treatment (baseline). 
Characteristic 
or parameter 
No of 
patients 
inhA mutations  OR (95% CI)a  
P No. %  Crude Adjusted 
Rifampicin resistance        0.496 
No 1163 57 4.9  1 1  
Yes 50 7 14.0  3.2 (1.4-7.4) 1.6 (0.5-5.4)  
Streptomycin resistance       <0.001 
No 889 31 3.5  1 1  
Yes 324 33 10.2  3.1 (1.9-5.2) 4.4 (2.4-8.1)  
Ethambutol resistance       0.122 
No 1184 59 5.0  1 1  
Yes 29 5 17.2  4.0 (1.5-10.8) 3.3 (0.8-14.3)  
KatG mutation       <0.001 
No 1042 56 5.4  1 1  
Yes 171 8 4.7  0.9 (0.4-1.8) 0.2 (0.1-0.6)  
a “ djusted” means f r a   other variables in the model.  
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Smear positive pulmonary TB registered : 1364
Enrolled: 1331
Inclusion criteria not met: 33
Sputum submitted for culture: 1298
Missing data: 33
Results available: 1295
Laboratory technical errors: 3
Culture negative: 62
Culture positive: 1233
Non-tuberculous Mycobacteria: 20
M. tuberculosis genotype available for analysis: 1213
Excluded data: 51
defaulting: 9
transferred out: 3
lost data: 30
regimen changed: 2
reinfection: 7
New TB patients: 1102
Cured: 989 available for analysis of relapse Treatment failure: 21
Recurrences: 31
Retreated TB patients: 111
1051new TB patients available for analysis treatment outcome
Deaths: 411010 new TB patients for analysis treatment failure
Not included for follow up: 5 984 with follow up data
Reinfections: 9 Relapses: 22
 
 
Figure 1. Schematic presentation of enrollment of the study population. TB, 
tuberculosis. 
 
Characteristics for inhA promoter region mutations 
In univariate analysis, inhA mutations were associated with previous TB treatment 
(OR 2.7), with resistance to rifampicin (OR 3.2), streptomycin (OR 3.1) or ethambutol 
(OR 4.0) and with living in one of the districts (Caibe, OR 2.4), but not with sex, age, 
residence or genotype. In multivariate analysis also including resistance to other drugs, 
inhA mutations remained significantly associated with resistance to streptomycin (ORadj 
4.4; 95%CI 2.4-8.1) and previous TB treatment (ORadj 2.5; 95%CI 1.2-5.4), and near-
significantly associated with Caibe district (ORadj 2.1; P = 0.066), but not with 
resistance to rifampicin or ethambutol (Table 3). There was significant interaction 
between previous TB treatment and streptomycin resistance: inhA mutations were 
significantly associated with streptomycin resistance among new TB patients (ORadj 6.5, 
P<0.001) but not among previously treated patients (ORadj 0.36, P>0.05). 
 
Predictors of treatment failure 
Of 1,102 new TB patients, 51were excluded due to loss of data (30), re-infection 
(7), defaulting (9), transfer-out (3) and changed treatment regimen because of side 
effects (2). Furthermore, we excluded 41 patients who died during treatment, leaving 
1,010 new patients for this analysis (Figure 1). Of these 21 (2.1%) had a treatment 
failure (Table 4). 
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In univariate analysis, the risk of treatment failure was significantly increased for 
isoniazid-resistant strains having at least a katG315 mutation (OR 13.6; 95%CI 5.3-
35.4) but not for isoniazid-resistant strains having inhA mutations only (OR 2.9; 95%CI 
0.3-14.0) or no mutations (OR 6.9; 95%CI 0.8-59.6). After multivariable adjustment for 
district and resistance to rifampicin, streptomycin or ethambutol, the association 
between katG315 mutations and treatment failure (OR
adj
; 95%CI) was no longer 
significant (3.2; 0.8-12.8; Wald test, p=0.102). Similarly, neither inhA mutations only 
(1.0; 0.1-10.1) nor isoniazid resistance without mutations detectable by the GenoType® 
MTBDRplus assay (1.8; 0.1-24.1) showed significant association with treatment failure 
(Table 4). There was no significant difference in failure between patients with katG315 
and patients with inhA mutated strains. Isoniazid resistance mutations showed no 
association with treatment adherence, pretreatment smear grade and extent of 
pretreatment abnormalities, and none of these variables confounded the observed 
associations between resistance mutation and treatment failure. 
When the 41 patients who had died during treatment were included in the analysis 
and failure or death (62 of 1051 patients; 5.9%) was combined as unfavorable treatment 
outcome, its risk was significantly increased for isoniazid-resistant strains having at 
least a katG315 mutation (OR 3.7; 95%CI 2.0-6.7) or no mutations detectable by the 
GenoType® MTBDRplus assay (OR 3.7; 95%CI 1.1-13.3) but not for inhA mutations 
only (OR 1.0; 95%CI 0.2-4.4). In a multivariate model adjusting for covariates that 
appeared to confound this association (resistance to rifampicin or resistance to 
streptomycin) unfavorable treatment outcome remained significantly associated with 
the katG315 mutations (OR
adj
 3.0; 95%CI 1.4-6.8; Wald test P=0.007) but not with no 
detectable mutations (OR
adj
 3.4; 95%CI0.9-13.4; P=0.081) (Table 4).  
 
Predictors of relapse  
For this analysis, we included all 984 new patients who were smear and culture 
negative at the end of treatment and available for follow-up (Figure 1). We observed 31 
cases of recurrent TB, of which 9 were classified as reinfections and 22 (2.2%) were 
classified as relapse. There were no relapses among the 17 participants with isoniazid-
resistant isolates that did not display any mutation in the GenoType® MTBDRplus 
assay. The three strains that displayed both a katG315 and an inhA mutation were 
included in the katG315 mutation category. 
In univariate analysis, both katG315 and inhA mutations were strongly associated 
with relapse; hazard ratios (HR) were 6.7 (95%CI 2.6-16.9) and 8.3 (95%CI 2.6-26.4), 
respectively (Figure 2). Relapse was also significantly more frequent among 
participants harboring strains that were of the Beijing genotype (HR 6.2) or 
streptomycin resistant (HR 4.0), and among those with MDR-TB (HR 7.4). 
After multivariable adjustment for genotype and resistance to streptomycin or 
rifampicin, relapse remained strongly associated with katG315 mutations (HR
adj
 4.3; 
95%CI 1.4-13.6, p=0.013) and inhA mutations (HR
adj
 8.7; 95%CI 2.5-30.0, p=0.001) 
compared against isoniazid-susceptible strains (Table 5). The relapse rate did not differ 
significantly between strains with katG315 mutations and strains with inhA mutations. 
We found no significant interactions. 
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Figure 2. Inverted survival curve for tuberculosis relapse cases among 984 patients 
after first line TB treatment, isoniazid resistance-conferring mutations. Log-rank test, 
P<0.001. Solid black line, cases due to katG codon 315 mutated strains. Interrupted 
black line, cases due to inhA promoter region-only mutated strains. Gray line, cases due 
to isoniazid-susceptible strains. y axis, proportion of relapse cases. INH, isoniazid. 
 
 
Discussion 
In this population-based study conducted in Vietnam, katG315 mutations 
occurred in 75% of the isoniazid-resistant strains and were more often found in strains 
resistant to rifampicin, streptomycin or ethambutol. In contrast, the inhA promoter 
region mutations were less frequent among isoniazid-resistant strains and only 
associated with streptomycin resistance. Follow-up of new TB patients on standard 
first-line treatment showed that katG315 and inhA promoter region mutations were both 
strongly associated with relapse. KatG315 mutations showed a 3-fold but non-
significant association with treatment failure, while inhA promoter region mutations 
showed no such association at all. Unfavorable treatment outcome was however, 
significantly associated with katG315 mutations, as previously reported by Tolani et al. 
[35]. This was expected because these mutations confer high-level isoniazid resistance 
[13]. The independent association between katG315 and failure was non-significant, 
probably because of small numbers, which is supported by the finding that the 
association was of similar magnitude but now significant when treatment failure and 
death were combined. We found no associations between katG315 or inhA mutations 
and the Beijing genotype. 
  
Table 4. Multivariable associations for treatment failure or treatment failure and death during treatment combined 
 
 Failure
a 
 Failure or death
b 
Resistance Total
 
No. % 
Adjusted OR 
(95%CI) 
P 
 
Total
 
No. % 
Adjusted OR 
(95%CI) 
P 
Isoniazid resistance     0.370      0.046 
Susceptible 834 7 0.8 1   866 39 4.5 1  
Any katG mutation 116 12 10.3 3.2 (0.8-12.8) 0.102  122 18 14.8 3.0 (1.4-6.8) 0.007 
InhA mutations only 42 1 2.4 1.0 (0.1-10.0) 0.974  43 2 4.7 1 (0.2-4.5) 0.994 
No mutations 18 1 5.6 1.8 (0.1-24.1) 0.657  20 3 15.0 3.4 (0.9-13.4) 0.081 
Rifampicin resistance     0.001      <0.001 
No 986 12 1.2 1   1027 53 5.2 1  
Yes 24 9 37.5 7.6 (1.7-34.1)   24 9 37.5 6.3 (2.3-17.1)  
Streptomycin 
resistance 
    0.191 
 
    0.348 
No 760 7 0.9 1   794 41 5.2 1  
Yes 250 14 5.6 2.3 (0.7-8.2)   257 21 8.2 0.7 (0.3-1.5)  
Ethambutol resistance     0.056       
No 997 15 1.5 1   1038 56 5.4 --  
Yes 13 6 46.2 5.9 (1.0-32.3)   13 6 46.2   
a
 The model for the OR and P values includes the following covariates: district, isoniazid resistance, rifampin resistance, streptomycin resistance, and 
ethambutol resistance. 
b 
The model for the OR and P values includes the following covariates: isoniazid resistance, rifampin resistance, and streptomycin resistance. 
Chapter 6 
96 
Table 5. Multivariable associations for relapse in 967 new tuberculosis patients 
a
. 
 No. of 
relapses 
Incidence per 
100 person-
years 
of follow up 
Adjusted 
b
 
Hazard 
ratio 
95% CI P value 
Total 22     
Isoniazid resistance     0.004 
Susceptible 10 0.78 1 --  
Any katG mutations 8 5.14 4.3 1.4-13.6 0.013 
InhA mutations only 4 6.34 8.7 2.5-30 0.001 
Rifampicin resistance  2 9.21 1.2 0.3-5.7 0.821 
Streptomycin resistance  12 3.50 1.1 0.4-3.1 0.900 
Genotype     <0.001 
Beijing 16 3.46 5.1 1.9-14  
Non-Beijing 6 0.58 1 --  
a
 Total of 17 patients with isoniazid-resistant strains for which no mutation was found were 
excluded from the analysis 
b
 Variables in the model: isoniazid resistance mutations, Beijing genotype, streptomycin 
resistance, rifampicin resistance  
 
A strong association between both kạtG315 and inhA mutations and relapse may 
be caused by the 8-month 2SHRZ/6EH regimen used for new TB patients in Vietnam. 
This means that not only with high-level but also with low-level isoniazid resistance the 
supplementation of isoniazid with only ethambutol in the continuation phase of 
treatment is not effective in sterilizing MTB. Interestingly, the association between 
isoniazid resistance and relapse was most pronounced for inhA mutations. Since the 
catalase-peroxidase release is a component of the bacterial OxyR response, this helps 
the bacteria to survive inside macrophages [36]. Hence, the probability of survival of 
bacteria with an inhA mutation inside macrophages is higher than for the katG315 
mutant strains, because they still have full catalase-peroxidase expression. Whether the 
increased risk of relapse, in particular for inhA mutations, also exists with the WHO-
recommended 6-month regimen (2RHEZ/4RH), remains to be studied.  
In the univariate analysis katG315 mutations were strongly associated with the 
Beijing genotype. Although in accordance with previous studies [9, 17, 18], this 
association completely disappeared after adjustment for streptomycin resistance. In our 
study 47% of the Beijing strains were resistant to streptomycin of which 48% also had 
katG315 mutations, suggesting that in the Beijing strains streptomycin resistance and 
katG315 mutations are often present simultaneously. This correlation is not unexpected; 
streptomycin resistance was also associated with the Beijing genotype, MDR-TB and 
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increased transmission in the same study area [37]. The association between 
streptomycin resistance and high-level isoniazid resistance and MDR, especially among 
Beijing strains, needs further study. It might be related to a specific combination of low-
fitness c st mutati ns c nferring these resistances and the strain’s genetic background. 
In additi n, yet unkn wn c mpensat ry mutati ns may c ntribute t  the strain’s fitness. 
Our findings also have consequences for the choice of the standard first-line 
regimen in Vietnam. In line with WHO recommendations, the 8-month regimen for the 
treatment of new TB patients should be replaced by the 6-month regimen, including 
rifampicin in the continuation phase.  
There were limitations to our study. We only tested isolates for mutations that 
showed phenotypic resistance to isoniazid and may have missed genotypically 
isoniazid-resistant isolates. However, drug susceptibility testing was done by an 
internationally recognized reference laboratory that has consistently shown high 
concordance rates in proficiency testing therefore this risk is small. We did not 
determine the minimum inhibitory concentrations of isoniazid for the MTB isolates. We 
also did not use other genotyping methods to assess the type of mutations conferring 
isoniazid resistance other than those included in the GenoType® MTBDRplus test. 
However, the GenoType® MTBDRplus test covers ≥ 90% of the isoniazid mutations in 
MTB isolates in Vietnam, as shown previously [15]. HIV testing was not routinely 
performed for all patients. However, the HIV infection prevalence in Vietnam is 
estimated to be 0.4% of the adult population, with substantially lower prevalence in 
rural provinces than in major cities. We collected no data on clinical characteristics 
known to predict treatment failure or relapse, such as the presence of co-morbidities or 
cavities on the chest x-ray. Since it is unlikely that these would be associated with 
specific isoniazid resistance-conferring mutations before treatment, we do not expect 
that this resulted in uncontrolled confounding of the observed associations.  
In conclusion, isoniazid resistance was most frequently due to mutations in the 
katG315 gene, and these mutations were associated with multidrug and polydrug 
resistance, whereas inhA mutations were less frequent and only associated with 
streptomycin resistance. Both katG315 and inhA mutations increased the risk of relapse. 
Our results also suggest that in Vietnam the 8-month regimen should be discontinued 
and be replaced by the WHO-recommended 6-month regimen for the treatment new TB 
patients. 
 
Acknowledgements 
This study was supported by KNCV Tuberculosis Foundation, the Netherlands 
Committee Netherlands-Vietnam and the World Health Organization.  
We thank all TB patients participating in this study and the staff of the National 
Tuberculosis Program of Tiengiang province for recruiting the patients as well as the 
staff of the National Tuberculosis Program in Pham Ngoc Thach hospital for delivering, 
supervising and checking the data. We thank Dai Viet Hoa, Phan Thi Hoang Anh, Nhut 
Kim Phuong, Ho Thi Kim Loan and other staff in Pham Ngoc Thach laboratory for 
performing culture, DST and GenoType® MTBDRplus testing. 
Chapter 6 
98 
We are grateful to Anne-Marie van den Brandt, Mimount Enaimi, Arnout Mulder, 
Jessica de Beer and other staff of the Tuberculosis Reference Laboratory at the National 
Institute for Public Health and the Environment (The Netherlands) for providing us the 
knowledge and practice on the molecular techniques used in this study. We thank 
Maxine Caws and her staff at the laboratory of the Oxford University Clinical Research 
Unit (Ho Chi Minh City) for their help in performing the VNTR typing.  
 
References 
1. World Health Organization. 2012. Global Tuberculosis Control 2012. Geneva: World 
Health Organization. 
2. Wright A, Zignol M, Van Deun A, Falzon D, Gerdes SR, Feldman K, et al. 2009. 
Epidemiology of antituberculosis drug resistance 2002-07: an updated analysis of the 
Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Lancet 373:1861-73. 
3. Menzies D, Benedetti A, Paydar A, Royce S, Madhukar P, Burman W, Vernon A, et al. 
2009. Standardized treatment of active tuberculosis in patients with previous treatment 
and/or with mono-resistance to isoniazid: a systematic review and meta-analysis. PLoS 
Med 6:e1000150. 
4. Espinal MA, Kim SJ, Suarez PG, Kam KM, Khomenko AG, Migliori GB, et al. 2000. 
Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes 
in 6 countries. JAMA 283:2537-45. 
5. Banerjee A, Dubnau E, Quemard A, Balasubramanian V, Um KS, Wilson T, et al. 1994. 
inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium 
tuberculosis. Science 263:227-30. 
6. Musser JM, Kapur V, Williams DL, Kreiswirth BN, van Soolingen D, van Embden JD. 
1996. Characterization of the catalase-peroxidase gene (katG) and inhA locus in 
isoniazid-resistant and -susceptible strains of Mycobacterium tuberculosis by automated 
DNA sequencing: restricted array of mutations associated with drug resistance. J Infect 
Dis 173:196-02. 
7. Kelley CL, Rouse DA, Morris SL. 1997. Analysis of ahpC gene mutations in isoniazid-
resistant clinical isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother 
41:2057-8. 
8. Lee AS, Teo AS, Wong SY. 2001. Novel mutations in ndh in isoniazid-resistant 
Mycobacterium tuberculosis isolates. Antimicrob Agents Chemother 45:2157-9. 
9. Mokrousov I, Narvskaya O, Otten T, Limeschenko E, Steklova L, Vyshnevskiy B. 2002. 
High prevalence of KatG Ser315Thr substitution among isoniazid-resistant 
Mycobacterium tuberculosis clinical isolates from northwestern Russia, 1996 to 2001. 
Antimicrob Agents Chemother 46:1417-24. 
10. Telenti A, Honore N, Bernasconi C, March J, Ortega A, Heym B, et al. 1997. Genotypic 
assessment of isoniazid and rifampin resistance in Mycobacterium tuberculosis: a blind 
study at reference laboratory level. J Clin Microbiol 35:719-23. 
11. Barnard M, Albert H, Coetzee G, O'Brien R, Bosman ME. 2008. Rapid molecular 
screening for multidrug-resistant tuberculosis in a high-volume public health laboratory 
in South Africa. Am J Respir Crit Care Med 177:787-92. 
12. Zhang Y, Heym B, Allen B, Young D, Cole S. 1992. The catalase-peroxidase gene and 
isoniazid resistance of Mycobacterium tuberculosis. Nature 358:591-3. 
Chapter 6 
99 
13. Ando H, Kondo Y, Suetake T, Toyota E, Kato S, Mori T, Kirikae T. 2010. Identification 
of katG mutations associated with high-level isoniazid resistance in Mycobacterium 
tuberculosis. Antimicrob Agents Chemother 54:1793-9. 
14. Dalla Costa ER, Ribeiro MO, Silva MS, Arnold LS, Rostirolla DC, Cafrune PI, et al. 
2009. Correlations of mutations in katG, oxyR-ahpC and inhA genes and in vitro 
susceptibility in Mycobacterium tuberculosis clinical strains segregated by spoligotype 
families from tuberculosis prevalent countries in South America. BMC Microbiol 9:39. 
15. Huyen MN, Tiemersma EW, Lan NT, Cobelens FG, Dung NH, Sy DN, et al. 2010. 
Validation of the GenoType MTBDRplus assay for diagnosis of multidrug resistant 
tuberculosis in South Vietnam. BMC Infect Dis 10:149. 
16. van Doorn HR, de Haas PE, Kremer K, Vandenbroucke-Grauls CM, Borgdorff MW, van 
Soolingen D. 2006. Public health impact of isoniazid-resistant Mycobacterium 
tuberculosis strains with a mutation at amino-acid position 315 of katG: a decade of 
experience in The Netherlands. Clin Microbiol Infect 12:769-75. 
17. Hillemann D, Kubica T, Rusch-Gerdes S, Niemann S. 2005. Disequilibrium in 
distribution of resistance mutations among Mycobacterium tuberculosis Beijing and non-
Beijing strains isolated from patients in Germany. Antimicrob Agents Chemother 
49:1229-31. 
18. Ghebremichael S, Groenheit R, Pennhag A, Koivula T, Andersson E, Bruchfeld J, et al. 
2010. Drug resistant Mycobacterium tuberculosis of the Beijing genotype does not spread 
in Sweden. PloS One 5:e10893. 
19. Anh DD, Borgdorff MW, Van LN, Lan NT, van Gorkom T, Kremer K, et al. 2000. 
Mycobacterium tuberculosis Beijing genotype emerging in Vietnam. Emerg Infect Dis 
6:302-5. 
20. Glynn JR, Kremer K, BorgdorffMW, Rodriguez MP, Soolingen DV. 2006. Beijing/W 
genotype Mycobacterium tuberculosis and drug resistance. Emerg Infect Dis 12:736-743. 
21. Buu TN, Huyen MN, Lan NT, Quy HT, Hen NV, Zignol M, et al. 2009. The Beijing 
genotype is associated with young age and multidrug-resistant tuberculosis in rural 
Vietnam. Int J Tuberc Lung Dis 13:900-6. 
22. Burman WJ, Bliven EE, Cowan L, Bozeman L, Nahid P, Diem L, Vernon A. 2009. 
Relapse associated with active disease caused by Beijing strain of Mycobacterium 
tuberculosis. Emerg Infect Dis 15:1061-7. 
23. Huyen MN, Buu TN, Tiemersma E, Lan NT, Dung NH, Kremer K, et al. 2013. 
Tuberculosis relapse in Vietnam is significantly associated with Mycobacterium 
tuberculosis Beijing genotype infections. J Infect Dis 207:1516-24. 
24. Hoa NB, Sy DN, Nhung NV, Tiemersma EW, Borgdorff MW, Cobelens FG. 2010. 
National survey of tuberculosis prevalence in Vietnam. Bull World Health Organ 88:273-
80. 
25. Huong NT, Lan NT, Cobelens FG, Duong BD, Co NV, Bosman MC, et al. 2006. 
Antituberculosis drug resistance in the south of Vietnam: prevalence and trends. J Infect 
Dis 194:1226-32. 
26. Buu TN, Huyen MN, van Soolingen D, Lan NT, Quy HT, Tiemersma EW, et al. 2010. 
The Mycobacterium tuberculosis Beijing genotype does not affect tuberculosis treatment 
failure in Vietnam. Clin Infect Dis 51:879-86. 
27. Huong NT, Duong BD, Co NV, Quy HT, Tung LB, Bosman M, et al. 2005. 
Establishment and development of the National Tuberculosis Control Programme in 
Vietnam. Int J Tuberc Lung Dis 9:151-6. 
Chapter 6 
100 
28. World Health Organization. 2003. Guidelines for surveillance of drug resistance in 
tuberculosis. 2
nd
 ed. WHO/CDS/TB/2003.320. Geneva: World Health Organization. 
29. van Soolingen D, de Haas PEW, Kremer K. 2001. Restriction fragment length 
polymorphism typing of mycobacteria, p. 165-203. In T. Parish, Stoker NG (ed.), In: 
Mycobacterium tuberculosis protocols. Humana Press Inc., Totowa, New Jersey, USA. 
30. Kamerbeek J, Schouls L, Kolk A, van Agterveld M, van Soolingen D, Kuijper S, et al. 
1997. Simultaneous detection and strain differentiation of Mycobacterium tuberculosis 
for diagnosis and epidemiology. J Clin Microbiol 35:907-14. 
31. Supply P, Allix C, Lesjean S, Cardoso-Oelemann M, Rusch-Gerdes S, Willery E, et al. 
2006. Proposal for standardization of optimized mycobacterial interspersed repetitive 
unit-variable-number tandem repeat typing of Mycobacterium tuberculosis. J Clin 
Microbiol 44:4498-510. 
32. World Health Organization. 2009. Treatment of tuberculosis: guidelines. 4
th
 ed. 
WHO/HTM/TB/2009.420. Geneva: World Health Organization. 
33. Kremer K, Glynn JR, Lillebaek T, Niemann S, Kurepina NE, Kreiswirth BN, et al. 2004. 
Definition of the Beijing/W lineage of Mycobacterium tuberculosis on the basis of 
genetic markers. J Clin Microbiol 42:4040-9. 
34. Brudey K, Driscoll JR, Rigouts L, Prodinger WM, Gori A, Al-Hajoj SA, et al. 2006. 
Mycobacterium tuberculosis complex genetic diversity: mining the fourth international 
spoligotyping database (SpolDB4) for classification, population genetics and 
epidemiology. BMC Microbiol 6:23. 
35. Tolani MP, D'Souza D T, Mistry NF. 2012. Drug resistance mutations and 
heteroresistance detected using the GenoType MTBDRplus assay and their implication 
for treatment outcomes in patients from Mumbai, India. BMC Infect Dis 12:9. 
36. Farr SB, Kogoma T. 1991. Oxidative stress responses in Escherichia coli and Salmonella 
typhimurium. Microbiol Rev 55:561-85. 
37. Buu TN, van Soolingen D, Huyen MN, Lan NT, Quy HT, Tiemersma EW, et al. 2012. 
Increased transmission of Mycobacterium tuberculosis Beijing genotype strains 
associated with resistance to streptomycin: a population-based study. PloS One 7:e42323. 
 
 
  
CHAPTER 7 
Characterization of Mycobacterium tuberculosis isolates lacking IS6110 
in Vietnam 
 
Mai. N.T.Huyen
1
, Edine W. Tiemersma
3,4
, Kristin Kremer
2,5
, Petra de Haas
5
, Nguyen 
T.N. Lan
1
, Tran N. Buu
1
, Christophe Sola
7
, Frank G.J. Cobelens
3,4
 and Dick van 
Soolingen
5,6 
 
1. Pham Ngoc Thach Hospital, Ho Chi Minh City, Vietnam. 
2. Tuberculosis and M/XDR-TB Programme, Division of Communicable Diseases, 
Health Security & Environment, World Health Organization, Regional Office for 
Europe, Copenhagen, Denmark. 
3. KNCV Tuberculosis Foundation, The Hague, The Netherlands. 
4. Department of Global Health, Amsterdam Institute of Global Health and 
Development, Academic Medical Centre, Amsterdam, The Netherlands. 
5.  National Tuberculosis Reference Laboratory, Centre for Infectious Disease Control 
(CIb/LIS), National Institute for Public Health and the Environment (RIVM), 
Bilthoven, The Netherlands. 
6. Departments of Pulmonary Diseases and Medical Microbiology, Radboud 
University Medical Center, Nijmegen, The Netherlands. 
7. Institute of Genetics and Microbiology, University Paris-Sud, Orsay, France. 
 
International Journal of Tuberculosis and Lung Disease, 2013, 17(11): 1479-1485. 
 
 
 
 
 
 
 
Chapter 7 
102 
Abstract 
Background 
The molecular diagnosis of tuberculosis (TB) in Vietnam is often based on the detection 
of insertion sequence IS6110 in Mycobacterium tuberculosis. However, 8-11% of M. 
tuberculosis strains in South-East Asia do not contain this target and this undermines 
the validity of these molecular tests. 
 
Methods 
We quantified the frequency of M. tuberculosis strains lacking IS6110 in rural Vietnam 
and studied their epidemiological and clinical characteristics. 
Consecutively diagnosed adult TB patients in rural Southern Vietnam submitted two 
sputum samples for culture, IS6110 restriction fragment length polymorphism (RFLP), 
spoligotyping and 15-loci variable number tandem repeat (VNTR) typing. Polymerase 
chain reaction (PCR) was performed to confirm the absence of the IS6110 elements in 
strains lacking IS6110 hybridization in RFLP.  
 
Results 
Among 2,664 TB patient isolates examined, 109 (4.1%) had no IS6110 element. 
Compared to other strains, these no-copy strains were less often resistant to anti-
tuberculosis drugs, particularly to streptomycin (adjusted odds ratio 0.2, 95% 
confidence interval 0.1-0.5) and showed significant geographic variation. No 
associations with TB history or demographic factors were found. 
 
Conclusions 
Strains without the IS6110 target pose a problem in Vietnam as regards false-negative 
molecular TB diagnosis in PCR. Compared to other strains circulating in Vietnam, no-
copy strains are more susceptible to anti-tuberculosis drugs. 
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Introduction 
Tuberculosis (TB) remains one of the most important infectious diseases 
worldwide. In 2011, 8.7 million TB cases were notified by the World Health 
Organization (WHO) and approximately 1.4 million people died of the disease [1]. The 
vast majority of TB cases are still diagnosed using acid-fast bacilli smear microcopy 
[2], which, due to its low sensitivity, means that many TB patients are not diagnosed in 
time and continue to transmit TB in the community.  
New approaches in the diagnosis of TB are being explored, including polymerase 
chain reaction (PCR), in which a specific fragment of DNA in the causative agent, 
Mycobacterium tuberculosis, is targeted and amplified to a detectable level. PCR is 
rapid, sensitive and specific, and can be used for the rapid diagnosis of both pulmonary 
[3] and extra-pulmonary TB [4]. The insertion sequence (IS) 6110 element is one of the 
most widely used targets, due to its omnipresence in M. tuberculosis complex strains 
and its absence in non-tuberculous mycobacteria [5,6].
 
However, the number of IS6110 
copies varies significantly by strain, from 0 to 25, and the consequences of this 
variation as regards fluctuations in sensitivity have not yet been explored. M. 
tuberculosis strains that lack an IS6110 element (no-copy strains) exist, as was already 
described in 1993 [7] soon after the introduction of IS6110 restriction fragment length 
polymorphism (RFLP) typing for an isolate from an Indian patient, and the existence of 
such no-copy strains in Vietnam was confirmed as early as 1995 [8]. Using RFLP 
typing, one study in India reported a proportion of no-copy strains of 11% [9], whereas 
in the United States such strains are extremely rare [10].  
The diagnostic laboratory test routinely used to diagnose TB in Vietnam is still 
Ziehl-Neelsen (ZN) microscopy, whereas IS6110 PCR is often used for ZN negative 
cases with a high suspicion of TB or in the private sector for early diagnosis of TB. 
There are diagnostic molecular assays that do not target IS6110, such as the Amplified 
MTD
®
 test (Gen-Probe, San Diego, CA, USA) and the GenoType
® 
MTBDRplus test 
(Hain Lifescience, Nehren, Germany); however, these are much more expensive than 
the locally produced commercial IS6110 PCR that is used in most Vietnamese 
laboratories. In Vietnam, strains without IS6110 DNA may therefore lead to significant 
diagnosis of false-negative TB among smear-negative patients.  
Most studies on biological variations between the different phylogenetic lineages 
have focused on strains of the Beijing genotype, which is highly prevalent in (South) 
East Asian countries such as China and Vietnam [11], and only a few studies have 
investigated no-copy strains [9,10]. It was recently estimated that no fewer than 8% of 
the M. tuberculosis strains in Vietnam lack IS6110 DNA (unpublished data), but their 
molecular characteristics and their clinical and epidemiological characteristics remain 
unclear.  
We performed a population-based prospective study on TB transmission 
dynamics in rural Vietnam, which gave us the opportunity to determine the frequency 
of no-copy strains more accurately. We also studied the molecular characteristics of 
these no-copy strains and determined their association with patient characteristics, 
spread and drug resistance patterns. 
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Material and methods 
Study population  
A population-representative sample of smear-positive sputum specimens was 
collected from TB patients in three adjacent rural districts (Cailay, Caibe, Chauthanh) in 
Tien Giang Province, situated in the Mekong River Delta in Southern Vietnam. 
Molecular typing was performed at the Pham Ngoc Thach Hospital in Ho Chi Minh 
City, Vietnam. 
All patients aged ≥15 years, resident in the study area and registered f r treatment 
of smear-positive pulmonary TB between 1 January 2003 and 28 June 2007 at the 
participating district TB units or at the provincial TB hospital were eligible for inclusion 
in the study. Confirmation of the TB diagnosis relied on examination of at least two 
ZN-stained sputum smears [12].
 
Eligible patients were included after providing written 
informed consent; each submitted two sputum samples. For each patient sex, age, 
bacilles Calmette-Guerine (BCG) vaccination status, education, marital status, 
profession and previous history of anti-tuberculosis treatment were recorded using a 
standard questionnaire. Human immunodeficiency virus testing was not routinely 
performed. Patients who had been on treatment for TB for more than two weeks for this 
disease episode were excluded.  
This study was approved by the ethical health committee of the Ho Chi Minh City 
Council. 
 
Mycobacterium tuberculosis culture  
Sputum specimens were kept refrigerated and transported to Pham Ngoc Thach 
hospital in Ho Chi Minh City within 72 h. They were decontaminated and liquefied 
with 1% N-acetylcystine, 2% sodium hydroxide, inoculated on modified Ogawa 
medium and incubated at 37ºC. Cultures were examined for growth after 1, 2, 4, 6 and 8 
weeks of incubation. Cultures with no growth after 8 weeks were reported as negative. 
M. tuberculosis complex was identified using the niacin and the nitrate tests [13].  
 
Drug susceptibility testing 
Drug susceptibility testing was performed by the proportion method per WHO 
guidelines. Criteria f r drug resistance were ≥1% c   ny gr wth at 28  r 42 days  n 
Löwenstein-Jensen (LJ) medium compared to drug-free control LJ medium, at the 
following drug concentrations: isoniazid (INH) 0.2 g/ml, rifampicin (RMP) 40 g /ml, 
streptomycin (SM) 4 g /ml and ethambutol (EMB) 2 g /ml [14].  
 
DNA typing 
Genomic DNA was extracted from positive cultures by a method described 
elsewhere [15].
 
IS6110 RFLP and spoligotyping were performed as per internationally 
standardized methods [15-17].
 
Variable number tandem repeat (VNTR) typing was 
performed on the basis of 15 loci, as described by Supply et al. [18].
 
To determine the 
presence of IS6110 elements in the M. tuberculosis genome, the template DNA was 
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targeted by specific IS6110 primers on PCR, and PCR products were checked on 1.5% 
agarose gel [15].  
 
Selection of the no IS6110 copy strains 
In 2004, we reported that more than 30% of M. tuberculosis in this area were East 
African-Indian (EAI) strains, EAI 4VNM and EAI 5, which often harbour fewer than five 
IS6110 copies [19].
 
RFLP typing was thus unable to discriminate between such low-copy 
strains, and we replaced RFLP by VNTR typing for all strains. As RFLP analysis was 
conducted for only a subset of the isolates in this study, we used similarity on the basis 
of spoligotyping results to trace other potential no-copy strains among these strains 
without RFLP results.   sp  ig  pr t type  f the “zer  c py” c ade suggested in 2006 
by Brudey et al. has the spoligo international type (SIT n°) 405 [20]. Spoligo patterns of 
all isolates were compared using a dendrogram. Isolates that showed ≥ 90% similarity 
with the spoligo patterns of the no-copy strains detected using RFLP typing in the 
dendrogram were subjected to IS6110 PCR. If this PCR did not yield a PCR product, 
the strains were considered no-copy strains. 
No-copy strains were defined as M. tuberculosis complex strains with no bands 
in IS6110 RFLP typing or with a spoligo pattern characteristic of no-copy strains and 
no product in the IS6110 PCR. 
 
Data management and analysis  
Data were double-entered in Epi Info, version 6.04 (Centers for Disease Control 
and Prevention, Atlanta, GA, USA); discrepancies were corrected based on the raw 
data. Bionumerics software, version 3.0 (Applied Maths, Sint-Martens Latem, Belgium) 
was used for the analysis and comparison of IS6110 RFLP, spoligo and VNTR patterns. 
Statistical analyses were performed in Epi Info 6.04 and Stata 10SE (Stata 
Corp., College Station, TX, USA). For comparison of categorical variables, we used the 
chi-squared and 2-sided Fisher’s exact tests, as appropriate. Associations with 
explanatory variables were expressed as odds ratios (ORs); confounding effects were 
investigated by multivariable logistic regression modeling. All tests were performed at 
the 5% significance level. In a secondary analysis, we excluded from the comparator all 
Beijing strains, as these may have specific characteristics, including associations with 
resistance. 
 
Results 
During the study period 2,851 smear-positive TB patients were registered, of 
whom 2,664 (93.4%) were available for analysis, including 1,996 (74.9%) males and 
668 (25.1%) females, with a median age of 49 years (25
th
 and 75
th
 percentile 36 and 
65.5 years, respectively). Of these, 2,386 (89.6%) were new patients, 255 (9.6%) had 
been previously treated and the remaining 23 (0.8%) were of unknown status. Among 
2,664 isolates with spoligotyping results, 2,526 (94.8%) were successfully subjected to 
VNTR typing and yielded a complete 15-loci pattern, and 1,797 (67.5%) were subjected to 
RFLP typing. Based on our definition for the selection of no IS6110 copy strains, 60 no-
copy strains were identified directly using RFLP. For 59 potential no-copy strains, no 
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RFLP pattern was available. These strains were selected because their spoligo patterns 
showed ≥ 90% similarity to strains known to lack IS6110 using RFLP typing. In total, 
109 of 2664 (4.1%) strains were confirmed as lacking any IS6110 element on IS6110 PCR 
(Figure 1). 
Of 109 no-copy strains, 71 (65.1%) were missingspacers 19 to 41, and 13 (11.9%) 
strains were missing spacers 19 to 25 and 27 to 41. The remaining strains missed other 
spacers, but were observed less frequently (<6%; Figure 2) [21]. Of 109 no-copy strains, 
20 (18.3%) had the VNTR pattern 642253245272461 often seen in EAI but not in Beijing 
strains; the remaining VNTR patterns were observed in <10% of the isolates (Table 1).  
 
 
Figure 1. Study flow chart. The data analysis is based on isolates for which a spoligo 
pattern was available. RFLP = restriction fragment length polymorphism; IS = insertion 
sequence; PCR = polymerase chain reaction. 
 
 
Association between no-copy signature and epidemiological factors and drug 
resistance 
In univariate analysis, there were no significant associations between the IS6110 
no-copy signature and sex, age or year of inclusion of the patient nor with susceptibility 
of the isolate to EMB. A no-copy signature was significantly associated with 
susceptibility to INH (P=0.003) and SM (P<0.001), and was significantly more frequent 
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in one of the three districts (Chauthanh; P=0.027). In a multivariable model including 
the variables districts, sex, age, history of TB, INH resistance and SM resistance, a no-
copy signature remained significantly associated with susceptibility to SM (adjusted OR 
[aOR] 0.2, 95%CI 0.1-0.5) and Chauthanh district (aOR 2.0, 95%CI 1.2-.3.1) (Table 2).  
Compared to all strains except those belonging to the Beijing genotype, no-copy 
signatures were significantly associated with susceptibility to SM (aOR for resistance 
versus susceptibility to SM 0.4, 95%CI 0.2-0.9) and being isolated from Chauthanh 
district (data not shown). 
 
 
Figure 2. Spoligotyping patterns of the 109 no-copy M. tuberculosis strains identified 
in this study. The figure shows the UPGMA (Unweighted Pair Group Method with 
Arithmetic Mean) dendrogram (left) that was constructed based on the similarity of the 
spoligo patterns, the spoligo patterns (middle) and the number of strains showing 
similar spoligo pattern results (right). Among the 109 no-copy strains, 17 different 
spoligo patterns were identified. A spacer showing weak signal was considered to be 
absent when its intensity was 15% or less of the average intensities of the other bands in 
the same lane [21].
  
 
 
Discussion 
In this population-based study among TB patients in a rural area in Southern 
Vietnam, we found that no-copy IS6110 strains are relatively frequent, with a prevalence 
of 4.1%. No-copy signatures were associated with susceptibility to anti-tuberculosis 
drugs, especially SM. These associations are in contradiction with those found earlier 
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for the Beijing genotype family, which was significantly associated both with resistance 
to anti-tuberculosis drugs, especially SM and INH [22], and with multidrug resistant TB 
[23-25]. The analysis yielded similar results after excluding Beijing strains. 
 
Table 1. Frequency of 66 no-copy strains sharing VNTR patterns between M. tuberculosis 
families * 
VNTR patterns 
often shared by 
strains 
No-copy 
Strains 
(n=109) 
n (%) 
East-African 
Indian strains 
(n=917) 
n (%) 
Other genotype 
Strains 
(n=580) 
n (%) 
Beijing 
strains 
(n=910) 
N 
642253245272461  20  (18.3)  101 (11)
¥
  28 (4.7) 0 
642253245272421  10  (9.2)  1  (0.1)  0  0 
642253245262461  9  (8.3)  7  (0.8)  3  (0.5) 0 
542253245272461  6  (5.5)  8  (0.9)  6  (1) 0 
642253245272261  5  (4.6)  1  (0.1)  1  (0.2) 0 
542251245272461  3  (2.8)  2  (0.2)  2  (0.3) 0 
742253245272461  1  (0.9)  7  (0.8)  1  (0.2) 0 
642253246272461  1  (0.9)  1  (0.1)   0  0 
642252245272461  1  (0.9)  1  (0.1)  17 (2.9) 0 
642252245272451  1  (0.9)  2  (0.2)  2  (0.3) 0 
542253245262461  1  (0.9)  2  (0.2)  1  (0.2) 0 
542253245272561  1  (0.9)  1  (0.1)  1  (0.2) 0 
642253245172461  1  (0.9)  4  (0.4)  0 0 
642253245262561  1  (0.9)  2  (0.2)  0 0 
632253245272461  1  (0.9)  23  (2.5)  8  (1.4) 0 
642253245252461  1  (0.9)  3  (0.3)  2  (0.3) 0 
642253245272661  1  (0.9)  1  (0.1)  0 0 
642253245282461  1  (0.9)  1  (0.1)  0 0 
642253245272411  1  (0.9)  1  (0.1)  0 0 
*43 no-copy strains with different VNTR patterns are not mentioned in this table. 
Mycobacterium families were confirmed based on SpolDB4 [20].
  
¥
The most frequent common VNTR pattern between the no-copy and the EAI. 
VNTR = variable number tandem repeat; EAI = East- African- Indian. 
 
 
As these strains have no copy of the IS6110 element in their genome, which is used 
as a target sequence in the IS6110 PCR, they cannot be detected by this test. To date, at 
least six laboratories in the South Vietnam have used the IS6110-based PCR to diagnose 
TB; this implies that a significant number of smear-negative TB patients may currently be 
misdiagnosed by PCR in this area and may remain a source of TB transmission in the 
community. IS6110 PCR should thus be replaced by another PCR method does not use 
IS6110 as a target, such as, for example, a specific rpoB gene signature, which is used 
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in GeneXpert
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 MTB/RIF (Cepheid, Sunnyvale, CA, USA)[26] and is present in all M. 
tuberculosis complex strains, or by IS1081, which is usually present in multiple copies 
in strains that lack IS6110 [7,27].  
The frequency of no-copy strains (4.1%) in our study was significantly lower (P 
<0.001) than in previous studies in Vietnam and India, both of which detected no-copy 
strains using RFLP only, and in which the frequency of these strains was estimated at 
respectively 8% and 11% of tested isolates (N.T.N. Lan, personal communication) [9]. 
This difference is probably due not only to the differences in geographical distribution of 
genotypes of M. tuberculosis, but also to the identification and verification of no-copy 
strains. We used RFLP and spoligotyping to screen for IS6110-devoid strains and used 
PCR to confirm IS6110 PCR for verification. It is conceivable that this approach has a 
higher specificity for detecting no-copy strains, resulting in fewer misclassifications of 
strains with IS6110 bands as no-copy strains than when only RFLP typing is performed. 
Lok et al. found that no-copy strains were extremely rare in the United States (0.18%) 
and that these were usually found in persons originating from South-East Asia [10].
  
 A potential explanation as to why South-East Asians are more frequently infected 
with no-copy strains than, for example, Americans of other origins may be the historical 
geographical isolation of South-East Asian populations, or an as yet unknown co-
evolution of host and pathogen. No-copy strains are represented among the EAI lineage 
(as defined by spoligotyping, Brudey et al. [20], also known as Lineage 1 or Rim of 
Indian Ocean, as defined by single nucleotide polymorphisms [SNPs]) [28,29]. Based 
on SNPs, no-c py strains represent the “ancient  ineage”, a  ineage that has m re 
similarity to the common ancestor of all M. tuberculosis complex strains than strains of 
the “m dern  ineage”, which have underg ne m re mutati ns. Strains of the Beijing 
genotype, which, in contrast to the no-copy strains, show a strong association with anti-
tuberculosis drug resistance, belong to the modern lineage. The acquired mutations may 
have given the Beijing genotype strains an advantage in their adaptation to the pressure 
of BCG vaccination [30] and treatment by anti-tuberculosis drugs. Moreover, in a 
recent study by De Steenwinkel et al., it was shown that a part of the Beijing genotype 
strains have much higher intrinsic resistance to treatment by RMP, as well as a higher 
mutation frequency in the generation of RMP-resistant mutants in comparison with EAI 
isolates [31]. 
This most likely indicates that no-copy strains are, in terms of evolution, less fit to 
deal withthe current measures against TB; they may therefore represent an interesting 
group of strains for studying the evolutionary development and adaptation of M. 
tuberculosis to the current measures against TB. 
There are some limitations in our study. First, we did not use other markers such as 
TbD1 to test no-copy strains. Second, RFLP typing was not applied to screen for IS6110 in 
all isolates; however, all isolates were screened using spoligotyping, and the results were 
confirmed using IS6110 PCR. Finally, this study included only patients from a limited 
area in the south of Vietnam, and it is not known if the findings can be extrapolated to 
other regions in this country. 
 
  
TABLE 2. Uni- and multivariable associations between no-copy strains and epidemiological characteristics and drug resistance.  
Characteristics  Total Patients 
n (%) 
Crude 
OR 
P value Adjusted 
OR* 
95% CI P value 
Age (yrs)    0.278   0.265 
15-34 563  18  (3.2) 1  1   
35-64 1397  56  (4) 1.3  1.3 0.8-2.3  
 >= 65 704  35  (5) 1.6  1.6 0.9-2.9  
Sex    0.880   0.790 
Male 1996  81  (4.1) 1  1   
Female 668  28  (4.2) 1.03  1.06 0.7-1.7  
District    0.027   0.015 
Cailay 1084  33  (3.0) 1  1   
Caibe 784  32  (4.1) 1.4  1.3 0.8-2.1  
Chauthanh 796  44  (5.5) 1.9  2.0 1.2-3.1  
TB treatment history     0.051   0.141 
New patient 2386  105  (4.4) 1  1   
Previously treated patient 255  4  (1.6) 0.4  0.5 0.2-1.3  
Unknown 23  0      
Isoniazid resistance    0.003   0.726 
Yes 543  10  (1.8) 0.4  0.9 0.4-1.8  
No 2121  99  (4.7) 1  1   
Rifampicin resistance    0.061    
Yes 126  1  (0.8) 0.18     
No 2538  108  (4.3) 1     
Streptomycin resistance    <0.001   <0.001 
Yes 743  8  (1.1) 0.1  0.2 0.1-0.5  
No 1921  101  (5.3) 1  1   
  
 
 
 
Table 2, continued. Uni- and multivariable associations between no-copy strains and epidemiological characteristics and drug resistance. 
Characteristics  Total Patients 
n (%) 
Crude 
OR 
P value Adjusted 
OR* 
95% CI P value 
Ethambutol resistance    0.479    
Yes 48  1  (2.1) 0.49     
No 2616  108  (4.1) 1     
Multidrug resistance    0.09    
Yes 108  1  (0.9) 0.2     
No 2556  108  (4.2) 1     
* Adjustment for districts, sex, age, history of TB, and isoniazid and streptomycin resistance. 
OR = odds ratio; CI = confidence interval; TB = tuberculosis. 
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Conclusions 
The frequency of strains without IS6110 DNA in a rural part of South Vietnam 
was 4.1%. This suggests that TB is underdiagnosed in Vietnam, as PCR tests targeting 
IS6110 are commonly used in Vietnam. Compared to other strains, drug resistance, 
especially to SM, occurred at lower frequencies in the no-copy family. 
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Abstract 
 
Background 
In comparison to restriction fragment length polymorphism (RFLP) typing, variable 
number of tandem repeat (VNTR) typing is easier to perform, faster and yields results 
in a simple, numerical format. Therefore, this technique has gained recognition as the 
new international gold standard in typing of Mycobacterium tuberculosis. However, 
some reports indicated that VNTR typing may be less suitable for Beijing genotype 
isolates. We therefore compared the performance of internationally standardized RFLP 
and 24 loci VNTR typing to discriminate among 100 Beijing genotype isolates from the 
Southern Vietnam. 
 
Methods 
Hundred Beijing genotype strains defined by spoligotyping were randomly selected and 
typed by RFLP and VNTR typing. The discriminatory power of VNTR and RFLP 
typing was compared using the Bionumerics software. 
 
Results 
Among 95 Beijing strains available for analysis, 14 clusters were identified comprising 
34 strains and 61unique profiles in 24 loci VNTR typing ((Hunter Gaston 
Discrimination Index (HGDI = 0.994)). 13 clusters containing 31 strains and 64 unique 
patterns in RFLP typing (HGDI = 0.994) were found. Nine RFLP clusters were 
subdivided byVNTR typing and 12 VNTR clusters were split by RFLP. Five isolates 
(5%) revealing double alleles or no signal in two or more loci in VNTR typing could 
not be analyzed. 
 
Conclusions 
Overall, 24 loci VNTR typing and RFLP typing had similar high-level of discrimination 
among 95 Beijing strains from Southern Vietnam. However, loci VNTR 154, VNTR 
2461 and VNTR 3171 had hardly added any value to the level of discrimination. 
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Background 
The IS6110 restriction fragment length polymorphism (RFLP) typing was 
previously considered the gold standard in the molecular epidemiology of tuberculosis 
[1]. Although this typing technique generally revealed a high level of discrimination 
among Mycobacterium tuberculosis isolates, it was considered complicated, technically 
demanding, and time consuming. In addition, a part of the strains contained too few 
copies of IS6110 to enable a reliable typing. Variable number of tandem repeat (VNTR) 
typing is easier and faster to perform, and yields results in a numerical format. 
Therefore, this technique has become the new international typing method for M. 
tuberculosis since 2006 [2]. Several studies indicated that VNTR typing is as 
discriminative as RFLP typing and more suitable to type strains with few copies of 
IS6110 [3,4]. However, doubt remained whether VNTR typing is as good as RFLP 
typing in discriminating Beijing genotype strains. As in Vietnam about 40% of the M. 
tuberculosis isolates are of this genotype, we in this study compared the performance of 
RFLP and internationally standardized 24 loci VNTR typing to discriminate among one 
hundred Beijing genotype isolates from the South of Vietnam.  
 
Methods 
Study population 
In total 100 M. tuberculosis isolates of the Beijing genotype family were selected 
from a previous study on the dynamics of tuberculosis transmission in Vietnam. The 
study area consisted of three adjacent rural districts in Tiengiang Province, in the 
Mekong River Delta in Southern Vietnam.     patients were aged ≥15 years, resident in 
the study area and registered for treatment of smear-positive pulmonary tuberculosis 
(TB) between 1 January 2003 and 28 June 2007 at the participating District 
Tuberculosis Units, or at the provincial TB hospital and were eligible for inclusion into 
the study. Each eligible patient submitted two sputum samples for TB culture, drug 
susceptibility testing and genotyping and completed an interview form. The details of 
this study have been published previously [5]. 
 
Ethical approval 
Ethical clearance was obtained from the ethical health committee of the Ho Chi 
Minh City Council (reference number 1106/UBND-VX). All included patients provided 
written informed consent. 
 
Mycobacterium tuberculosis culture  
Sputum specimens were kept refrigerated and transported to Pham Ngoc Thach 
Hospital in Ho Chi Minh City within 72 hrs after collection. They were decontaminated 
and liquefied using 1% N-acetylcysteine/2% NaOH, inoculated on modified Ogawa 
medium and incubated at 37
0
C. Cultures were examined for growth after 1, 2, 4, 6 and 8 
weeks of incubation. Cultures with no growth after 8 weeks were considered negative. 
M. tuberculosis was identified using the niacin and the nitrate tests [6]. 
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DNA typing 
Genomic DNA was extracted from positive cultures using an earlier described 
method [7]. IS6110 RFLP typing and spoligotyping were performed according to the 
internationally standardized methods [1,8]. The VNTR typing was executed on the basis of 
15 loci and 24 loci as described by Supply et al.[2]. 
 
Random selection of one hundred Beijing genotype strains  
Among 1,797 M. tuberculosis isolates that were successfully typed in RFLP and 
spoligotyping, 819 strains represented the Beijing genotype according to spoligo typing 
patterns. After the isolate numbers had been sorted in numerical order, every 8
th
 Beijing 
genotype was selected until a total of 100 isolates was reached.  
 
Data analysis  
 Gene Marker software, version 1.5 (Softgenetics, PA, USA) was used for analysis 
and automated allele calling of the VNTR patterns. The Bionumerics software, version 
3.0 (Applied Maths, Sint-Martens Latem, Belgium) was used for the analysis and 
comparison of IS6110 RFLP and VNTR typing patterns. 
The Hunter Gaston Discrimination Index (HGDI) was used to analyse the discrimination 
power of VNTR and RFLP typing results [9]: 
  
Where n is the total number of strains in the sample population, s is the total number of 
types described, and nj is the number of strains belonging to the j
th
 type. This equation 
is derived as follows: the probability that a single strain sampled at random will belong 
to the j
th
 group is nj/n and the probability that two strains sampled consecutively will 
belong to that group is nj(nj - 1)/n(n - 1). 
 
Definitions 
Beijing lineage (genotype) strains were defined as strains having at least three of the 
nine spacers 35 to 43 and lacking spacers 1-34 based on the 43 spacer spoligo patterns 
[8,10]. If a strain missed all spacers 1-34 and also one or a few of the spacers 35-43, the 
Beijing strains was considered to represent the Atypical branch of the Beijing genotype 
lineage [11].  
Two strains were defined as a cluster if they had identical RFLP patterns or 
identical VNTR profiles (Bionumerics), or if VNTR types differed by no more than a 
single locus [2].  
 
Results  
In the period January 2003 to June 2007, a total of 2,664 M. tuberculosis strains 
were isolated from eligible patients, of which 1,795 were successfully typed in RFLP 
and spoligo typing. Of these, 819 (45.6%) were of the Beijing genotype based on the 
spoligo patterns; the remaining 976 (54.4%) were of other genotypes. Among the 819 
1
1
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S
j
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Beijing genotype strains, 41 (5.0%) most likely belonged to Atypical Beijing lineage, as 
they missed one or more spacers of the characteristic 9 spacer signature.  
Of the 819 Beijing strains, 353 (43.1%) were isolated from patients in the Cailay 
district; 221 strains (27%) isolated from patients in the Caibe district, and the remaining 
245 strains (29.9%) from patients in the Chauthanh district. Regarding the gender of 
patients, 592/819 (72.3%) of the strains were isolated from male patients, the remaining 
227 (27.7%) from females.  
 
2664 Mycobacterium tuberculosis isolates
1795 isolates withRFLP+ spoligotypes available
819 Beijing lineage strains
976 other genotypes
778 Typical Beijing strains
41 Atypical Beijing strains
100 Beijing strains random selection subjected to 24 loci VNTR 
5 strains excluded
- missing at least 2 loci: 3
- double alleles at least 2 loci: 2
95 strains available for analysis 
869 no RFLP available
Figure 1. Study flow chart. 
 
From these 819 Beijing genotype strains, 100 strains were randomly selected as 
described above, of which 5% were most likely Atypical Beijing strains because they 
missed one or two spacers of the characteristic nine spacer panel 35-43. 
Among the 100 selected Beijing genotype strains, 38 (38%) were isolated in the 
Cailay district, 32 (32%) in the Caibe district and 30 (30%) in the Chauthanh district. 
The gender distribution was 71% males and 29% female patients. Therefore, the 
distribution of sex, districts, age (data not shown) in the representative Beijing strains 
was similar to that in the total collection of 819 Beijing strains (P>0.05). 
Among the 100 Beijing isolates that were subjected to 24 loci VNTR typing, 95 
yielded results suitable for analysis (including 88 that yielded results for all 24 loci and 
7 with double alleles or that missed one locus only), the remaining 5 strains were 
excluded because ambiguous PCR results were obtained or double alleles were 
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observed in at least two loci. Among 3/5 isolates at least two loci could not be amplified 
and two isolates had double alleles in two or more loci (Figure 1). 
Of the 24 loci analyzed, VNTR 154, VNTR 2461 and VNTR 3171 had no 
discrimination power and hence, the HGDI was zero. Loci VNTR 2347, VNTR 580, 
VNTR1644, VNTR 0577, VNTR 2531, VNTR 2401 and VNTR 802 had a HGDI of 
less than 0.2. The loci having a HGDI of more than 0.4 were VNTR 424, VNTR 960, 
VNTR 2996, VNTR 4052, VNTR 1955, VNTR 2165 and VNTR 2163b. Locus VNTR 
2163b had the highest allelic diversity, with a HGDI of 0.64 (Figure 2 and Table 1). 
 
 
Figure 2. Hunter Gaston discrimination index of 24 VNTR loci among 95 Beijing 
strains. Y axis: Hunter Gaston discrimination index. 
 
In the 24 loci VNTR typing of the remaining 95 isolates, 14 clusters of isolates 
were found; one cluster of four isolates, four clusters of three isolates and nine clusters 
of two strains. Sixty-one isolates revealed a unique VNTR pattern. The HGDI 
amounted to 0.994. Twelve of the VNTR clusters were subdivided in RFLP typing. 
In RFLP typing, 13 clusters of isolates were found, comprising in total of 31 
strains. There were ten clusters of two, two clusters of three and one cluster of five 
isolates. Sixty-four isolates had a unique RFLP pattern (HGDI = 0.994). Nine RFLP 
clusters were subdivided in VNTR typing. 
 
Discussion 
From 1993 to 2006, RFLP typing was considered the gold standard in typing of 
M. tuberculosis isolates, especially for strains harboring multiple IS6110 copies, like 
the ones of the Beijing genotype family. However, this typing method is technically 
demanding and time consuming [4]. Furthermore, the discriminatory power of RFLP 
typing among strains with a low number of IS6110 copies (<= 5 copies) is very poor 
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[3]. Therefore, in recent years VNTR typing has increasingly been explored in the 
molecular epidemiology worldwide and with the proposal on international 
standardization of this technique in 2006 it has in fact become the new gold standard 
[2]. VNTR typing introduced major advantages in typing in comparison to RFLP 
typing, such as its ease in use, its suitability for standardization, and that the  
results that are displayed in numbers can be analyzed easily and exchanged efficiently 
between laboratories. Moreover, the turnaround time of VNTR typing is much shorter 
than that of RFLP typing, because it is PCR-based and only a little amount of 
mycobacterial DNA is required.  
 
Table 1. Hunter Gaston discrimination index (HGDI) values obtained for each locus in 
the present compared to two other studies. 
VNTR locus Present study Kremer et al. [4] Alonso et al. [12] 
154 0.00  0.23 
2461 0.00 0.00  
3171 0.00   
2347 0.02   
580 0.02 0.019 0.21 
1644 0.06 0.058 0.455 
577 0.06 0.165 0.63 
2531 0.08  0.655 
2401 0.10  0.65 
802 0.16 0.196 0.73 
3192 0.21  0.36 
4156 0.23  0.53 
2687 0.24  0.06 
2059 0.26  0.16 
3690 0.27  0.64 
3007 0.31  0.13 
4348 0.37 0.32 0.09 
424 0.42  0.66 
960 0.44 0.377 0.685 
2996 0.46 0.2 0.46 
4052 0.50 0.299 0.8 
1955 0.57  0.65 
2165 0.635 0.201 0.61 
2163b 0.64 0.618 0.78 
 
Many researchers have carried out comparisons between RFLP and 12 or 15 loci 
VNTR typing methods for discriminating M. tuberculosis isolates [3,4,12]. Their 
findings showed that the discriminative power of 12 loci VNTR was lower than that of 
15 loci VNTR (with HGDI of 0.978-0.995) [12] and 15 loci VNTR has high level of 
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discrimination with HGDI 0.990-0.995 [4,12], but this was still lower than that of RFLP 
typing (0.998) [4]. However, Supply et al. [2] proposed to apply 24 instead of 15 loci in 
VNTR typing and this improved the level of discrimination significantly.  
In our study, we compared the performance of 15 and 24 loci VNTR typing and 
RFLP typing using 95 Beijing strains and we found that the discrimination index 
(HGDI) of 15 loci VNTR was the lowest (0.992), followed by both RFLP typing and 24 
loci VNTR typing (0.994). However, the differences observed were small. The HGDI 
of some loci (VNTR 154, VNTR 2461, VNTR 3171) were low in our study, which 
means that these loci are less useful in discriminating Beijing strains in the South of 
Vietnam and presumably elsewhere. The HGDI of VNTR 2461, VNTR 577, VNTR 
2163b, VNTR 580, VNTR 802, VNTR 960, VNTR 1644 and VNTR 4348, were similar 
to that observed in a previous study in Hong Kong [4] (Table 1), whereas the HGDI of 
VNTR 2996, VNTR 4052, and VNTR 2165 were significantly higher than the ones in 
that study [4] (Table 1), for unknown reasons. It may be that because BCG vaccination 
has been introduced much earlier in Hong Kong than in Vietnam, the ongoing selection 
of particular strains of the Beijing lineage [11] may be more advanced in the former 
than in the latter area and the mentioned loci may have a different level of 
discriminative power among the circulating strains in both areas. 
Our study further found the HGDI of VNTR 1955, 2163b and 2165 to be very 
high (>0.50) and the best differentiation, similar to two previous studies [4,12], was 
obtained with VNTR 2163b (Table 1 and Figure 2).  
Some of the HGDI of individual loci in our study were significantly different to 
the ones found in the study of Alonso et al. [12] (Table 1), because we performed 
VNTR typing of exclusively Beijing strains, whereas Alonso et al. [12] carried out 
VNTR typing on a strain collection consisting of 32% LAM, 28% Haarlem and only 
2% Beijing strains.  
A disadvantage of VNTR typing encountered in this study was that six strains 
revealed double alleles in a single locus, and two strains even in two and more than two 
loci. It is not clear whether the latter observation was associated with a mixed infection 
[13]. However, the revealed genomic instability in particular loci decreases the utility of 
VNTR typing significantly, as this hampers a reliable interpretation. Also in RFLP 
typing transposition of IS6110 sometimes interfered with a reliable interpretation, but 
such a genetic turn-over was observed less frequently [14]. However, we cannot 
exclude the possibility that these multiple alleles may reflect important phenomena in 
the epidemiology of TB currently unknown, and these observations, although 
technically demanding, may be associated with the ongoing adaptation of M. 
tuberculosis to the current TB control measures.  
A major limitation of this study was that we did not have epidemiological 
information available to verify the transmission links indicated by both typing methods. 
It was therefore, not possible to ascertain the validity of epidemiological links indicated. 
Conclusions 
In comparison to 15 loci VNTR, RFLP typing and 24 loci VNTR typing revealed 
the highest level of discrimination among 95 isolates of the Beijing genotype from 
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Southern Vietnam. For this and other practical reasons, the last method is preferred in 
investigations on transmission of Beijing strains in Vietnam. The VNTR typing method 
is in principle also useful in screening for possible mixed infections, after which 
positive findings (more than two loci with double alleles) would be confirmed by other 
methods. 
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New molecular methods are useful for early diagnosis of MDR-TB in Vietnam 
We re-cultured 111 MTB MDR-TB, rifampin-resistant- or pan-susceptible M. 
tuberculosis isolates according to conventional DST and tested these with the 
GenoType® MTBDRplus test. We found a high specificity and positive predictive 
value of the GenoType® MTBDRplus test for MDR-TB (Chapter 2); our results were 
similar to some previous studies in other geographic areas [1, 2]. 
Early diagnosis of multidrug resistant tuberculosis (MDR-TB) plays an important 
role in interruption of MDR-TB transmission and in improving treatment outcome, 
whereas the conventional drug susceptibility testing requires 2 to 4 months for results. 
The Genotype® MTBDRplus test is one of the rapid and commercially available 
drug susceptibility tests that have been introduced in various countries for routine 
diagnosis of MDR-TB [1, 3-5]. This test has a high sensitivity and a very high 
specificity, in test situations and in routine use, as we showed in this thesis, and which 
was also found by others [1, 2]. Given the high sensitivity and specificity as well as the 
associated high positive and negative predictive values, the test has greatly reduced the 
diagnostic delay for MDR-TB patients. 
In September 2009, the National TB Program (NTP) in Vietnam approved routine 
use of this test in two TB reference laboratories for the rapid diagnosis of MDR-TB in 
patients suspected of MDR-TB. Also, the NTP provided free of charge MDR-TB 
treatment to MDR-TB patients diagnosed by the GenoType® MTBDRplus test. While 
we tested an older version of the test that was designed to test smear-positive sputum 
samples, recently a new version of the test that can also be used for smear negative TB 
patients was released. However, appropriate use of the GenoType® MTBDRplus test 
requires skilled technicians, three separate rooms (for preparation of the PCR mix, 
DNA extraction, and amplification); and a 24-hour turnaround time. For these reasons, 
this test is not suitable for use in district laboratories.  
In late 2009, the Cepheid company released the GeneXpert MTB/RIF assay, a 
nucleic acid-amplification test (NAAT) for M. tuberculosis detection and MDR-TB 
screening with high sensitivity and specificity [6]. Contrary to the GenoType® 
MTBDRplus test, the GeneXpert MTB/RIF can be performed by low skilled 
technicians in a peripheral laboratory and it can be applied to smear negative samples 
within a 2-hour turnaround time [6]. With such advantages, the GeneXpert MTB/RIF is 
becoming a common test around the world for the detection of MDR-TB. However, 
compared to the GenoType® MTBDRplus test, the disadvantages are that the test is not 
able to detect rifampicin resistance in mixed samples of resistant and sensitive strains, 
in which the concentration of resistant strain is less than 65% of the bacteria in the 
whole isolate [7], and that it gives a rifampicin resistance result, if the band WT8 is 
absent and the rpoB MUT3 probe does not develop, a such combination may be a 
L533P mutation that shows sensitivity to rifampicin in conventional tests [2].  
Recently, the MTBDRsl test has been introduced to diagnose XDR-TB, with high 
sensitivity and specificity for detection of fluoroquinolone and aminoglycoside 
resistance [8, 9]. Since 2012, this test has been used as a routine test to exclude XDR-
TB among MDR-TB patients in the STREAM study in Vietnam.  
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Thanks to these tests at least a part of the MDR-TB patients will be treated with 
appropriate drugs, therefore the transmission of MDR-TB and XDR-TB in the 
community will be reduced. 
 
The variable number of tandem repeat (VNTR) typing is a faster and easier tool than 
restriction fragment length polymorphism (RFLP) typing for tracking of TB 
transmission and for detecting mixed infections 
Hundred Beijing genotype strains, as defined by spoligotyping, were randomly 
selected and typed by RFLP and VNTR typing. The discriminatory power of VNTR and 
RFLP typing was compared using the Bionumerics software. Overall, 24 loci VNTR 
typing and RFLP typing had similar high-levels of discrimination among 95 Beijing 
strains from Southern Vietnam (Chapter 8). 
Previous studies indicated that VNTR typing is as discriminative as RFLP typing 
and more suitable to type strains with few copies of IS6110 [10, 11]. The 24 loci VNTR 
is also reliable in discriminating MTB strains having high number of IS6110 copies in 
their genome, such as Beijing genotype (Chapter 8, [11]). Therefore, 24 loci VNTR 
typing is an appropriate method for epidemiological investigation of TB transmission in 
Vietnam, where East African Indian genotype (few IS6110 copies) and Beijing 
genotype are two most predominantly circulating lineages [12]. However, the revealed 
genomic instability in particular loci decreases the utility of VNTR typing significantly, 
as this hampers a reliable interpretation. It remains to be determined how many 
different loci or how many loci having double alleles should be considered indications 
of two different strains, because different loci or double alleles in few loci could also 
represent the regular evolutionary development of the bacterium.  
 
Mixed infections are prevalent in Vietnam and patients with multiple infections could 
have an increased immunological tolerance to M. tuberculosis infections. 
In Chapter 3, 1,248 M. tuberculosis isolates from the same number of patients 
were subjected to RFLP-, spoligo- and VNTR typing. A patient was defined as having a 
mixed infection when his/her M. tuberculosis isolate exhibited RFLP and spoligotype 
patterns of two different M. tuberculosis lineages. 
Mixed infections were confirmed in 39 (3.1%) patients; all were cured by 
standard treatment. Mixed infections occurred more frequently in new than in re-
treatment patients, were significantly associated with minor X-ray abnormalities and 
there was a near-to-significant trend for lower sputum smear grades, both suggesting 
association with less extensive pathology. Simultaneous infection with two strains of 
Mycobacterium tuberculosis was previously detected by applying phage typing or 
genotyping techniques such as the IS6110 RFLP-, spoligo- and VNTR typing [13-18] 
(Chapter 3 and Chapter 8). The Genotype® MDRTBplus assay, can in principle also 
diagnose mixed infections of drug sensitive and drug resistant strains (Chapter 2). 
Based on RFLP and spoligotyping, we revealed that the rate of mixed infections 
of strains of two distinct lineages in a rural area in Vietnam with a population density of 
only 837/km
2
 and an observed TB incidence of new smear positive cases of 
100/100,000 in 2005 (National Tuberculosis Program Vietnam, unpublished data) and a 
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very low (0.5%) prevalence of HIV [19], 3.1% was lower than the rates reported in 
similar studies in South Africa, where the prevalence of TB and HIV are very high 
[20,14]. Our results show that mixed infections can also occur in an area with an 
incidence of TB of about 100/100000 population per year, with a low HIV co-infection 
rate, and that mixed infections are not related to TB symptoms or drug resistance. 
With 100% of the cases being cured, we do not have an indication that mixed 
infections lead to higher failure rates. In fact, in our population, they were associated 
with less extensive chest X-ray abnormalities than single infections. Moreover, mixed 
infections were associated with a lower degree of smear positivity; one hypothesis 
could be that patients with multiple infections have an increased immunological 
tolerance to M. tuberculosis infections. This finding, however, requires further study 
(Chapter 3). 
 
Besides Beijing and East African Indian strains, also strains without IS6110 are 
prevalent in Vietnam; therefore IS6110-based PCR is unreliable in TB diagnosis  
Consecutively diagnosed adult TB patients in rural Southern Vietnam submitted 
two sputum samples for culture, IS6110 RFLP-, spoligo- and 15 loci VNTR typing. 
PCR was performed to confirm the absence of the IS6110 elements in strains lacking 
IS6110 hybridization in RFLP. Among 2,664 TB patient isolates examined, 109 (4.1%) 
had no IS6110 element. Compared to other strains, these no-copy strains were less often 
resistant to anti-tuberculosis drugs, especially to streptomycin (adjusted odds ratio 0.2, 
95% CI: 0.1-0.5), and showed significant variation in geographic site of isolation. No 
associations with TB history or demographic factors were found. Hence, strains without 
the IS6110 target pose a problem in Vietnam regarding false-negative molecular TB 
diagnosis in PCR (Chapter 7). Based on spoligotyping, Brudey et al. found many 
different genotypes of MTB occurring worldwide [21], in which Beijing genotype is the 
best known genotype, because it was not only encountered in many countries with high 
prevalence especially in East and South East Asia [22-25], but also associated with drug 
resistance and MDR [22, 26-30]. 
From 1,084 MTB isolates collected in a nationwide drug resistance survey done 
in 2005 in Vietnam, Hung et al. found that 35% was of the Beijing genotype and 44.4% 
of the East African Indian (EAI) lineage. The Beijing genotype was more frequent in 
the South than in the North of Vietnam (39% vs. 30%, respectively) [12]. Besides the 
Beijing and EAI genotypes, the no-copy was considered more frequent in Asia, 
especially South East Asia [31]. In our study, 4.1% of the TB patients was infected with 
no-copy strains in a rural area of Vietnam (Chapter 7); this rate is significantly lower 
than the 11% reported previously in India [32]. This difference is probably due to the 
differences in geographical distribution of genotypes of M. tuberculosis, but also in 
identification and verification of no-copy strains. We used RFLP and spoligotyping to 
screen for IS6110-devoid strains and used PCR to confirm IS6110 PCR for verification. It 
is conceivable that this approach has a higher specificity for detecting no-copy strains, 
resulting in fewer misclassifications of strains with IS6110 bands as no-copy strains, than 
when only RFLP typing is applied (Chapter 7). 
Chapter 9 
129 
The characteristics of no-copy strains were completely opposite to those of 
Beijing strains. The huge differences between the no-copy and the Beijing genotype 
strains in correlation with factors like resistance to tuberculosis drugs may be due to the 
fact that the latter belong to the modern lineage, which have undergone more mutations, 
whereas the former seem to belong to an earlier ancestor of the M. tuberculosis complex 
[33, 34]. Furthermore, the Beijing genotype strains themselves may have a much higher 
intrinsic resistance to treatment by rifampicin, as well as a higher mutation frequency 
regarding the generation of rifampicin resistant mutants [35]. 
In 2002, Lok et al. showed that the prevalence of no-copy strains among TB 
patients with genotyping results was 0.18% in European countries [31], compared to 
Asian countries, where about 11% of all genotyped isolates concerns IS6110-devoid 
strains [32], while this was 4.1% in a rural area of Vietnam (Chapter 7). To our 
knowledge, so far, nowhere in the world, an outbreak has been reported caused by a no-
copy genotype strain. This genotype mostly occurs among elderly patients aged 65 
years and above, who are believed to develop TB disease mainly due to endogenous 
reactivation of remote infections rather than by acquisition of a recent infection [8]. 
This most likely indicates that no-copy strains are in terms of evolution less fit to deal 
with the current measures against TB, and will disappear in the coming decades. 
Alternatively, they may lose IS6110 DNA during latency in the patients.  
Since in our no-copy strain study, 4% of all isolates found in a population-based 
sample in rural South Vietnam represented a no-copy strain, this urges the IS6110 PCR 
to be replaced by another PCR method not using IS6110 as a target, for instance a 
specific rpoB gene signature present in all M. tuberculosis complex strains, such as in 
the GeneXpert® MTB/RIF (Chapter 7). 
 
In Vietnam, patients infected with MTB resistant to isoniazid, have an increased risk 
of poor treatment outcomes 
By use of the Genotype® MTBDRplus test, we found that in the rural South 
Vietnam katG codon 315 mutations were most frequent (Chapter 2, Chapter 6). Among 
251 isoniazid resistant strains, 75.3 % revealed katG codon 315 mutations (Chapter 6); 
this rate was similar to some previous reports in South Africa (64.1%, 72%), 
respectively [1, 36]. Both katG codon 315 and inhA promoter region mutations are 
strongly associated with relapse, and katG codon 315 mutations were also associated 
with unfavorable treatment outcome (treatment failure and death). In addition, katG 
codon 315 mutations were strongly related to rifampicin, streptomycin and ethambutol 
resistance, which was similar to the findings in two previous studies [37, 38]. These 
findings raise the hypothesis that mutations in codon 315 of katG gene may trigger the 
acquisition of other mutations conferring resistance to other drugs such as rifampicin, 
streptomycin, and ethambutol. Alternatively, the reduction in fitness in 315 mutants 
may be lower than for other mutants, yielding more persistent infections and a higher 
chance of developing additional resistance. 
Against strains with such INH resistance mutations, the regimen 2SHRZ/6EH is 
far less effective, which may further elucidate why these mutations are associated with 
unfavorable treatment outcome in our study (Chapter 6) and in T  ani’s study [37]. As 
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mentioned in this thesis, the 2SHRZ/6EH regimen used in Vietnam may be one of the 
reasons for the high rate of relapse in this country (Chapter 4 and Chapter 6). The 2010 
WHO TB treatment guidelines advised to replace 8-month regimens by a 6-month 
regimen (2HRZE/4RH) with rifampicin throughout. In populations with known or 
suspected high levels of isoniazid resistance, new TB patients may receive HRE as 
therapy in the continuation phase as an acceptable alternative to HR [39]. Vietnam is a 
country with high levels of isoniazid resistance in new TB patients [40], making 
implementation of the 2HRZE/4RHE regimen for treatment of new TB patients 
necessary. In early July 2013, the Vietnamese National TB program decided to apply 
the 6-month regimen (2HRZE/4RHE) to new TB patients in Ho Chi Minh City, where a 
high prevalence of Beijing genotype strains exists and this regimen may be used in the 
whole country in the near future (National TB Program, unpublished data). 
In previous studies, Buu et al. conceded that streptomycin resistance, a 
prerequisite for the outbreak of MDR-TB Beijing strains in Vietnam, played an 
important role in the association between Beijing genotype and MDR-TB, and 
increased the probability of transmission of the Beijing genotype strains [41]. In 
Chapter 6, likewise, we disclosed that MTB-TB strains having katG codon 315 
mutations are more frequent among Beijing genotype strains that are also resistant to 
streptomycin. Taken together, these findings suggest that streptomycin may be 
ineffective for treatment of TB in patients infected with Being genotype or isoniazid 
resistant MTB strains. Thus, the 2HRZE/4HRE regimen should be used in settings 
where Beijing genotype strains are circulating at high prevalence like in Vietnam. 
 
The Beijing genotype is one of the risk factors causing relapse in Vietnam; therefore, 
the 2SHRZ/6EH regimen needs to be replaced  
Beijing strains are one of the two common MTB genotypes in Vietnam, making 
up 35% of all genotypes found in rural South Vietnam [29]; the Beijing genotype is 
more frequent in the South than in the North of Vietnam (39% vs. 30%, respectively) 
[12]. These strains are associated with young people, streptomycin and isoniazid 
resistance as well as with MDR-TB, relapse and treatment failure [22, 29, 42]. The rate 
of relapse in patients infected with Beijing strains was 5.5 times higher than in patients 
infected with other MTB strains and this association was independent of TB treatment 
history and pretreatment drug resistance pattern. Furthermore, in our relapse study 
(Chapter 4), relapse was significantly associated with resistance to isoniazid, suggesting 
that the use of a combination of isoniazid and ethambutol only in the continuation phase 
of treatment seems to be ineffective to kill Beijing strains, as also shown by Jindani et 
al. [43], (Chapter 4, Chapter 6).  
Increased relapse rates may in fact reflect increased failure rate with very low 
bacterial loads, resulting in negative cultures at the end of treatment but increasing 
numbers of bacilli once drug treatment is stopped. This may explain why we find 
shorter intervals between cure and relapse in cases caused by Beijing strains. However, 
in our failure study (Chapter 5), we found no association between genotype and 
treatment failure, and no other study clearly did so, except for a study in Indonesia [44]. 
In our relapse study, we found that the average time from cure to relapse was shorter in 
Chapter 9 
131 
patients infected with Beijing genotype strains than in patients infected with other 
strains: 10.5 versus 15.8 months (Chapter 4). Indeed, based on results of a study from 
The Gambia, De Jong and colleagues suggested that Beijing strains have higher rates of 
progression from latent infection to disease [45]. 
For Vietnam, an increased relapse rate of Beijing strains seems to be an extra 
reason to move from the 8-month to the recommended 6-month regimen [39]. In 
addition, if the increased relapse rate reflects increased rates of treatment failure, this 
may be a reason to strengthen the continuation phase of the treatment regimen for new 
TB patients in Vietnam, e.g. by adding ethambutol to the 4-month continuation phase 
(2HRZE/4HRE) (Chapter 4 and Chapter 6). 
 
CONCLUSIONS AND RECOMMENDATIONS FOR IMPROVING TUBER-
CULOSIS CONTROL IN VIETNAM 
Molecular epidemiology plays an important role in identifying associations 
between TB genotypes and treatment outcome or/and clinical characteristics. It greatly 
improved our understanding of the transmission dynamics of M. tuberculosis within 
different populations. Furthermore, molecular techniques aided in discovering 
mutations conferring resistance to TB drugs for early diagnosis MDR-TB and XDR-TB. 
In 2009, we applied the GenoType® MTBDRplus test in routine applications to 
diagnose suspected MDR-TB patients and to treat such patients with an appropriate 
regimen. This is an important turning point that effectively supports the National TB 
program in controlling and treating MDR-TB patients.  
Based on our findings in this thesis and in previous studies, we conclude that the 
Beijing genotype and East African Indian are two most common genotypes circulating 
in Vietnam. Among them, Beijing genotype plays an important role in the problems in 
control of tuberculosis in Vietnam.  
Streptomycin resistance is a prerequisite factor that favors Beijing genotype 
strains to succeed in spreading, developing drug resistance in Vietnam. 
In Vietnam, nearly 90% of isoniazid resistant M. tuberculosis is caused by katG 
codon 315 mutations and mutations in the inhA promoter region, in which the former 
mutations are predominant. TB patients infected with M. tuberculosis having one or two 
of these mutations may develop relapse more easily. Moreover, the katG codon 315 
mutations are linked to death and treatment failure; hence, those patients need to be 
strictly followed up at least 2 years after treatment.  
Streptomycin is highly important in the development of MDR-TB. Therefore, 
streptomycin should be taken out of the eight-month regimen 2SHRZ/6EH being in use 
in Vietnam as a standard category 1 treatment regimen for new TB patients; the 6-
m nth regimen 2HRZE/4HR sh u d be app ied f    wing the WHO’s guide ines [39] 
and could be strengthened with ethambutol in the continuation phase for settings that 
have high prevalence of Beijing genotype strains and isoniazid resistance, like in 
Vietnam. 
In addition, the GeneXpert and the Genotype®MTBDRplus test are useful tools 
to control MDR-TB. These tests are now used routinely for screening of suspected 
MDR-TB patients in some provinces in Vietnam. To control MDR-TB more 
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effectively, the GeneXpert MTB/RIF or Genotype®MTBDRplus test should be 
available for all TB patients. If this becomes reality we may succeed in the battle 
against (resistant) tuberculosis in the near future. 
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This thesis provides insight in the distribution of Mycobacterium tuberculosis 
genotypes in the rural South of Vietnam, and their relationship with anti-tuberculosis 
drug resistance, clinical characteristics and treatment outcome. Thanks to a combination 
of molecular biological and epidemiological methods, this thesis demonstrates that the 
GenoType® MTBDRplus test is a reliable tool to diagnose multidrug resistant 
tuberculosis (MDR-TB). Furthermore, the Beijing genotype of M. tuberculosis and 
isoniazid resistance are two predictors of relapse for TB patients. These effects may be 
specific for the Vietnamese situation in which patients are treated with an 8-
month regimen (2SRHZ/6HE), and one could therefore speculate that this regimen may 
be one of the reasons for the high rate of relapse in Vietnam and should be replaced 
with the 6-month regimen 2HRZE/4RHE according to the WHO recommendation. 
Moreover, this thesis shows that mixed infections are not only present in regions with a 
high TB prevalence, a high density of human population and a high rate of HIV, but 
also in regions with a medium TB prevalence and a low rate of HIV. In addition, strains 
without the target IS6110 pose a problem in Vietnam regarding false-negative 
molecular diagnosis in PCR IS6110. 
Chapter 1 provides a general introduction on the burden and epidemiology of 
tuberculosis worldwide and in Vietnam. Also, the population structure of M. 
tuberculosis in this country is introduced, and molecular techniques for genotyping and 
diagnosis are summarized. Moreover, the aims of this thesis are described in this 
chapter. 
The findings in Chapter 2, taking advantage of the nationwide TB drug 
resistance survey (DRS) in Vietnam conducted in 2004-2005, indicate that the 
GenoType® MTBDRplus assay has a high sensitivity, specificity, and an acceptable 
positive and negative predictive value for the routine diagnosis of multidrug resistant 
tuberculosis (MDR-TB), with a test sensitivity and specificity of 89% and 100%, 
respectively. Moreover, the GenoType® MTBDRplus assay disclosed several mixed 
infections of resistant and sensitive strains of M. tuberculosis and of non-tuberculous 
mycobacteria (NTM) and M. tuberculosis.  
In Chapter 3, based on spoligotyping and restriction fragment length 
polymorphism (RFLP) typing, Mycobacterium tuberculosis strains isolated from a 
population-based study, we found that at least 3.1% of the TB patients in rural South of 
Vietnam, where TB prevalence was around 100/100.000 population in 2005, were 
suffering from double M. tuberculosis infections. Such double infections were often a 
mixture of a Beijing and an East African Indian strain; the two most common genotypes 
in Vietnam. In this study we also found that mixed infections were not associated with 
clinical symptoms and drug resistance. However, they were significantly less likely to 
occur in patients with extensive chest X-ray abnormalities and high sputum smear 
grades, suggesting that patients with multiple infections have an increased 
immunological tolerance to M. tuberculosis infections.  
In Chapter 4 and Chapter 5, we assessed the relationship between the Beijing 
genotype and relapse or treatment failure, based on a prospective cohort study. In 
Chapter 4, we found that the relative risk of relapse after curative treatment was larger 
for Beijing versus non-Beijing strains (OR 5.5; 95% CI, 2.1-14.6). This rate was more 
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pronounced than that earlier observed in the multi-country trial of Bumman et al. in 
which patients were also monitored for recurrent TB. The higher rate of recurrent TB in 
cases caused by Beijing strains may be associated with the use of the 8-month 
2SRHZ/6HE regimen in new patients. Because ethambutol is a bacteriostatic drug, it 
can prevent the growth of bacilli, but cannot kill them. So once drug treatment is 
stopped, the remaining bacilli may start replicating again causing symptoms and 
positive cultures within months. However, the Beijing genotype does not directly affect 
the rate of treatment failure, as mentioned in Chapter 5. 
In a prospective, population-based study described in Chapter 6, we used the 
GenoType® MTBDRplus assay to detect mutations associated with INH resistance in 
all INH resistant MTB strains and determined the association of mutations in the codon 
315 of the katG gene and inhA mutations with clinical characteristics, drug resistant 
patterns, genotypes of the causative strains and treatment outcome. Both the 315 katG 
and inhA mutations were significantly associated with relapse in new patients treated by 
2SRHZ/6HE. In addition, 315 katG mutations were associated with poly-drug 
resistance such as the combination of streptomycin, rifampicin and ethambutol. 
Although 315 katG mutations were not associated with treatment failure solely, these 
mutations were related to unfavorable treatment (treatment failure and death), as well as 
with Beijing genotype strains with resistance to streptomycin. This finding indicated 
that streptomycin resistance played an important role in the association between Beijing 
genotype and 315 katG mutations and increased probability of unfavorable treatment of 
315 katG mutant strains. Therefore streptomycin should be discontinued in TB 
treatment regimen for new TB patients in Vietnam.  
In Chapter 7, using isolates collected in a population-based study, we described 
that 4.1% of the strains circulating in a rural South of Vietnam lacked IS6110 DNA. 
Therefore, the PCR assay to detect M. tuberculosis in clinical material that targets 
IS6110, which is widely used in laboratories in Vietnam, should be replaced with PCRs 
targeting other sequences, such as rpoB or IS1081 to avoid missing TB cases of patients 
infected with strains lacking IS6110. In contrast to Beijing genotype, strains without 
IS6110 were more sensitive to anti-TB drugs.  
In Chapter 8, we compared the discriminative power of RFLP typing and 24 loci 
variable number of tandem repeat (VNTR) typing in clustering of 95 Beijing strains 
randomly selected from a population-based study. We found that 24 loci VNTR typing 
and RFLP typing had a similar, high level of discrimination among these strains with 
Hunter Gaston Discrimination Index was 0.994. Although loci VNTR 154, VNTR 2461 
and VNTR 3171 hardly added any value to the level of discrimination, in comparison to 
15 loci VNTR and RFLP typing, 24 loci VNTR typing revealed the highest level of 
discrimination among the 95 Beijing genotype isolates. For this and other practical 
reasons (VNTR typing is faster and easier to perform than RFLP typing), the last 
method is preferred in investigations on transmission of Beijing strains in Vietnam.  
Chapter 9 discusses the findings of this thesis in the light of the literature and 
their meaning for tuberculosis control in Vietnam. It concludes that molecular 
epidemiology of Mycobacterium tuberculosis plays an important, indirect role in 
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studying the epidemiology of tuberculosis in this country and can support the National 
TB Program significantly. 
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Luận án này mang đến một cái nhìn sâu sắc về sự phân bố các kiểu gen của vi 
khuẩn  a  Mycobacterium tuberculosis tại một vùng nông thôn ở miền Nam Việt Nam, 
và mối  iênhệ của chúng với sự đề kháng thuốc  a , với các đặc điểm  âm sàng và với 
kết quả điều trị. Nhờ có sự phối hợp của các phương pháp sinh học phân tử và dịch tễ 
học phân tử,  uận án này đã chứng minh được thử nghiệm GenoType® MTBDRplus là 
một công cụ tốt để chẩn đ án  a  đa kháng thuốc (MDR-TB), cũng như kiểu gen Bắc 
Kinh và sự đề kháng is niazid  à hai chỉ số dự đ án tình hình tái phát  a . Phát hiện này 
có thể chuyên biệt ở Việt Nam nơi mà những bệnh nhân  a  được điều trị với phác đồ 8 
tháng (2SRHZ/6HE); vì vậy ch  nên người ta có thể dự đóan rằng phác đồ trên có thể  à 
một tr ng những nguyên nhân gây ra tỷ  ệ tái phát ca  ở Việt Nam và nên được thay thế 
bằng phác đồ 6 tháng (2HRZE/4RHE) the  khuyến nghị của Tổ chức y tế thế giới. Hơn 
nữa, qua  uận án này chúng ta cũng biết được, nhiễm hỗn hợp cùng  úc hai   ại vi khuẩn 
 a  không chỉ hiện diện ở những vùng có tỷ  ệ bệnh  a  ca , mật độ dân số ca  và tỷ  ệ 
nhiễm HIV ca , mà còn có mặt ở những nơi có tỷ  ệ  a  trung bình, tỷ  ệ HIV thấp. 
Thêm và  đó, các chủng không có đ ạn IS6110 cũng gây khó khăn ch  Việt Nam tr ng 
việc chẩn đ án  a  ch  các trường hợp âm giả khi x t nghiệm PCR IS6110. 
Chương 1 giới thiệu tổng quan về gánh nặng và dịch tễ học của bệnh  a  trên t àn 
thế giới và tại Việt Nam. Đồng thời, chúng tôi cũng giới thiệu về cấu trúc phân tử của vi 
khuẩn  a , và sơ  ược những kỹ thuật phân tử dùng để đánh dấu gene và chẩn đ án 
bệnh. Mục đích của  uận án cũng được mô tả tr ng chương này. 
Những phát hiện tr ng Chương 2, sử dụng các số  iệu từ cuộc khả  sát  a  kháng 
thuốc t àn quốc (DRS) tại Việt Nam thực hiện tr ng giai đ ạn 2004-2005, ch  thấy thử 
nghiệm Genotype® MTBDRplus có độ nhạy và độ đặc hiệu ca , đồng thời các giá trị 
tiên đ án dương và âm có thể chấp nhận được tr ng chẩn đ án thường quy  a  đa kháng 
(MDR-TB), với độ nhạy cảm và độ đặc hiệu  ần  ượt  à 89% và 100%. Thêm và  đó, 
thử nghiệm GenoType® MTBDRplus cũng phát hiện được tình trạng nhiễm hỗn hợp 
của các chủng kháng và nhạy của vi khuẩn  a , h ặc hỗn hợp của vi khuẩn  a  MTB và 
vi khuẩn  a  không điển hình (NTM). 
Tr ng chương 3, dựa trên hai phương pháp sp  ig typing và Restricti n Fragment 
Length Polymorphism (RFLP), chúng tôi đã đánh dấu các chủng Mycobacterium 
tuberculosis phân  ập từ một nghiên cứu dựa trên dân số, và thấy ở nông thôn miền 
Nam Việt Nam, nơi có tỷ  ệ  a  năm 2005  à kh ảng 100/100.000 dân số, có ít nhất 
3,1% số bệnh nhân  a , đã bị nhiễm cùng  úc hai  ọai vi khuẩn  a . Nhiễm trùng kép 
như vậy thường  à một hỗn hợp của một chủng Bắc Kinh với một chủng East  frican 
Indian,  à hai kiểu gen phổ biến nhất ở Việt Nam. Tr ng nghiên cứu này chúng tôi thấy 
rằng nhiễm hỗn hợp không  iên quan đến các triệu chứng  âm sàng và sự đề kháng 
thuốc. Tuy rằng, nhiễm hỗn hợp cũng ít xảy ra ở những bệnh nhân có tổn thương X 
quang ngực  an rộng và có đàm s i dương ca , điều này ch  thấy những bệnh nhân 
nhiễm k p có khả năng đáp ứng miễn dịch gia tăng khi nhiễm  a . 
Trong chương 4 và chương 5, chúng tôi đánh giá mối quan hệ giữa kiểu gen Bắc 
Kinh với tái phát h ặc thất bại điều trị dựa trên một nghiên cứu đ àn hệ tiến cứu. Tr ng 
chương 4, chúng tôi thấy rằng nguy cơ tương đối của tái phát sau khi điều trị khỏi đối 
với các chủng Bắc Kinh ca  hơn s  với các chủng khác (OR 5.5; 95% CI, 2,1-14,6). Tỉ 
 ệ này ca  hơn một nghiên cứu đa quốc gia trước đây của Bumman và cộng sự, tr ng đó 
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các bệnh nhân cũng được the  dõi  a  tái phát chủ động. Tỉ  ệ tái phát  a  ca  hơn tr ng 
các trường hợp nhiễm chủng Bắc Kinh, có thể  iên quan đến việc sử dụng phác đồ điều 
trị 2SRHZ/6HE ch  các bệnh nhân lao mới. Vì ethambut    à một thuốc kìm khuẩn, có 
thể ngăn cản vi khuẩn tăng trưởng nhưng không thể tiêu diệt chúng, d  đó khi ngưng 
điều trị thuốc  a , các vi khuẩn còn sống sót sẽ tăng trưởng trở  ại gây ra triệu chứng  a  
và cấy dương tính tr ng vài tháng sau đó. Tuy nhiên chủng Bắc kinh không  iên quan 
trực tiếp đến tỉ  ệ thất bại điều trị  a , như đề cập tr ng Chương 5. 
Tr ng một nghiên cứu tiến cứu dựa trên dân số được mô tả, tr ng Chương 6, 
chúng tôi dùng thử nghiệm GenoType® MTBDRplus để phát hiện các đột biến kháng 
INH tr ng tất cả các chủng  a  kháng is niazid, sau đó xác định mối  iên quan giữa các 
đột biến 315katG và inhA với các đặc điểm  âm sàng, kiểu kháng thuốc, kiểu gene của 
các vi khuẩn  a  gây bệnh, và kết quả điều trị. Cả hai đột biến này đều  iên quan mật 
thiếtđến  a  tái phát ở bệnh nhân  a  mới, được điều trị với phác đồ 2SRHZ/6HE, ng ài 
ra đột biến 315katG còn kết hợp có ý nghĩa với kháng nhiều thuốc như strept mycin, 
ethambut   và rifampicin, mặc dùđột biến 315katG không kết hợp với thất bại điều trị 
đơn thuần và chủng  a  Bắc Kinh, nhưng đột biến này có  iên quan đến kết quả điều trị 
k m (thất bại điều trị và tử v ng), cũng như kết hợp có ý nghĩa với chủng  a  Bắc Kinh 
khi chủng này kháng với strept mycin. Phát hiện này thừa nhận rằng kháng 
strept mycin đóng một vai trò quan trọng tr ng sự kết hợp giữa chủng Bắc Kinh và đột 
biến 315katG cũng như gia tăng khả năng đáp ứng điều trị k m của đột biến 315katG. 
Vì vậy nên ngừng sử dụng strept mycin tr ng phác đồ  a  ch  bệnh nhân  a  mới tại 
Việt Nam.  
Tr ng Chương 7, sử dụng các chủng thu thập từ nghiên cứu dân số, chúng tôi 
nhận thấy kh ảng 4.1% chủng vi khuẩn  a  thiếu đ ạn IS6110 (no-copy) đang  ưu hành 
tại vùng nông thôn Việt Nam. D  đó thử nghiệm PCR dựa và  đ ạn đích IS6110, đang 
được sử dụng rộng rãi tại các phòng x t nghiệm tại Việt Nam để phát hiện vi khuẩn  a  
tr ng các bệnh phẩm  âm sàng, nên được thay thế bằng các thử nghiệm PCR với đích  à 
các trình tự khác như rpoB hay IS1081 để tránh bỏ sót các trường hợp bệnh nhân nhiễm 
chủng  a  thiếu đọan IS6110. Khác với chủng Bắc Kinh, chủng n -c py thường nhạy 
cảm với thuốc kháng  a .  
Tr ng chương 8, chúng tôi s  sánh độ phân nhóm của phương pháp Restricti n 
Fragment Length Polymorphism (RFLP) và 24 loci Variable Number of Tandem 
Repeat (VNTR). Tr ng số 95 chủng Bắc Kinh được chọn ngẫu nhiên từ một nghiên cứu 
dân số, chúng tôi nhận thấyphương pháp VNTR 24   civà RFLP có độ phân nhóm ca  
tương đương nhau đối với chủng Bắc Kinh, vớichỉ số phân nhóm Hunter Gast n  à 
0.994. Tuy nhiên các locus VNTR 154, VNTR 246 và VNTR 3171 hầu như không có 
giá trị để phân nhóm các chủng Bắc Kinh. S  với 15   ci VNTR thì RFLP và 24   ci 
VNTR có độ phân nhóm 95 chủng Bắc Kinh ca  nhất. Vì  ý d  này và những  ý d  thực 
tế khác (VNTR thực hiện dễ hơn và nhanh hơn s  với RFLP), ch  nên phương pháp 24 
loci VNTR được ưa thích hơn tr ng việc điều tra nguồn  âycủacác chủng Bắc Kinh tại 
Việt nam. 
 Chương 9, bàn  uận về những kết quả phát hiện tr ng  uận án này dựa the  tài  iệu 
từ các nghiên cứu trước và về ý nghĩa của  uận án đối với việc kiểm s át  a  tại Việt 
Nam. Từ đó kết  uận rằng dịch tễ học phân tử của vi khuẩn  a  đóng một vai trò gián 
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tiếp quan trọng tr ng việc nghiên cứu dịch tễ học của bệnh  a  tại Việt nam và có thể 
trợ giúp ch  Chương Trình Chống La  Quốc Gia một cách có ý nghĩa. 
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Dit proefschrift biedt inzicht in de distributie van Mycobacterium tuberculosis 
genotypen in het rurale zuiden van Vietnam, en hun relatie met resistentie tegen anti-
tuberculose middelen, klinische karakteristieken en behandeluitkomst. Dankzij de 
combinatie van moleculair-biologische- en epidemiologische methoden, toont dit 
proefschrift aan dat de GenoType® MTBDRplus test een betrouwbare methode is om 
multidrug resistente tuberculose (MDR-TB) te diagnosticeren. Verder zijn het Beijing 
genotype van M. tuberculosis en isoniazide resistentie twee voorspellers van recidieven 
bij tbc patiënten. Het is mogelijk dat deze effecten specifiek zijn voor de situatie in 
Vietnam waar eerste-lijnsbehandeling plaatsvindt met een 8-maanden schema 
(2SRHZ/6HE). Men zou kunnen speculeren dat dit schema één van de oorzaken is van 
het hoge percentage relapsen in Vietnam, en dat dit vervangen zou moeten worden door 
een 6-maanden schema (2HRZE/4RHE) in overeenstemming met de aanbevelingen van 
de WHO. Bovendien toont dit proefschrift aan dat multipele infecties van M. 
tuberculosis niet al een aanwezig zijn in regi ’s met een h ge preva entie van tbc, een 
hoge dichtheid aan bevolking en een hoge prevalentie van HIV. Tevens vormen 
stammen zonder de PCR target IS6110 een probleem in Vietnam betreffende fout-
negatieve moleculaire diagnose in de IS6110 PCR. 
Hoofdstuk 1 geeft een algemene introductie over de omvang van het probleem en 
de epidemiologie van tuberculose wereldwijd en in Vietnam. Tevens wordt hierin de 
populatiestructuur van M. tuberculosis in dit land geïntroduceerd, alsmede de 
moleculaire technieken voor genotypering en de diagnose. Bovendien worden de 
doelstellingen van dit proefschrift beschreven in dit hoofdstuk. 
De bevindingen in Hoofdstuk 2, gebruikmakend van een nationale tbc resistentie 
survey in Vietnam die werd uitgevoerd in 2004-2005, geven aan dat de GenoType® 
MTBDRplus test een hoge sensitiviteit, specificiteit, en een acceptabele positieve- en 
negatieve voorspellende waarde heeft in de routinediagnostiek van meervoudig 
resistente tuberculose (MDR-TB), met een test sensitiviteit en specificiteit van 89% en 
100%, respectievelijk. Bovendien toonde de GenoType® MTBDRplus test diverse 
meervoudige infecties aan van resistente en gevoelige stammen van M. tuberculosis en 
van nontuberculeuze mycobacteriën (NTM) en M. tuberculosis.  
In Hoofdstuk 3, op basis van spoligotypering en restriction fragment lengte 
polymorfisme (RFLP) typering van Mycobacterium tuberculosis stammen die 
geïsoleerd waren bij een populatie-gebaseerde studie, vonden we dat minstens 3.1% van 
de tbc patiënten in het rurale Zuid-Vietnam, waar de tbc prevalentie ongeveer 
100/100.000 mensen bedroeg in 2005, geconfronteerd waren met meervoudige infecties 
van M. tuberculosis. Zulke dubbele infecties waren vaak een mengsel van een Beijing- 
en een East African Indian stam; de twee meest voorkomende genotypen in Vietnam. In 
deze studie vonden we ook dat gemengde infecties niet geassocieerd waren met 
klinische symptomen en geneesmiddelenresistentie. Deze meervoudige infecties 
kwamen significant minder vaak v  r bij patiënten met th raxf t ’s die uitgebreide 
afwijkingen vertoonden en met sterk positieve sputum microscopie, hetgeen suggereert 
dat patiënten met multipele infecties een verhoogde tolerantie hebben voor M. 
tuberculosis infecties.  
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In Hoofdstuk 4 en 5 bepaalden we de correlatie tussen het Beijing genotype en de 
kans op recidieven en falende behandeling, gebaseerd op een prospectieve cohort 
studie. In Hoofdstuk 4 vonden we dat het relatieve risico op recidief na curatieve 
behandeling groter was voor patiënten met Beijing- versus non-Beijing isolaten (OR 
5.5; 95% CI, 2.1-14.6). Deze verhouding was meer uitgesproken dan eerder werd 
waargenomen in de meerlanden studie van Burman et al. waarbij patiënten werden 
gevolgd op het opnieuw ontwikkelen van tbc. Het hogere percentage van terugkerende 
tbc in ziektegevallen die veroorzaakt waren door Beijing stammen zou geassocieerd 
kunnen zijn met het gebruik van de 8-maanden 2SRHZ/6HE schema’s in nieuwe 
patiënten. Omdat ethambutol een bacteriostatisch middel is, kan het wel de groei van 
bacteriën remmen, maar het kan ze niet doden. Dus wanneer de behandeling wordt 
gestopt, kunnen de overgebleven bacteriën weer gaan repliceren en binnen een paar 
maanden weer symptomen veroorzaken en positieve kweken. Alhoewel; het Beijing 
genotype op zich beïnvloedt het falen van de behandeling niet, zoals staat vermeld in 
Hoofdstuk 5. 
In een prospectieve, populatie-gebaseerde studie die beschreven is in Hoofdstuk 
6, gebruikten we de GenoType® MTBDRplus test om mutaties te detecteren die 
geassocieerd zijn met INH resistentie in alle INH resistente MTB stammen en 
bepaalden we de associatie van mutaties in het codon 315 van het katG gen en inhA 
mutaties met klinische karakteristieken, resistentiepatronen,genotypen van de causale 
stammen en behandeluitkomst. Zowel de 315katG als de inhA mutaties bleken 
significant geassocieerd met recidief in nieuwe patiënten die behandeld werden volgens 
het schema 2SRHZ/6HE. Verder waren 315katG mutaties geassocieerd met poly-drug 
resistentie, zoals de combinatie van resistentie tegen streptomycine, rifampicine en 
ethambutol. Alhoewel 315katG mutaties op zich niet geassocieerd waren met falende 
behandeling, waren deze mutaties wel gerelateerd aan ongunstige uitkomst (falende 
behandeling en sterfte gecombineerd), en ook Beijing genotype stammen met resistentie 
tegen streptomycine. Deze bevinding geeft aan dat streptomycine resistentie een 
belangrijke rol speelt in de associatie tussen het Beijing genotype en 315katG mutaties 
en toegenomen kans op ongunstige behandeluitkomst bij patiënten met 315katG 
mutantenstammen. Daarom zou het gebruik van streptomycine gediscontinueerd 
moeten worden in de behandeling van nieuwe tbc patiënten in Vietnam.  
In Hoofdstuk 7, gebruikmakend van isolaten die verzameld waren in het kader 
van een populatie-gebaseerde studie, beschrijven we dat 4.1% van de stammen die in 
het rurale deel van Zuid-Vietnam circuleren geen IS6110 DNA bevatten. Daarom zou 
de PCR methode om M. tuberculosis in klinisch materiaal aan te tonen en die gebaseerd 
is op de detectie van IS6110 en die gebruikt wordt in veel laboratoria in Vietnam, 
vervangen moeten worden door PCR methoden die andere sequenties detecteren, zoals 
rpoB of IS1081, dit om te voorkomen dat er tbc gevallen gemist worden van patiënten 
die met stammen zijn geïnfecteerd die IS6110 missen. In tegenstelling tot het Beijing 
genotype, zijn stammen zonder IS6110 gevoeliger voor anti-tuberculose drugs.  
In Hoofdstuk 8 hebben we het discriminerende vermogen onderzocht van RFLP 
typering en 24 loci variable number of tandem repeat (VNTR) typering bij 95 Beijing 
genotype stammen die random waren geselecteerd uit een populatie-gebaseerde studie. 
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We vonden hierbij dat 24 loci VNTR- en RFLP typering een vergelijkbaar, hoog niveau 
van discriminatie vertoonden, zoals bepaald met de Hunter Gaston Discrimination 
Index (0.994). Alhoewel de loci VNTR 154, VNTR 2461 and VNTR 3171 nauwelijks 
iets toevoegden aan het niveau van discriminatie, vertoonde in vergelijking met 15 loci 
VNTR- en RFLP typering, 24 loci VNTR typering het hoogste niveau van discriminatie 
onder de 95 Beijing genotype isolaten. Om deze en andere, meer praktische redenen 
(VNTR typering is sneller en gemakkelijker uit te voeren dan RFLP typering), is de 24 
loci VNTR typering daarom eerste keuze voor onderzoek naar transmissie van Beijing 
genotype stammen in Vietnam.  
Hoofdstuk 9 belicht de bevindingen in dit proefschrift in het kader van de 
literatuur en hun betekenis voor de tuberculosebestrijding in Vietnam. Er wordt 
geconcludeerd dat de moleculaire epidemiologie van tuberculose een belangrijke, zij het 
indirecte rol speelt in het bestuderen van de epidemiologie van tuberculose in dit land, 
en dat het daarom het nationale tbc-bestrijdingsprogamma in belangrijke mate kan 
ondersteunen. 
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